Improved antigen-binding receptors
Humanized antigen binding receptors with specific binding to a mutated Fc domain address ACT's toxicities and off-target issues, enhancing safety and efficacy by ensuring T cell activation only in the presence of targeted antibodies, thus improving tumor cell lysis.
Patent Information
- Application Number
- JP2024531293
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-11-25
- Filing Date
- 2022-11-23
- Publication Date
- 2024-11-19
- Estimated Expiration
- 2042-11-23
AI Technical Summary
Existing adoptive T-cell therapies (ACT) face limitations due to treatment-related toxicities and off-target effects driven by tumor-targeting antigen-binding moieties, and the complexity of immune synapses and non-human antibodies can lead to anti-drug antibodies, affecting safety and efficacy.
Development of humanized antigen binding receptors with specific binding to a mutated Fc domain, reducing off-target effects and improving safety by using transduced T cells that are activated only in the presence of antibodies with the P329G mutation, thereby minimizing non-specific activation and enhancing therapeutic specificity.
The humanized antigen binding receptors provide stable and highly expressed T cells with reduced off-target effects and improved safety profiles, allowing targeted tumor cell lysis with enhanced therapeutic efficacy.
Smart Images

Figure 2024543152000034 
Figure 2024543152000035 
Figure 2024543152000036
Abstract
Description
[Technical field]
[0001] The present invention generally relates to a humanized antigen-binding receptor capable of specifically binding to an Fc domain comprising the amino acid mutation P329G according to EU numbering. The present invention also relates to T cells transduced with the antigen-binding receptor that are recruited by specifically binding / interacting with the mutated Fc domain of a therapeutic antibody. [Background technology]
[0002] Adoptive T cell therapy (ACT) is a powerful therapeutic approach that uses cancer-specific T cells (Rosenberg and Restifo, Science 348(6230)(2015),62-68). ACT can use naturally occurring tumor-specific cells or T cells made specific by genetic engineering using T cells or chimeric antigen receptors (Rosenberg and Restifo, Science 348(6230)(2015),62-68). ACT can successfully treat and induce remission even in patients with progressive and other treatment-resistant diseases, such as acute lymphoblastic leukemia, non-Hodgkin's lymphoma or melanoma (Dudley et al., J Clin Oncol 26(32)(2008), 5233-5239; Grupp et al., N Engl J Med 368(16)(2013), 1509-1518; Kochenderfer et al., J Clin Oncol.(2015)33(6):540-549, doi:10.1200 / JCO.2014.56.2025.Epub 2014 Aug 25).
[0003] However, ACT, despite its remarkable clinical efficacy, is limited by treatment-related toxicity. The specificity of engineered T cells used in ACT and the resulting on-target and off-target effects are mainly driven by the tumor-targeting antigen-binding moiety implemented in the antigen-binding receptor. Non-exclusive expression of tumor antigens or time lag in expression levels may cause severe side effects or even lead to the discontinuation of ACT due to unacceptable toxicity of the treatment.
[0004] Furthermore, the availability of tumor-specific T cells for efficient tumor cell lysis depends on the long-term survival and proliferation capacity of engineered T cells in vivo, whereas in vivo survival and proliferation of T cells may also result in undesirable long-term effects due to the persistence of uncontrolled T cell responses that may result in damage to healthy tissues (Grupp et al. 2013 N Engl J Med 368(16):1509-18, Maude et al. 2014 2014 N Engl J Med 371(16):1507-17).
[0005] One approach to suppress severe treatment-related toxicity and improve the safety of ACT is to limit T cell activation and proliferation by introducing adaptor molecules into the immune synapse. Such adaptor molecules include small molecule bimodal switches, such as the recently described folate-FITC switch (Kim et al. J Am Chem Soc 2015;137:2832-2835). Further approaches included artificially modified antibodies containing tags that induce T cell specificity to target tumor cells (Ma et al. PNAS 2016;113(4):E450-458, Cao et al. Angew Chem 2016;128:1-6, Rogers et al. PNAS 2016;113(4):E459-468, Tamada et al. Clin Cancer Res 2012;18(23):6436-6445).
[0006] However, existing approaches have several limitations. The immune synapse, which relies on molecular switches, requires the introduction of additional elements that may induce immune responses or cause non-specific off-target effects. Moreover, the complexity of such multi-component systems may limit therapeutic efficacy and tolerability. Meanwhile, the introduction of tag structures into existing therapeutic monoclonal antibodies may affect the efficacy and safety profile of these constructs. Moreover, the addition of tags requires additional modification and purification steps that make the production of the antibodies more complicated, as well as additional safety testing.
[0007] Furthermore, the in vivo use of non-human or partially human antibodies can result in the formation of anti-drug antibodies (ADAs), including anti-idiotypic or human anti-mouse antibodies (HAMAs) (Blanco et al Clin Immunol 17, 96-106 (1997)). These ADAs can affect the pharmacokinetic properties, safety and functionality of the administered antibodies, and humanization has been applied to address this (Carter et al PNAS 89, 4285-4289 (1992)). Similarly, ADAs have been observed for mouse-based CAR-T cells. Human anti-mouse IgG antibodies are known to occur with CAR-transduced T cells, but have not been thought to have adverse clinical consequences. Maus et al. were the first to describe anaphylaxis caused by CAR-modified T cells, most likely mediated by IgE antibodies specific for the CAR. These results indicate that the potential immunogenicity of antigen-binding receptors derived from mouse antibodies may be a safety issue, especially when administered using intermittent dosing schedules (Maus et al Cancer Immunol Res 1,26-31(2013)). Therefore, there is a need to improve targeted tumor therapy, especially adoptive T cell therapy, to meet the needs of cancer patients. Therefore, there is still a need to improve the safety and efficacy of ACT and provide improved means that have the potential to overcome the above-mentioned shortcomings. Summary of the Invention
[0008] The present invention provides antigen-binding receptors with improved properties, in particular humanized antigen-binding receptors that are stable and highly expressed in transduced cells.
[0009] Provided herein is an antigen binding receptor comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 129. In one embodiment, the antigen binding receptor comprises the amino acid sequence of SEQ ID NO: 129. In one embodiment, the antigen binding receptor consists of the amino acid sequence of SEQ ID NO: 129.
[0010] In one embodiment, an antigen binding receptor is provided that comprises an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 132. In one embodiment, the antigen binding receptor comprises the amino acid sequence of SEQ ID NO: 132. In one embodiment, the antigen binding receptor consists of the amino acid sequence of SEQ ID NO:132.
[0011] In one embodiment, the antigen binding receptor does not comprise the amino acid sequence of SEQ ID NO:19. In one embodiment, there is provided an isolated polynucleotide encoding an antigen binding receptor as described herein above.
[0012] In one embodiment, the isolated polynucleotide comprises the sequence of SEQ ID NO:130.
[0013] In one embodiment, the isolated polynucleotide comprises the sequence of SEQ ID NO:133.
[0014] In one embodiment, there is provided a polypeptide encoded by an isolated polynucleotide as described herein above.
[0015] In one embodiment there is provided a vector, particularly an expression vector, comprising a polynucleotide as described herein above.
[0016] In one embodiment, there is provided a transduced T cell comprising a polynucleotide or vector as described herein above.
[0017] In one embodiment, a transduced T cell is provided that is capable of expressing an antigen binding receptor as described herein above.
[0018] In one embodiment, (A) a transduced T cell capable of expressing an antigen-binding receptor as described herein above; and (B) An antibody that binds to a target cell antigen and comprises an Fc domain that includes the amino acid mutation P329G according to EU numbering. A kit is provided comprising:
[0019] In one embodiment, (A) an isolated polynucleotide encoding an antigen-binding receptor as described herein above; and (B) An antibody that binds to a target cell antigen and comprises an Fc domain that includes the amino acid mutation P329G according to EU numbering. A kit is provided comprising:
[0020] In one embodiment, (A) an isolated polynucleotide or vector as described herein above; and (B) An antibody that binds to a target cell antigen and comprises an Fc domain that includes the amino acid mutation P329G according to EU numbering. A kit is provided comprising:
[0021] In one embodiment, the Fc domain is an IgG1 or IgG4 Fc domain, in particular a human IgG1 Fc domain.
[0022] In one embodiment, the target cell antigen is selected from the group consisting of fibroblast activation protein (FAP), carcinoembryonic antigen (CEA), mesothelin (MSLN), CD20, folate receptor 1 (FOLR1) and tenascin (TNC).
[0023] In one embodiment there is provided a kit as described herein above for use as a medicament.
[0024] In one embodiment there is provided an antigen binding receptor or a transduced T cell as described herein above for use as a medicament, wherein the transduced T cell expressing the antigen binding receptor is administered before, simultaneously with or after administration of an antibody which binds to a target cell antigen, in particular a cancer cell antigen, and which comprises an Fc domain comprising the amino acid mutation P329G according to EU numbering.
[0025] In one embodiment there is provided a kit as described herein above for use in the treatment of a disease, in particular for use in the treatment of cancer.
[0026] In one embodiment there is provided an antigen binding receptor or a transduced T cell as described herein above for use in the treatment of cancer, wherein the treatment comprises administering a transduced T cell expressing the antigen binding receptor prior to, concomitantly with or following administration of an antibody which binds to a cancer cell antigen and comprises an Fc domain which comprises the amino acid mutation P329G according to EU numbering.
[0027] In one embodiment, the cancer is selected from cancers of epithelial, endothelial or mesothelial origin and hematological cancers.
[0028] In one embodiment, the cancer antigen is selected from the group consisting of fibroblast activation protein (FAP), carcinoembryonic antigen (CEA), mesothelin (MSLN), CD20, folate receptor 1 (FOLR1) and tenascin (TNC).
[0029] In one embodiment, the transduced T cells are derived from cells isolated from the subject to be treated.
[0030] In one embodiment, the transduced T cells are not derived from cells isolated from the subject to be treated.
[0031] In one embodiment, a method of treating a disease in a subject is provided, comprising administering to the subject transduced T cells capable of expressing an antigen binding receptor as described herein above, and administering, prior to, concomitant with, or following administration of the transduced T cells, a therapeutically effective amount of an antibody that binds to a target cell antigen and comprises an Fc domain that comprises the amino acid mutation P329G according to EU numbering.
[0032] In one embodiment, the method additionally comprises isolating T cells from the subject and generating transduced T cells by transducing the isolated T cells with a polynucleotide or vector as described herein above.
[0033] In one embodiment, the T cells are transduced with a retroviral or lentiviral vector construct, or a non-viral vector construct.
[0034] In one embodiment, the transduced T cells are administered to the subject by intravenous infusion.
[0035] In one embodiment, the transduced T cells are contacted with an anti-CD3 antibody and / or an anti-CD28 antibody prior to administration to a subject.
[0036] In one embodiment, the transduced T cells are contacted with at least one cytokine, preferably interleukin-2 (IL-2), interleukin-7 (IL-7), interleukin-15 (IL-15) and / or interleukin-21 or variants thereof, prior to administration to a subject.
[0037] In one embodiment, the disease is cancer.
[0038] In one embodiment, the cancer is selected from cancers of epithelial, endothelial or mesothelial origin and hematological cancers.
[0039] In one embodiment, a method of inducing lysis of a target cell is provided, comprising contacting the target cell with a transduced T cell capable of expressing an antigen-binding receptor as described herein above in the presence of an antibody that binds to a target cell antigen and comprises an Fc domain that comprises the amino acid mutation P329G according to EU numbering.
[0040] In one embodiment, the target cell is a cancer cell.
[0041] In one embodiment, the target cells express an antigen selected from the group consisting of fibroblast activation protein (FAP), carcinoembryonic antigen (CEA), mesothelin (MSLN), CD20, folate receptor 1 (FOLR1) and tenascin (TNC).
[0042] In one embodiment there is provided the use of an antigen binding receptor, a polynucleotide, or a transduced T cell as described herein above for the manufacture of a medicament.
[0043] In one embodiment, the medicament is for the treatment of cancer.
[0044] In one embodiment, the cancer is selected from cancers of epithelial, endothelial or mesothelial origin and hematological cancers. [Brief description of the drawings]
[0045] [Figure 1A-B] Schematic diagram of second generation chimeric antigen binding receptors with anti-P329G binding moieties in scFv format, VHxVL scFv (Figure 1A) and VLxVH (Figure 1B) orientations. Figures 1C and 1D show DNA constructs encoding the antigen binding receptors shown in Figures 1A and 1B, respectively. [Figure 1C-D] Schematic diagram of second generation chimeric antigen binding receptors with anti-P329G binding moieties in scFv format, VHxVL scFv (Figure 1A) and VLxVH (Figure 1B) orientations. Figures 1C and 1D show DNA constructs encoding the antigen binding receptors shown in Figures 1A and 1B, respectively. [Diagram 2]CAR surface expression of different humanized scFv variants (Figure 2A) and correlating GFP expression (Figure 2B) serving as a transduction control are shown. [Figure 3A] Evaluation of non-specific signaling of anti-P329G CAR Jurkat reporter T cells using different humanized versions of the P329G binder as binding moiety. Activation was assessed by quantifying the intensity of CD3 downstream signaling in the presence of antibodies with different Fc variants or in the presence of antibodies containing the P329G Fc variant but without target cells using the anti-P329G CAR Jurkat-NFAT reporter assay. Depicted are the averages of triplicates of technical values, error bars indicate SD. [Figure 3B] Evaluation of non-specific signaling of anti-P329G CAR Jurkat reporter T cells using different humanized versions of the P329G binder as binding moiety. Activation was assessed by quantifying the intensity of CD3 downstream signaling in the presence of antibodies with different Fc variants or in the presence of antibodies containing the P329G Fc variant but without target cells using the anti-P329G CAR Jurkat-NFAT reporter assay. Depicted are the averages of triplicates of technical values, error bars indicate SD. [Figure 3C] Evaluation of non-specific signaling of anti-P329G CAR Jurkat reporter T cells using different humanized versions of the P329G binder as binding moiety. Activation was assessed by quantifying the intensity of CD3 downstream signaling in the presence of antibodies with different Fc variants or in the presence of antibodies containing the P329G Fc variant but without target cells using the anti-P329G CAR Jurkat-NFAT reporter assay. Depicted are the averages of triplicates of technical values, error bars indicate SD. [Figure 3D]Evaluation of non-specific signaling of anti-P329G CAR Jurkat reporter T cells using different humanized versions of the P329G binder as binding moiety. Activation was assessed by quantifying the intensity of CD3 downstream signaling in the presence of antibodies with different Fc variants or in the presence of antibodies containing the P329G Fc variant but without target cells using the anti-P329G CAR Jurkat-NFAT reporter assay. Depicted are the averages of triplicates of technical values, error bars indicate SD. [Figure 3E] Evaluation of non-specific signaling of anti-P329G CAR Jurkat reporter T cells using different humanized versions of the P329G binder as binding moiety. Activation was assessed by quantifying the intensity of CD3 downstream signaling in the presence of antibodies with different Fc variants or in the presence of antibodies containing the P329G Fc variant but without target cells using the anti-P329G CAR Jurkat-NFAT reporter assay. Depicted are the averages of triplicates of technical values, error bars indicate SD. [Figure 3F] Evaluation of non-specific signaling of anti-P329G CAR Jurkat reporter T cells using different humanized versions of the P329G binder as binding moiety. Activation was assessed by quantifying the intensity of CD3 downstream signaling in the presence of antibodies with different Fc variants or in the presence of antibodies containing the P329G Fc variant but without target cells using the anti-P329G CAR Jurkat-NFAT reporter assay. Depicted are the averages of triplicates of technical values, error bars indicate SD. [Figure 4A]Activation of anti-P329G CAR Jurkat reporter T cells using different humanized versions of P329G binders in combination with antibodies with high (16D5), medium (16D5 W96Y) or low (16D5 G49S / K53A) affinity for FolR1 in the presence of FolR1+ target cells with high (HeLa-FolR1), medium (Skov3) and low (HT29) target expression levels. Activation was assessed by quantification of the intensity of CD3 downstream signaling using the anti-P329G CAR Jurkat-NFAT reporter assay. Depicted are the mean of triplicates of technical values, error bars indicate SD. [Figure 4B] Activation of anti-P329G CAR Jurkat reporter T cells using different humanized versions of P329G binders in combination with antibodies with high (16D5), medium (16D5 W96Y) or low (16D5 G49S / K53A) affinity for FolR1 in the presence of FolR1+ target cells with high (HeLa-FolR1), medium (Skov3) and low (HT29) target expression levels. Activation was assessed by quantification of the intensity of CD3 downstream signaling using the anti-P329G CAR Jurkat-NFAT reporter assay. Depicted are the mean of triplicates of technical values, error bars indicate SD. [Figure 4C] Activation of anti-P329G CAR Jurkat reporter T cells using different humanized versions of P329G binders in combination with antibodies with high (16D5), medium (16D5 W96Y) or low (16D5 G49S / K53A) affinity for FolR1 in the presence of FolR1+ target cells with high (HeLa-FolR1), medium (Skov3) and low (HT29) target expression levels. Activation was assessed by quantification of the intensity of CD3 downstream signaling using the anti-P329G CAR Jurkat-NFAT reporter assay. Depicted are the mean of triplicates of technical values, error bars indicate SD. [Figure 4D]Activation of anti-P329G CAR Jurkat reporter T cells using different humanized versions of P329G binders in combination with antibodies with high (16D5), medium (16D5 W96Y) or low (16D5 G49S / K53A) affinity for FolR1 in the presence of FolR1+ target cells with high (HeLa-FolR1), medium (Skov3) and low (HT29) target expression levels. Activation was assessed by quantification of the intensity of CD3 downstream signaling using the anti-P329G CAR Jurkat-NFAT reporter assay. Depicted are the mean of triplicates of technical values, error bars indicate SD. [Figure 4E] Activation of anti-P329G CAR Jurkat reporter T cells using different humanized versions of P329G binders in combination with antibodies with high (16D5), medium (16D5 W96Y) or low (16D5 G49S / K53A) affinity for FolR1 in the presence of FolR1+ target cells with high (HeLa-FolR1), medium (Skov3) and low (HT29) target expression levels. Activation was assessed by quantification of the intensity of CD3 downstream signaling using the anti-P329G CAR Jurkat-NFAT reporter assay. Depicted are the mean of triplicates of technical values, error bars indicate SD. [Figure 4F] Activation of anti-P329G CAR Jurkat reporter T cells using different humanized versions of P329G binders in combination with antibodies with high (16D5), medium (16D5 W96Y) or low (16D5 G49S / K53A) affinity for FolR1 in the presence of FolR1+ target cells with high (HeLa-FolR1), medium (Skov3) and low (HT29) target expression levels. Activation was assessed by quantification of the intensity of CD3 downstream signaling using the anti-P329G CAR Jurkat-NFAT reporter assay. Depicted are the mean of triplicates of technical values, error bars indicate SD. [Figure 4G]Activation of anti-P329G CAR Jurkat reporter T cells using different humanized versions of P329G binders in combination with antibodies with high (16D5), medium (16D5 W96Y) or low (16D5 G49S / K53A) affinity for FolR1 in the presence of FolR1+ target cells with high (HeLa-FolR1), medium (Skov3) and low (HT29) target expression levels. Activation was assessed by quantification of the intensity of CD3 downstream signaling using the anti-P329G CAR Jurkat-NFAT reporter assay. Depicted are the mean of triplicates of technical values, error bars indicate SD. [Figure 4H] Activation of anti-P329G CAR Jurkat reporter T cells using different humanized versions of P329G binders in combination with antibodies with high (16D5), medium (16D5 W96Y) or low (16D5 G49S / K53A) affinity for FolR1 in the presence of FolR1+ target cells with high (HeLa-FolR1), medium (Skov3) and low (HT29) target expression levels. Activation was assessed by quantification of the intensity of CD3 downstream signaling using the anti-P329G CAR Jurkat-NFAT reporter assay. Depicted are the mean of triplicates of technical values, error bars indicate SD. [Figure 4I] Activation of anti-P329G CAR Jurkat reporter T cells using different humanized versions of P329G binders in combination with antibodies with high (16D5), medium (16D5 W96Y) or low (16D5 G49S / K53A) affinity for FolR1 in the presence of FolR1+ target cells with high (HeLa-FolR1), medium (Skov3) and low (HT29) target expression levels. Activation was assessed by quantification of the intensity of CD3 downstream signaling using the anti-P329G CAR Jurkat-NFAT reporter assay. Depicted are the mean of triplicates of technical values, error bars indicate SD. [Diagram 5]Activation of anti-P329G CAR Jurkat NFAT reporter T cells using different humanized versions of the P329G binder as binding moiety. The activity of reporter cells was evaluated in the presence of IgG and anti-FolR1 (16D5) P329G IgG1 targeting HeLa (FolR1+) target cells (Figure 5A). Antibody dose-dependent activation was assessed by quantification of the intensity of CD3 downstream signaling using the anti-P329G CAR Jurkat-NFAT reporter assay and the area under the curve was calculated (Figure 5B). Depicted are the averages of triplicates of technical values, error bars indicate SD. [Figure 6] Activation of anti-P329G CAR Jurkat NFAT reporter T cells using different humanized versions of the P329G binder as binding moiety. The activity of reporter cells was evaluated in the presence of IgG and anti-HER2 (Pertuzumab) P329G IgG1 targeting HeLa (HER2+) target cells (Figure 6A). Antibody dose-dependent activation was assessed by quantification of the intensity of CD3 downstream signaling using the anti-P329G CAR Jurkat-NFAT reporter assay and the area under the curve was calculated (Figure 6B). Depicted are the mean of triplicates of technical values, error bars indicate SD. [Figure 7] CAR surface expression of disulfide-stabilized VHxVL1 scFv variants. [Figure 8] Schematic diagram of HuR968B and HuR9684M CAR constructs. For the HuR9684M construct IgG4M-CD28TM-CD28CSD-CD3z was used, and for HuR968B G4S-CD8TM-4-1BBCSD-CD3z was used. [Figure 9] Depicted is the expression of HuR968B and HuR9684M in HEK293T cells. [Figure 10A] Representative flow cytometry data showing expression of each PG CAR construct HuR968B and HuR9684M (Figure 9A) and the non-transduced control (Figure 9A). Total expression of CAR ranges from 18% to 36%. [Figure 10B]Representative flow cytometry data showing expression of each PG CAR construct HuR968B and HuR9684M (Figure 9A) and the non-transduced control (Figure 9A). Total expression of CAR ranges from 18% to 36%. [Figure 11] The killing efficacy of PG CARs using HuR968B, HuR9684M constructs, and conventional 8E5 CAR-T cells as measured by xCELLigence is demonstrated. Claudin 18.2 expressing DAN-G18.2 tumor cells were used as target cells and tested with donor (PCH20201100004) T cells expressing HuR9684M or HuR968B PG CARs. P329G Claudin 18.2 A6 antibody was used at an IgG concentration of 100ng / ml with an E:T ratio of 1:2. [Figure 12] Figure 2 shows the killing effect of HuR968B CAR-T cells in combination with different concentrations of A6 or Zmab PG IgG as measured by LDH release.DAN-G18.2 expressing CLDN18.2 were used as target cells and HuR968B CAR-T cells were used as effector cells. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0046] definition Unless otherwise defined below, terms are used herein as commonly used in the art.
[0047] For purposes herein, an "acceptor human framework" is a framework that comprises the amino acid sequence of a light chain variable domain (VL) framework or a heavy chain variable domain (VH) framework derived from a human immunoglobulin framework or a human consensus framework, as defined below. An acceptor human framework "derived from" a human immunoglobulin framework or a human consensus framework may comprise the same amino acid sequence or may contain amino acid sequence changes. In some embodiments, the number of amino acid changes is 10 or less, 9 or less, 8 or less, 7 or less, 6 or less, 5 or less, 4 or less, 3 or less, or 2 or less. In some embodiments, the VL acceptor human framework is identical in sequence to the VL human immunoglobulin framework sequence or the human consensus framework sequence.
[0048] An "activating Fc receptor" is an Fc receptor that, following binding of the Fc domain of an antibody, triggers signaling events that stimulate a receptor-bearing cell to carry out an effector function. Human activating Fc receptors include FcγRIIIa (CD16a), FcγRI (CD64), FcγRIIa (CD32) and FcαRI (CD89).
[0049] "Antibody-dependent cell-mediated cytotoxicity" ("ADCC") is an immune mechanism that leads to the lysis of antibody-coated target cells by immune effector cells. The target cells are cells to which an antibody or derivative thereof that contains an Fc region specifically binds, usually via a protein portion that is N-terminal to the Fc region. As used herein, the term "reduced ADCC" is defined as either a reduction in the number of target cells that are lysed in a given time at a given antibody concentration in the medium surrounding the target cells by the mechanism of ADCC as defined above, and / or an increase in the antibody concentration in the medium surrounding the target cells required to achieve lysis of a given number of target cells in a given time by the mechanism of ADCC. The reduced ADCC is relative to the ADCC mediated by the same antibody, but not engineered, produced by the same type of host cell, using the same standard production, purification, formulation and storage methods, which are known to those skilled in the art. For example, the reduced ADCC mediated by an antibody that contains an ADCC-reducing amino acid substitution in the Fc domain is relative to the ADCC mediated by the same antibody that does not contain this amino acid substitution in the Fc domain. Suitable assays for measuring ADCC are well known in the art (see, for example, PCT Publication No. WO2006 / 082515 or PCT Publication No. WO2012 / 130831).
[0050] An "effective amount" of an agent, eg, a pharmaceutical composition, refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired therapeutic or prophylactic result.
[0051] "Affinity" refers to the strength of the sum of non-covalent interactions between a single binding site of a molecule (e.g., an antibody) and its binding partner (e.g., an antigen). Unless otherwise indicated, as used herein, "binding affinity" refers to the intrinsic binding affinity that reflects a 1:1 interaction between members of a binding pair (e.g., an antibody and an antigen). The affinity of a molecule X for its partner Y is generally determined by the dissociation constant (K D) Affinity can be measured by common methods known in the art, including those described herein. Specific illustrative exemplary methods for measuring binding affinity are described below.
[0052] The term "amino acid" refers to naturally occurring and synthetic amino acids, as well as amino acid analogs and amino mimetics that function similarly to naturally occurring amino acids. Naturally occurring amino acids are those encoded by the genetic code and those that are later modified, such as hydroxyproline, γ-carboxyglutamic acid, and O-phosphoserine. Amino acid analogs refer to compounds that have the same basic chemical structure as a naturally occurring amino acid, i.e., an α carbon bonded to a hydrogen, a carboxyl group, an amino group, and an R group, such as homoserine, norleucine, methionine sulfoxide, and methionine methylsulfonium. Such analogs have modified R groups (e.g., norleucine) or modified peptide backbones, but retain the same basic chemical structure as a naturally occurring amino acid. Amino acid mimetics refer to compounds that have a structure that differs from the general chemical structure of an amino acid, but that function similarly to a naturally occurring amino acid. Amino acids may be represented herein by either their commonly known three letter symbols or the one-letter symbols recommended by the IUPAC-IUB Biochemical Nomenclature Commission.
[0053] The term "amino acid mutation" as used herein is meant to encompass amino acid substitution, deletion, insertion, and modification. Any combination of substitution, deletion, insertion, and modification can be made to arrive at the final construct, provided that the final construct has the desired characteristics (e.g., reduced binding to Fc receptors or increased association with another peptide). Deletions and insertions in the amino acid sequence include amino- and / or carboxy-terminal deletions and insertions of amino acids. Particular amino acid mutations are amino acid substitutions. Non-conservative amino acid substitutions, i.e., replacing one amino acid with another amino acid having different structural and / or chemical properties, are particularly preferred, e.g., to alter the binding properties of the Fc region. Amino acid substitutions include replacement with non-naturally occurring amino acids or with naturally occurring amino acid derivatives of the 20 standard amino acids (e.g., 4-hydroxyproline, 3-methylhistidine, ornithine, homoserine, 5-hydroxylysine). Amino acid mutations can be generated using genetic or chemical methods well known in the art. Genetic methods can include site-directed mutagenesis, PCR, gene synthesis, and the like. It is contemplated that methods of modifying the side chain groups of amino acids other than genetic engineering, such as chemical modification, may also be useful. Various names may be used herein to indicate the same amino acid mutation. For example, a proline to glycine substitution at position 329 of the Fc domain is represented by 329G, G329, G 329 , P329G or Pro329Gly.
[0054] The term "antibody" is used herein in the broadest sense and encompasses a variety of antibody structures, including, but not limited to, monoclonal antibodies, polyclonal antibodies, multispecific antibodies (e.g., bispecific antibodies), and antibody fragments, so long as they exhibit the desired antigen-binding activity.
[0055] "Antibody fragment" refers to a molecule other than an intact antibody that contains a portion of an intact antibody that binds to the antigen to which the intact antibody binds. Examples of antibody fragments include, but are not limited to, Fv, Fab, Fab', Fab'-SH, F(ab')2; diabodies; linear antibodies; single-chain antibody molecules (e.g., scFv, and scFab); single domain antibodies (dAbs), and multispecific antibodies formed from antibody fragments. For a review of specific antibody fragments, see Holliger and Hudson, Nature Biotechnology 23:1126-1136 (2005).
[0056] The term "antigen-binding domain" refers to a part of an antibody that comprises an area that specifically binds to and is complementary to part or all of an antigen. An antigen-binding domain may, for example, be provided by one or more antibody variable domains (also called antibody variable regions). In particular, an antigen-binding domain comprises an antibody light chain variable domain (VL) and an antibody heavy chain variable domain (VH).
[0057] As used herein, the term "antigen-binding molecule" in its broadest sense refers to a molecule that specifically binds to an antigenic determinant. Examples of antigen-binding molecules are immunoglobulins and derivatives thereof, such as fragments thereof, and antigen-binding receptors and derivatives thereof.
[0058] As used herein, the term "antigen-binding moiety" refers to a polypeptide molecule that specifically binds to an antigenic determinant. In one embodiment, an antigen-binding moiety can direct the entity to which it binds (e.g., a cell expressing an antigen-binding receptor that includes the antigen-binding moiety) to a target site, e.g., to a particular type of tumor cell or tumor stroma that bears the antigenic determinant. Antigen-binding moieties include antibodies and fragments thereof as further defined herein. Particular antigen-binding moieties include the antigen-binding domain of an antibody (e.g., an scFv fragment), which includes an antibody heavy chain variable region and an antibody light chain variable region. In certain embodiments, the antigen-binding moiety may include an antibody constant region as further defined herein and known in the art. Useful heavy chain constant regions include any of the five isotypes: alpha, delta, epsilon, gamma, or mu. Useful light chain constant regions include any of the two isotypes: kappa and lambda.
[0059] In the context of the present invention, the term "antigen-binding receptor" relates to an antigen-binding molecule comprising an anchor transmembrane domain and an extracellular domain comprising at least one antigen-binding moiety. Antigen-binding receptors can be made from polypeptide moieties from different sources. Thus, antigen-binding receptors can also be understood as "fusion proteins" and / or "chimeric proteins". Typically, a fusion protein is a protein made by joining two or more genes (preferably cDNAs) that originally encoded separate proteins. Translation of this fusion gene (or fusion cDNA) preferably results in a single polypeptide with functional properties derived from each of the original proteins. Recombinant fusion proteins are artificially made by recombinant DNA technology for use in biological research or therapy. Further details of the antigen-binding receptor of the present invention are described later in this specification. In the context of the present invention, a CAR (chimeric antigen receptor) is understood to be an antigen-binding receptor comprising an extracellular portion comprising an antigen-binding moiety fused by a spacer sequence to an anchor transmembrane domain which is itself fused to an intracellular signaling domain.
[0060] "Antigen-binding site" refers to the site of an antigen-binding molecule, i.e., one or more amino acid residues, that provides interaction with an antigen. For example, the antigen-binding site of an antibody contains amino acid residues from the complementarity determining regions (CDRs). A naturally occurring immunoglobulin molecule typically has two antigen-binding sites, while a Fab molecule typically has a single antigen-binding site.
[0061] The term "antigen-binding domain" refers to a portion of an antibody or antigen-binding receptor that comprises an area that specifically binds to and is complementary to part or all of an antigen. An antigen-binding domain may be provided, for example, by one or more immunoglobulin variable domains (also called variable regions). In particular, antigen-binding domains include immunoglobulin light chain variable domains (VL) and immunoglobulin heavy chain variable domains (VH).
[0062] As used herein, the term "antigenic determinant" is synonymous with "antigen" and "epitope" and refers to a site on a polypeptide macromolecule to which an antigen-binding moiety binds to form an antigen-binding moiety-antigen complex (e.g., a conformational configuration composed of a contiguous stretch of amino acids or a distinct region of non-contiguous amino acids). Useful antigenic determinants can be found, for example, on the surface of tumor cells, on the surface of virally infected cells, on the surface of other diseased cells, on the surface of immune cells, free in serum, and / or in the extracellular matrix (ECM). Unless otherwise specified, a protein referred to herein as an antigen refers to the native form of the protein from any vertebrate source, including mammals such as primates (e.g., humans) and rodents (e.g., mice and rats). In certain embodiments, the antigen is a human protein. When a particular protein is referred to herein, the term encompasses not only the "full-length," unprocessed protein, but also any form of the protein that results from processing within the cell. The term also encompasses naturally occurring protein variants, e.g., splice variants or allelic variants.
[0063] An "antibody comprising a variant Fc domain" according to the invention, i.e. a therapeutic antibody, may have one, two, three or more binding domains and may be monospecific, bispecific or multispecific. The antibody may be full-length from a single species, chimerized or humanized. In the case of an antibody with more than two antigen-binding domains, some of the binding domains may be identical and / or have the same specificity.
[0064] The term "ATD" as used herein refers to an "anchor transmembrane domain" that defines a polypeptide stretch that can be integrated into one or more cell membranes of a cell. The ATM can be fused to an extracellular and / or intracellular polypeptide domain, which is localized to the cell membrane. In the case of the antigen-binding receptor of the present invention, the ATM confers membrane attachment and localization of the antigen-binding receptor of the present invention. The antigen-binding receptor of the present invention comprises at least one ATM and an extracellular domain that comprises an antigen-binding portion. The ATM may also be fused to an intracellular signaling domain.
[0065] "Specific binding" means that the binding is selective for the antigen and can be distinguished from undesired or non-specific interactions. The ability of an antigen-binding moiety to bind to a specific antigenic determinant can be measured by either enzyme-linked immunosorbent assay (ELISA) or other techniques known to those skilled in the art, such as surface plasmon resonance (SPR) techniques (analyzed on a BIAcore instrument) (Liljeblad et al., Glyco J 17, 323-329 (2000)) and traditional binding assays (Heeley, Endocr Res 28, 217-229 (2002)). In one embodiment, the extent of binding of the antigen-binding moiety to an unrelated protein is less than about 10% of the binding of the antigen-binding moiety to the antigen, as measured, for example, by SPR. In certain embodiments, an antigen-binding portion that binds to an antigen, or an antigen-binding molecule comprising an antigen-binding portion, has a specific binding affinity of ≦1 μM, ≦100 nM, ≦10 nM, ≦1 nM, ≦0.1 nM, ≦0.01 nM, or ≦0.001 nM (e.g., 10 -8M or less, e.g. 10 -8 M~10 -13 M, for example, 10 -9 M~10 -13 Dissociation constant (K D ).
[0066] The term "CDR" as used herein relates to "complementarity determining region" as known in the art. CDRs are the parts of an immunoglobulin or antigen-binding receptor that determine the specificity of the molecule and contact a specific ligand. CDRs are the most variable parts of the molecule and contribute to the antigen-binding diversity of such molecules. In each V domain, there are three CDR regions CDR1, CDR2 and CDR3. CDR-H represents the CDR region of the variable heavy chain and CDR-L represents the CDR region of the variable light chain. VH means variable heavy chain and VL means variable light chain. The CDR regions of the Ig-derived regions can be determined as described in "Kabat" (Sequences of Proteins of Immunological Interest", 5th ed., NIH Publication no. 91-3242 USDepartment of Health and Human Services (1991); Chothia J. Mol. Biol. 196 (1987), 901-917) or "Chothia" (Nature 342 (1989), 877-883).
[0067] The term "CD3z" refers to the T cell surface glycoprotein CD3 zeta chain, also known as the "T cell receptor T3 zeta chain" and "CD247."
[0068] The term "chimeric antigen receptor" or "chimeric receptor" or "CAR" refers to an antigen-binding receptor composed of the extracellular portion of the antigen-binding moiety (e.g., a single-chain antibody domain) fused to an intracellular signaling / co-signaling domain (e.g., those of CD3z and CD28) by a spacer sequence.
[0069] The "class" of an antibody refers to the type of constant domain or constant region carried by its heavy chain. There are five major classes of antibodies: IgA, IgD, IgE, IgG, and IgM, and some of these can be further divided into subclasses (isotypes), e.g., IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2. In certain embodiments, the antibody is of the IgG1 isotype. In certain embodiments, the antibody is of the IgG1 isotype with P329G, L234A, and L235A mutations to reduce Fc region effector function. In other embodiments, the antibody is of the IgG2 isotype. In certain embodiments, the antibody is of the IgG4 isotype with S228P mutation in the hinge region to improve the stability of IgG4 antibodies. The heavy chain constant domains corresponding to the different classes of immunoglobulins are called α, δ, ε, γ, and μ, respectively. The light chain of an antibody can be assigned to one of two types, called kappa (κ) and lambda (λ), based on the amino acid sequence of its constant domain.
[0070] The term "constant region from human origin" or "human constant region" as used in this application refers to the constant heavy chain region of a human antibody of subclass IgG1, IgG2, IgG3 or IgG4, and / or the constant light chain kappa or lambda region. Such constant regions can be used in human or humanized antibodies and are well known in the art and described, for example, in Kabat, EA, et al., Sequences of Proteins of Immunological Interest, 5th ed., Public Health Service, National Institutes of Health, Bethesda, MD (1991) (see also, for example, Johnson, G., and Wu, TT, Nucleic Acids Res. 28 (2000) 214-218; Kabat, EA, et al., Proc. Natl. Acad. Sci. USA 72 (1975) 2785-2788). Unless otherwise specified herein, numbering of amino acid residues in the constant region is according to the EU numbering system (also called the Kabat EU index), as described in Kabat, E. A. et al., Sequences of Proteins of Immunological Interest, 5th ed., Public Health Service, National Institutes of Health, Bethesda, MD (1991), NIH Publication 91-3242.
[0071] By "crossover" Fab molecule (also called "Crossfab") is meant a Fab molecule in which the variable domains of the Fab heavy chain and the variable domains of the Fab light chain are exchanged (i.e. replaced by each other), i.e. the crossover Fab molecule comprises a peptide chain composed of the light chain variable domain VL and the heavy chain constant domain 1 CH1 (VL-CH1, in the N-terminal to C-terminal direction) and a peptide chain composed of the heavy chain variable domain VH and the light chain constant domain CL (VH-CL, in the N-terminal to C-terminal direction). For clarity, in this specification, in a crossover Fab molecule in which the variable domains of the Fab light chain and the variable domains of the Fab heavy chain are exchanged, the peptide chain comprising the heavy chain constant domain 1 CH1 is referred to as the "heavy chain" of the crossover Fab molecule.
[0072] As used herein, the term "CSD" refers to costimulatory signaling domain.
[0073] "Effector function" refers to the biological activities attributable to the Fc region of an antibody, which vary depending on the antibody isotype. Examples of antibody effector functions include: C1q binding and complement dependent cytotoxicity (CDC), Fc receptor binding, antibody-dependent cell-mediated cytotoxicity (ADCC), phagocytosis, down-regulation of cell surface receptors (e.g., B cell receptor), and B cell activation.
[0074] As used herein, the terms "engineer, engineered, engineering" are intended to include any manipulation of the peptide backbone or post-translational modification of a naturally occurring or recombinant polypeptide or fragment thereof. Engineering includes modification of the amino acid sequence, modification of the glycosylation pattern or modification of the side groups of individual amino acids, as well as combinations of these techniques.
[0075] The term "expression cassette" refers to a recombinantly or synthetically produced polynucleotide having a set of specific nucleic acid elements that allow transcription of a specific nucleic acid in a target cell. A recombinant expression cassette can be incorporated into a plasmid, chromosome, mitochondrial DNA, plastid DNA, virus, or nucleic acid fragment. Typically, the recombinant expression cassette portion of an expression vector includes, among other sequences, a nucleic acid sequence to be transcribed and a promoter. In a particular embodiment, an expression cassette of the invention comprises a polynucleotide sequence encoding a bispecific antigen-binding molecule of the invention or a fragment thereof.
[0076] A "Fab molecule" refers to a protein consisting of the VH and CH1 domains of an immunoglobulin heavy chain (a "Fab heavy chain") and the VL and CL domains of a light chain (a "Fab light chain").
[0077] The term "Fc domain" or "Fc region" is used herein to define a C-terminal region of an immunoglobulin heavy chain that contains at least a portion of the constant region. This term includes native sequence Fc regions and variant Fc regions. Although the boundaries of the Fc region of an IgG heavy chain may vary slightly, the human IgG heavy chain Fc region is usually defined to extend from Cys226 or from Pro230 to the carboxy-terminus of the heavy chain. However, antibodies produced by a host cell may undergo post-translational truncation of one or more, particularly one or two, amino acids from the C-terminus of the heavy chain. Thus, upon expression of a particular nucleic acid molecule encoding a full-length heavy chain, an antibody produced by a host cell may contain a full-length heavy chain or a truncated variant of the full-length heavy chain (also referred to herein as a "truncated variant heavy chain"). This is the case when the last two C-terminal amino acids of the heavy chain are glycine (G446) and lysine (K447, numbering according to the Kabat EU index). Thus, the C-terminal lysine (Lys447) or the C-terminal glycine (Gly446) and lysine (K447) of the Fc region may or may not be present. The amino acid sequence of a heavy chain comprising an Fc domain (or a subunit of an Fc domain as defined herein) is shown herein without the C-terminal glycine-lysine dipeptide, unless otherwise indicated. In one embodiment of the invention, a heavy chain comprising a subunit of an Fc domain as defined herein comprises an additional C-terminal glycine-lysine dipeptide (G446 and K447, numbered according to the EU index of Kabat). In one embodiment of the invention, a heavy chain comprising a subunit of an Fc domain as defined herein comprises an additional C-terminal glycine residue (G446, numbered according to the EU index of Kabat). The compositions of the invention, such as the pharmaceutical compositions described herein, comprise a population of antigen-binding molecules of the invention. The population of antigen-binding molecules may comprise molecules having full-length heavy chains and molecules having truncated variant heavy chains.The population of antigen-binding molecules may be composed of a mixture of molecules with full-length heavy chains and molecules with truncated variant heavy chains, where at least 50%, at least 60%, at least 70%, at least 80% or at least 90% of the antigen-binding molecules have truncated variant heavy chains. In one embodiment of the invention, a composition comprising a population of antigen-binding molecules of the invention comprises antigen-binding molecules comprising a heavy chain comprising a subunit of an Fc domain as defined herein with an additional C-terminal glycine-lysine dipeptide (G446 and K447, numbering according to the EU index of Kabat). In one embodiment of the invention, a composition comprising a population of antigen-binding molecules of the invention comprises immunostimulatory Fc domain-binding molecules comprising a heavy chain comprising a subunit of an Fc domain as defined herein with an additional C-terminal glycine residue (G446, numbering according to the EU index of Kabat). In one embodiment of the invention, such compositions comprise a population of antigen-binding molecules comprised of molecules comprising a heavy chain comprising a subunit of an Fc domain as specified herein; molecules comprising a heavy chain comprising a subunit of an Fc domain as specified herein with an additional C-terminal glycine residue (G446, numbering according to the EU index of Kabat); and molecules comprising a heavy chain comprising a subunit of an Fc domain as specified herein with an additional C-terminal glycine-lysine dipeptide (G446 and K447, numbering according to the EU index of Kabat). Unless otherwise specified herein, the numbering of amino acid residues in an Fc region or constant region is according to the EU numbering system, also referred to as the EU index, as described in Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD, 1991 (see also supra).As used herein, a "subunit" of an Fc domain refers to one of the two polypeptides that form a dimeric Fc domain, i.e., a polypeptide that comprises the C-terminal constant region of an immunoglobulin heavy chain capable of stable self-association. For example, a subunit of an IgG Fc domain comprises the IgG CH2 and IgG CH3 constant domains.
[0078] "Framework" or "FR" refers to variable domain residues other than the complementarity determining regions (CDRs). The FR of a variable domain generally consists of four FR domains: FR1, FR2, FR3 and FR4. Thus, the CDR and FR sequences generally appear in the following order in a VH (or VL): FR1-CDR-H1 (CDR-L1)-FR2-CDR-H2 (CDR-L2)-FR3-CDR-H3 (CDR-L3)-FR4.
[0079] The terms "full length antibody," "intact antibody," and "whole antibody" are used interchangeably herein and refer to an antibody having a structure substantially similar to a native antibody structure or an antibody having a heavy chain that includes an Fc region as defined herein.
[0080] By "fused" it is meant that the components (eg, a Fab and a transmembrane domain) are linked together by a peptide bond, either directly or via one or more peptide linkers.
[0081] The terms "host cell," "host cell line," and "host cell culture" are used interchangeably and refer to cells into which exogenous nucleic acid has been introduced, including the progeny of such cells. Host cells include "transformants" and "transformed cells," which include the primary transformed cell and its progeny, regardless of the number of passages. The progeny may not be completely identical in nucleic acid content to the parent cell and may contain mutations. Mutant progeny that have the same function or biological activity as screened or selected for in the originally transformed cell are included herein.
[0082] A "human antibody" is an antibody having an amino acid sequence that corresponds to that of an antibody produced by a human or a human cell, or an antibody derived from a non-human source that utilizes a human antibody repertoire or other human antibody coding sequence. This definition of a human antibody specifically excludes humanized antibodies, which contain non-human antigen-binding residues.
[0083] A "human consensus framework" is a framework that represents the most commonly occurring amino acid residues in a selection of human immunoglobulin VL or VH framework sequences. Typically, the selection of human immunoglobulin VL or VH sequences is derived from a subgroup of variable domain sequences. Typically, the subgroup of sequences is a subgroup as in Kabat et al., Sequences of Proteins of Immunological Interest, 5th ed., NIH Publication 91-3242, Bethesda MD (1991), vols. 1-3. In one embodiment, for VL, the subgroup is subgroup kappa I as in Kabat et al., supra. In one embodiment, for VH, the subgroup is subgroup III as in Kabat et al., supra.
[0084] A "humanized" antibody (e.g., a humanized scFv fragment) refers to a chimeric antibody that comprises amino acid residues of non-human CDRs and amino acid residues of human FRs. In certain aspects, a humanized antibody comprises substantially all of at least one, and typically two, variable domains, with all or substantially all of the CDRs corresponding to the CDRs of a non-human antibody and all or substantially all of the FRs corresponding to the FRs of a human antibody. A humanized antibody may optionally comprise at least a portion of an antibody constant region derived from a human antibody. A "humanized form" of an antibody, e.g., a non-human antibody, refers to an antibody that has been subjected to humanization.
[0085] As used herein, the term "hypervariable region" or "HVR" refers to each region of an antibody variable domain which is hypervariable in sequence and which determines antigen-binding specificity, e.g., the "complementarity determining regions" (CDRs).
[0086] Generally, an antibody comprises six CDRs, three in the VH (CDR-H1, CDR-H2, CDR-H3) and three in the VL (CDR-L1, CDR-L2, CDR-L3). Exemplary CDRs herein include: (a) hypervariable loops located at amino acid residues 26-32 (L1), 50-52 (L2), 91-96 (L3), 26-32 (H1), 53-55 (H2), and 96-101 (H3) (Chothia and Lesk, J. Mol. Biol. 196:901-917 (1987)); (b) CDRs located at amino acid residues 24-34 (L1), 50-56 (L2), 89-97 (L3), 31-35b (H1), 50-65 (H2), and 95-102 (H3) (Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD (1991)); and (c) Antigen contact sites located at amino acid residues 27c-36 (L1), 46-55 (L2), 89-96 (L3), 30-35b (H1), 47-58 (H2), and 93-101 (H3) (MacCallum et al. J. Mol. Biol. 262:732-745 (1996)).
[0087] Unless otherwise specified, CDRs are determined according to Kabat et al., supra. Those skilled in the art will appreciate that the nomenclature of CDRs may also be determined according to Chothia, supra, McCallum, supra, or any other scientifically accepted nomenclature.
[0088] An "immunoconjugate" is an antibody conjugated to one or more heterologous molecules, including, but not limited to, a cytotoxic agent.
[0089] An "individual" or "subject" is a mammal. Mammals include, but are not limited to, domestic animals (e.g., cows, sheep, cats, dogs, horses), primates (e.g., humans and non-human primates such as monkeys), rabbits, and rodents (e.g., mice and rats). In certain aspects, an individual or subject is human.
[0090] An "isolated" antibody is one that has been separated from a component of its natural environment. In some embodiments, the antibody is purified to greater than 95% or 99% purity, for example, as determined by electrophoretic (e.g., SDS-PAGE, isoelectric focusing (IEF), capillary electrophoresis) or chromatographic (e.g., ion exchange or reverse phase HPLC) methods. For a review of methods for assessing antibody purity, see, e.g., Flatman et al., J. Chromatogr. B 848:79-87 (2007).
[0091] The term "immunoglobulin molecule" refers to a protein having the structure of a naturally occurring antibody. For example, immunoglobulins of the IgG class are heterotetrameric glycoproteins of about 150,000 daltons composed of two light chains and two heavy chains that are disulfide-bonded. From the N-terminus to the C-terminus, each heavy chain has a variable domain (VH), also called the variable heavy domain or heavy chain variable region, followed by three constant domains (CH1, CH2, and CH3), also called the heavy chain constant region. Similarly, from the N-terminus to the C-terminus, each light chain has a variable domain (VL), also called the variable light domain or light chain variable region, followed by a constant light domain (CL), also called the light chain constant region. The heavy chains of immunoglobulins can be assigned to one of five types, called α (IgA), δ (IgD), ε (IgE), γ (IgG) or μ (IgM), some of which can be further classified into subtypes, e.g., γ1 (IgG1), γ2 (IgG2), γ3 (IgG3), γ4 (IgG4), α1 (IgA1) and α2 (IgA2). The light chains of immunoglobulins may be assigned to one of two types, called kappa (κ) and lambda (λ), based on the amino acid sequence of their constant domain. Immunoglobulins essentially consist of two Fab molecules linked via an immunoglobulin hinge region and an Fc domain.
[0092] An "isolated nucleic acid" molecule or polynucleotide is a DNA or RNA that is a nucleic acid molecule that has been removed from its natural environment. For example, a recombinant polynucleotide encoding a polypeptide contained in a vector is considered isolated for the purposes of the present invention. Further examples of isolated polynucleotides include recombinant polynucleotides maintained in heterologous host cells or purified (partially or substantially) polynucleotides in solution. Isolated polynucleotides include polynucleotide molecules contained in cells that normally contain the polynucleotide molecule, but the polynucleotide molecule is present extrachromosomally or at a chromosomal location that differs from its natural chromosomal location. Isolated RNA molecules include in vivo or in vitro RNA transcripts of the present invention, as well as positive and negative stranded forms, and double-stranded forms. Additionally, isolated polynucleotides or nucleic acids of the present invention include such molecules produced synthetically. In addition, the polynucleotide or nucleic acid may be or may include a regulatory element, such as a promoter, a ribosome binding site, or a transcription terminator.
[0093] A nucleic acid or polynucleotide having a nucleotide sequence that is, for example, at least 95% "identical" to a reference nucleotide sequence of the present invention means that the nucleotide sequence of the polynucleotide is identical to the reference sequence, except that the nucleotide sequence of the polynucleotide may contain up to 5 point mutations per 100 nucleotides of the reference nucleotide sequence. In other words, to obtain a polynucleotide having a nucleotide sequence that is at least 95% identical to the reference nucleotide sequence, up to 5% of the nucleotides in the reference sequence may be deleted or replaced with another nucleotide, or up to 5% of the number of nucleotides in the reference sequence may be inserted into the reference sequence. Such modifications of the reference sequence may occur at the 5' or 3' terminal position of the reference nucleotide sequence, or at any position between these terminal positions, either individually interspersed among residues in the reference sequence or interspersed in one or more contiguous groups in the reference sequence. As a practical matter, whether any particular polynucleotide sequence is at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to a nucleotide sequence of the present invention can be conventionally determined using known computer programs such as those discussed below for polypeptides (e.g., ALIGN-2).
[0094] An "isolated" polypeptide or variant or derivative thereof refers to a polypeptide that is not in its natural environment. No particular level of purification is required. For example, an isolated polypeptide can be removed from its native or natural environment. Recombinantly produced polypeptides and proteins expressed in host cells are considered isolated for purposes of the present invention, as are native or recombinant polypeptides that have been separated, fractionated, or partially or substantially purified by any suitable technique.
[0095] A "modification that promotes the association of a first and a second subunit of an Fc domain" is a peptide backbone manipulation or a post-translational modification of an Fc domain subunit that reduces or prevents the association of a polypeptide comprising the Fc domain subunit with an identical polypeptide to form homodimers. As used herein, a modification that promotes association particularly includes a separate modification made to each of the two Fc domain subunits (i.e., the first and second subunits of the Fc domain) that are desired to be associated, which are complementary to each other to promote the association of the two Fc domain subunits. For example, a modification that promotes association can change the structure or charge of one or both of the Fc domain subunits to make their association sterically or electrostatically favorable, respectively. Thus, (hetero)dimerization occurs between a polypeptide comprising a first Fc domain subunit and a polypeptide comprising a second Fc domain subunit, which may not be identical in the sense that the further components (e.g., antigen-binding moieties) fused to each of the subunits are not the same. In some embodiments, a modification that promotes association includes an amino acid mutation, specifically an amino acid substitution, within the Fc domain. In a particular embodiment, the association-promoting modifications comprise separate amino acid mutations, specifically amino acid substitutions, in each of the two subunits of the Fc domain.
[0096] The term "monoclonal antibody" as used herein refers to an antibody obtained from a population of substantially homogeneous antibodies. That is, the individual antibodies that make up the population are identical and / or bind the same epitope, except for possible variant antibodies that are generally present in small amounts, including, for example, naturally occurring mutations or mutations that arise during the production of the monoclonal antibody preparation. In contrast to polyclonal antibody preparations, which typically contain different antibodies against different determinants (epitopes), each monoclonal antibody of a monoclonal antibody preparation is directed against a single determinant on the antigen. Thus, the modifier "monoclonal" indicates the character of the antibody as being obtained from a population of substantially homogeneous antibodies and should not be interpreted as requiring production of the antibody by any particular method. For example, monoclonal antibodies according to the invention can be produced by a variety of techniques, including, but not limited to, hybridoma methods, recombinant DNA methods, phage display methods, and methods utilizing transgenic animals containing all or part of the human immunoglobulin loci, such methods, as well as other exemplary methods for producing monoclonal antibodies, are described herein.
[0097] "Naked antibody" refers to an antibody that is not conjugated to a heterologous moiety (e.g., a cytotoxic moiety) or radiolabel. The naked antibody may be present in a pharmaceutical composition.
[0098] "Native antibody" refers to naturally occurring immunoglobulin molecules with various structures. For example, a native IgG antibody is a heterotetrameric glycoprotein of about 150,000 daltons composed of two identical light chains and two identical heavy chains that are disulfide-bonded. From the N-terminus to the C-terminus, each heavy chain has a variable domain (VH), also called the variable heavy domain or heavy chain variable region, followed by three constant heavy chain domains (CH1, CH2, and CH3). Similarly, from the N-terminus to the C-terminus, each light chain has a variable domain (VL), also called the variable light domain or light chain variable region, followed by a constant light chain (CL) domain.
[0099] "Percent (%) amino acid sequence identity" to a reference polypeptide sequence is defined as the percentage of amino acid residues in a candidate sequence that are identical to those in the reference polypeptide sequence, after aligning the sequences and introducing gaps if necessary to achieve the maximum percent sequence identity, without considering any conservative substitutions as part of the sequence identity for alignment. Alignment to determine percent amino acid sequence identity can be accomplished in a variety of ways within the skill of the art, for example, using publicly available computer software such as BLAST, BLAST-2, Clustal W, Megalign (DNASTAR) software or the FASTA program package. Those skilled in the art can determine appropriate parameters for aligning sequences, including any algorithms required to obtain maximum alignment over the entire length of the sequences being compared. Alternatively, percent identity values can be generated using the sequence comparison computer program ALIGN-2. The ALIGN-2 sequence comparison computer program was written by Genentech, Inc. and the source code is on file in the user documentation of the U.S. Copyright Office, Washington DC, 20559, registered under U.S. Copyright Registration No. TXU510087, and described in WO 2001 / 007611.
[0100] Unless otherwise indicated, for purposes herein, percent amino acid sequence identity values are generated using the ggsearch program of the FASTA package version 36.3.8c, or the BLOSUM50 comparison matrix followed by the FASTA program package described by WR Pearson and DJ Lipman (1988), "Improved Tools for Biological Sequence Analysis", PNAS 85:2444-2448; WR Pearson (1996) "Effective protein sequence comparison" Meth. Enzymol. 266:227-258; and Pearson et.al. (1997) Genomics 46:24-36, and is publicly available at www.fasta.bioch.virginia.edu / fasta_www2 / fasta_down.shtml or http: / / www.ebi.ac.uk / Tools / sss / fasta. Alternatively, sequences can be compared using the public server accessible at fasta.bioch.virginia.edu / fasta_www2 / index.cgi using the ggsearch (global protein:protein) program with default options (BLOSUM50; open:-10; ext:-2; Ktup=2) to ensure global, not local, alignment. The percent amino acid identity is indicated in the output alignment header. The term "nucleic acid molecule" refers to the sequence of bases, including purine and pyrimidine bases, that constitute a polynucleotide, which bases represent the primary structure of the nucleic acid molecule. Here, the term nucleic acid molecule includes DNA, cDNA, genomic DNA, RNA, synthetic forms of DNA, and mixed polymers containing two or more of these molecules. The term nucleic acid molecule also includes both sense and antisense strands. Additionally, the nucleic acid molecules described herein may contain non-natural or derivatized nucleotide bases, as will be readily appreciated by those of skill in the art.
[0101] The term "package insert" is used to refer to instructions typically included in commercial packaging of a therapeutic product that contain information about the indications, usage, dosage, administration, concomitant therapy, contraindications and / or warnings for the use of such therapeutic product.
[0102] The term "pharmaceutical composition" refers to a formulation in a form that effectively utilizes the biological activity of the active ingredient contained therein and does not contain additional components that are unacceptably toxic to the subject to which the formulation is administered. A pharmaceutical composition further comprises one or more pharma- ceutically acceptable carriers.
[0103] "Pharmaceutically acceptable carrier" refers to an ingredient in a pharmaceutical composition, other than an active ingredient, that is not toxic to a subject. Pharmaceutically acceptable carriers include, but are not limited to, buffers, additives, stabilizers, or preservatives.
[0104] As used herein, the term "polypeptide" refers to a molecule consisting of monomers (amino acids) linked in a linear chain by amide bonds (also known as peptide bonds).
[0105] The term "polypeptide" refers to any chain of two or more amino acids and does not refer to a specific length of the product. Thus, peptides, dipeptides, tripeptides, oligopeptides, "proteins," "amino acid chains," or any other terms referring to a chain of two or more amino acids are included within the definition of "polypeptide," and the term "polypeptide" may be used in place of or interchangeably with these terms. The term "polypeptide" is also intended to refer to products of post-expression modifications of the polypeptide, including, but not limited to, glycosylation, acetylation, phosphorylation, amidation, derivatization with known protecting / blocking groups, proteolytic cleavage, or modification with non-naturally occurring amino acids. Polypeptides may be obtained from natural biological sources or produced by recombinant technology, but are not necessarily translated from a designated nucleic acid sequence. Polypeptides may be generated by any method, including chemical synthesis. Polypeptides of the invention may be of a size of about 3 or more, 5 or more, 10 or more, 20 or more, 25 or more, 50 or more, 75 or more, 100 or more, 200 or more, 500 or more, 1000 or more, or 2000 or more amino acids. Polypeptides may, but do not necessarily, have a clearly defined three-dimensional structure: Polypeptides that have a clearly defined three-dimensional structure are said to be "folded" and polypeptides that do not have a clearly defined three-dimensional structure and can adopt a number of different conformations are said to be "unfolded."
[0106] The term "polynucleotide" refers to an isolated nucleic acid molecule or construct, such as messenger RNA (mRNA), RNA from a virus, or plasmid DNA (pDNA). A polynucleotide may contain conventional phosphodiester bonds or unconventional bonds (e.g., amide bonds as found in peptide nucleic acids (PNA)). The term nucleic acid molecule refers to any one or more nucleic acid segments, such as DNA or RNA fragments, present in a polynucleotide.
[0107] "Reduced binding", e.g., reduced binding to Fc receptors, refers to a reduced affinity for the respective interaction, e.g., as measured by SPR. For clarity, the term also includes a reduction in affinity to zero (or below the detection limit of the analytical method), i.e., a complete loss of interaction. Conversely, "increased binding" refers to an increase in binding affinity for the respective interaction.
[0108] The term "regulatory sequence" refers to DNA sequences necessary to effect expression of a ligated coding sequence. The nature of such regulatory sequences varies depending on the host organism. In prokaryotes, regulatory sequences usually include a promoter, a ribosome binding site, and a terminator. In eukaryotes, regulatory sequences usually include a promoter, a terminator, and optionally an enhancer, transactivator, or transcription factor. The term "regulatory sequence" is intended to include, at a minimum, all components necessary for expression, and may also include additional advantageous components.
[0109] As used herein, the term "single chain" refers to a molecule that comprises amino acid monomers linearly linked by peptide bonds. In certain embodiments, one of the antigen-binding moieties is a single-chain Fab molecule, i.e., a Fab molecule in which a Fab light chain and a Fab heavy chain are linked by a peptide linker to form a single peptide chain. In certain such embodiments, the C-terminus of the Fab light chain is linked to the N-terminus of the Fab heavy chain in the single-chain Fab molecule. In a preferred embodiment, the antigen-binding moiety is an scFv fragment.
[0110] As used herein, the term "SSD" refers to a "costimulatory signaling domain."
[0111] As used herein, "treatment" (and grammatical variations thereof, such as "treat" or "treating") refers to clinical intervention in an attempt to alter the natural course of a disease in the individual being treated, and may be performed prophylactically or during the course of clinical pathology. Desirable effects of treatment include, but are not limited to, preventing the onset or recurrence of disease, alleviating symptoms, diminishing direct or indirect pathological consequences of the disease, preventing metastasis, slowing the rate of disease progression, ameliorating or alleviating the disease state, and remission or improved prognosis. In some aspects, the antibodies of the invention are used to delay the onset of disease or to slow the progression of the disease.
[0112] As used herein, "T cell activation" refers to one or more cellular responses selected from proliferation, differentiation, cytokine secretion, release of cytotoxic effector molecules, cytotoxic activity, and expression of activation markers of T lymphocytes, particularly cytotoxic T lymphocytes. The immunoactivating Fc domain antigen binding molecules of the present invention can induce T cell activation. Suitable assays for measuring T cell activation are known in the art and described herein.
[0113] A "therapeutically effective amount" of an agent, e.g., a pharmaceutical composition, refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired therapeutic or prophylactic result. A therapeutically effective amount of an agent, for example, eliminates, reduces, delays, minimizes, or prevents the side effects of a disease.
[0114] The term "valency" as used herein indicates that a particular number of antigen-binding sites are present within an antigen-binding molecule. Thus, the term "monovalent binding to an antigen" indicates that one (and not more than one) antigen-binding site specific for that antigen is present within the antigen-binding molecule.
[0115] The term "variable region" or "variable domain" refers to the domain of an antibody heavy or light chain that is involved in binding the antibody to an antigen. The heavy and light chain variable domains (VH and VL, respectively) of natural antibodies generally have a similar structure, and each domain contains four conserved framework regions (FR) and three complementarity determining regions (CDR). (See, for example, Kindt et al. Kuby Immunology, 6 th ed., W. H. Freeman and Co., p. 91 (2007). A single VH or VL domain may be sufficient to confer antigen-binding specificity. Moreover, antibodies that bind to a specific antigen may be isolated using the VH or VL domain from an antibody that binds the antigen and screening a library of complementary VL or VH domains, respectively. See, e.g., Portolano et al., J. Immunol. 150:880-887 (1993); Clarkson et al., Nature 352:624-628 (1991).
[0116] The term "vector" as used herein refers to a nucleic acid molecule capable of propagating another nucleic acid to which it is linked. The term includes vectors as self-replicating nucleic acid structures and vectors that integrate into the genome of a host cell into which they are introduced. Certain vectors are capable of directing the expression of a nucleic acid to which they are operably linked. Such vectors are referred to herein as "expression vectors."
[0117] Antigen-binding receptor capable of specifically binding to a mutated Fc domain The present invention relates to an antigen-binding receptor capable of specifically binding to a mutated Fc domain of an antibody, for example a therapeutic antibody targeting cancer cells. In a preferred embodiment, the present invention relates to an antigen-binding receptor capable of specifically binding to a mutated Fc domain comprising the amino acid mutation P329G according to EU numbering. The antigen-binding receptor of the present invention comprises an extracellular domain comprising at least one antigen-binding portion capable of specifically binding to the mutated Fc domain but not to the parent non-mutated Fc domain. In a preferred embodiment, the antigen-binding portion of the antigen-binding receptor is a humanized or human antigen-binding portion, for example a humanized or human scFv. In one preferred embodiment, the amino acid mutation is P329G and the specific binding to the mutated Fc domain comprising the amino acid mutation P329G according to EU numbering is measured by SPR at 25°C.
[0118] The invention further relates to the transduction of T cells, such as CD8+ T cells, CD4+ T cells, CD3+ T cells, γδ T cells or natural killer (NK) T cells, preferably CD8+ T cells, with the antigen binding receptors described herein and their targeted recruitment, for example to tumors, by antibody molecules comprising a mutated Fc domain (e.g. an Fc domain comprising the amino acid mutation P329G according to EU numbering), e.g. therapeutic antibodies. In one embodiment, the antibody is capable of specifically binding to a tumor-specific antigen naturally present on the surface of tumor cells.
[0119] As shown in the appended examples, as a proof of concept, an antigen-binding receptor was constructed comprising an anchor transmembrane domain of the invention and a humanized extracellular domain (SEQ ID NO: 7, encoded by the DNA sequence shown in SEQ ID NO: 20), which is capable of specifically binding to a therapeutic antibody comprising a P329G mutation (represented by an anti-CD20 antibody comprising a heavy chain of SEQ ID NO: 102 and a light chain of SEQ ID NO: 103). Transduced T cells (Jurkat NFAT T cells) expressing a VH3VL1-CD8ATD-CD137CSD-CD3zSSD fusion protein (SEQ ID NO: 7, encoded by the DNA sequence shown in SEQ ID NO: 20) could be strongly activated by co-incubation of anti-CD20 antibodies comprising a P329G mutation in the Fc domain with CD20-positive tumor cells.
[0120] Treatment of tumor cells with a combination of an antibody against a tumor antigen containing the P329G mutation and transduced T cells expressing a VH3VL1-CD8ATD-CD137CSD-CD3zSSD fusion protein (SEQ ID NO: 7, encoded by the DNA sequence shown in SEQ ID NO: 20) surprisingly results in stronger activation of the transduced T cells compared to transduced T cells expressing VL1VH3-CD8ATD-CD137CSD-CD3zSSD (SEQ ID NO: 31, encoded by the DNA sequence shown in SEQ ID NO: 33).
[0121] As a further proof of concept, antigen binding receptors according to the invention (SEQ ID NOs: 129 and 132, respectively) and antigen binding receptors encoded by the DNA sequences shown in SEQ ID NOs: 130 and 133, respectively, were constructed. Expression and functionality of the antigen binding receptors was demonstrated in T cell lines and in T cells from human donors. Both receptors comprise a humanized antigen binding portion in the VHVL (i.e. VH3VL1) conformation according to the invention.
[0122] In the VH3VL1-CD8ATD-CD137CSD-CD3zSSD fusion protein, the VH domain (VH3) is fused at its C-terminus to the N-terminus of the VL domain (VL1) via a peptide linker to form an scFv. The scFv is fused at its C-terminus (C-terminus of the VL domain) to an anchor transmembrane domain (ATD) via a peptide linker. Meanwhile, in the VL1VH3-CD8ATD-CD137CSD-CD3zSSD fusion protein, the VL domain (VL1) is fused at its C-terminus to the N-terminus of the VH domain (VH3) via a peptide linker to form an scFv. The scFv is fused at its C-terminus (C-terminus of the VH domain) to an anchor transmembrane domain (ATD) via a peptide linker. Without wishing to be bound by theory, the observation that the VH3VL1-CD8ATD-CD137CSD-CD3zSSD fusion protein results in stronger activation of transduced T cells compared to VL1VH3-CD28ATD-CD137CSD-CD3zSSD suggests that the fusion of the VL domain to the anchor domain (via a peptide linker) results in a more potent antigen-binding receptor, which is unexpected and surprising.
[0123] The combination of VH domain VH3 and VL domain VL1 (both identified by the inventors) is particularly preferred because these variable domains are humanized antibody domains. Without being bound by theory, humanized antibody domains are preferred because fewer side effects (e.g., less formation of anti-drug antibodies (ADA)) can be expected when antigen-binding moieties comprising such humanized antibody domains are applied to human patients. However, humanization can result in loss of binding of antigen-binding moieties (e.g., those derived from non-human sources). As shown in the appended examples, the humanized VH3 and VL1 domains retain binding to Fc domains comprising the amino acid mutation P329G according to EU numbering. This result is unexpected, as shown, for example, by the inability of other humanized VH and VL domains to retain comparable binding to Fc domains comprising the amino acid mutation P329G according to EU numbering.
[0124] Thus, in one preferred embodiment of the invention there is provided an antigen-binding receptor comprising a humanized antigen-binding portion capable of specifically binding to an Fc domain comprising the amino acid mutation P329G according to EU numbering. The concept of the invention and its components (humanized antigen-binding receptor and therapeutic antibody) are described in further detail herein below.
[0125] According to the present invention, pairing of a tumor-specific antibody, i.e. a therapeutic antibody, comprising a mutated Fc domain (e.g. comprising the amino acid mutation P329G according to EU numbering) with a T cell transfected with an antigen-binding receptor comprising / consisting of an extracellular domain comprising an antigen-binding site capable of specifically binding to the mutated Fc domain results in specific activation of the T cell and subsequent lysis of the tumor cell. This approach has a major safety advantage over conventional T cell-based approaches, since in the absence of an antibody comprising a mutated Fc domain, the T cell is inactive. Thus, the present invention provides a versatile therapeutic platform, in which an IgG type antibody is used to mark or label tumor cells as a T cell inducer, and the transduced T cells are specifically targeted to tumor cells by providing specificity for the mutated Fc domain of the IgG type antibody. After binding to the mutated Fc domain of the antibody on the surface of the tumor cell, the transduced T cells described herein are activated and the tumor cell is subsequently lysed. This platform is flexible and specific by allowing the use of diverse (existing or newly developed) targeting antibodies or the co-administration of multiple antibodies with different antigen specificities but containing the same mutation in the Fc domain (such as the P329G mutation). The degree of T cell activation can be further tuned by adjusting the dosage of the co-administered therapeutic antibody or by switching to a different antibody specificity or format. The transduced T cells according to the invention are inactive even without the co-administration of a targeting antibody containing a mutated Fc domain, since the mutations to the Fc domain described herein do not occur in native or non-mutated immunoglobulins. Thus, in one embodiment, the mutated Fc domain does not naturally occur in (human) immunoglobulins.
[0126] Thus, the present invention relates to an antigen-binding receptor comprising an extracellular domain comprising at least one antigen-binding moiety capable of specifically binding to a mutated Fc domain, wherein the at least one antigen-binding moiety is incapable of specifically binding to the parent non-mutated Fc domain. Since effector functions, as detailed herein, can lead to serious side effects of antibody-based tumor therapy, it is particularly desirable to use therapeutic antibodies with reduced effector functions in cancer therapy.
[0127] In the context of the present invention, an antigen-binding receptor comprises an extracellular domain that is not naturally present in or on a T cell. Thus, the antigen-binding receptor can confer tailored binding specificity to a cell expressing the antigen-binding receptor according to the present invention. A cell, e.g., a T cell, transduced with one or more antigen-binding receptors of the present invention becomes capable of specifically binding to a mutated Fc domain, but not to a non-mutated parent Fc domain. The specificity is provided by the antigen-binding portion of the extracellular domain of the antigen-binding receptor. In the context of the present invention, an antigen-binding portion capable of specifically binding to a mutated Fc domain, as described herein, binds / interacts with the mutated Fc domain, but not with the non-mutated parent Fc domain.
[0128] antigen binding part In an exemplary embodiment of the present invention, as a proof of concept, a humanized antigen-binding receptor capable of specifically binding to a mutant Fc domain comprising the amino acid mutation P329G and an effector cell expressing the antigen-binding receptor are provided. The P329G mutation reduces Fcγ receptor binding and the associated effector function. Thus, the mutant Fc domain comprising the P329G mutation binds to Fcγ receptors with reduced or abolished affinity compared to the non-mutated Fc domain.
[0129] In one embodiment, the antigen-binding portion is capable of specifically binding to a mutated Fc domain composed of a first subunit and a second subunit capable of stable association. In one embodiment, the Fc domain is an IgG, specifically an IgG1 or IgG4 Fc domain. In one embodiment, the Fc domain is a human Fc domain. In one embodiment, the mutated Fc domain exhibits reduced binding affinity to Fc receptors and / or reduced effector function compared to a natural IgG1 Fc domain. In one embodiment, the Fc domain comprises one or more amino acid mutations that reduce binding to Fc receptors and / or effector function.
[0130] In a preferred embodiment, the mutated Fc domain comprises a P329G mutation and thus binds to Fcγ receptors with reduced or abolished affinity compared to the non-mutated Fc domain.
[0131] In one embodiment, the antigen binding receptor comprises an extracellular domain that comprises an antigen binding portion. In one embodiment, the antigen binding portion is capable of specifically binding to an Fc domain that comprises the amino acid mutation P329G according to EU numbering.
[0132] In one embodiment, the antigen binding portion comprises: (a) the heavy chain complementarity determining region (CDR H) 1 amino acid sequence of RYWMN (SEQ ID NO: 1); (b) the CDR H2 amino acid sequence of EITPDSSTINYAPSLKG (SEQ ID NO: 2) or EITPDSSTINYTPSLKG (SEQ ID NO: 40); and (c) CDR H3 amino acid sequence of PYDYGAWFAS (SEQ ID NO:3) The antibody comprises a heavy chain variable domain (VH) comprising at least one of:
[0133] In one embodiment, the antigen binding portion comprises: (d) the light chain (CDR L) 1 amino acid sequence of RSSTGAVTTSNYAN (SEQ ID NO: 4); (e) the CDR L2 amino acid sequence of GTNKRAP (SEQ ID NO:5); and (f) CDR L3 amino acid sequence of ALWYSNHWV (SEQ ID NO: 6) The present invention further comprises a light chain variable domain (VL) comprising at least one of:
[0134] In a preferred embodiment, the antigen-binding portion comprises: (a) the heavy chain complementarity determining region (CDR H) 1 amino acid sequence of RYWMN (SEQ ID NO: 1); (b) the CDR H2 amino acid sequence of EITPDSSTINYAPSLKG (SEQ ID NO: 2) or EITPDSSTINYTPSLKG (SEQ ID NO: 40); (c) CDR H3 amino acid sequence of PYDYGAWFAS (SEQ ID NO:3); A heavy chain variable domain (VH) comprising: (d) the light chain (CDR L) 1 amino acid sequence of RSSTGAVTTSNYAN (SEQ ID NO: 4); (e) the CDR L2 amino acid sequence of GTNKRAP (SEQ ID NO:5); and (f) CDR L3 amino acid sequence of ALWYSNHWV (SEQ ID NO: 6) The light chain variable domain (VL) comprises:
[0135] In one particular embodiment, the antigen-binding portion comprises: (a) the heavy chain complementarity determining region (CDR H) 1 amino acid sequence of RYWMN (SEQ ID NO: 1); (b) the CDR H2 amino acid sequence of EITPDSSTINYAPSLKG (SEQ ID NO: 2); (c) CDR H3 amino acid sequence of PYDYGAWFAS (SEQ ID NO:3); A heavy chain variable domain (VH) comprising: (d) the light chain (CDR L) 1 amino acid sequence of RSSTGAVTTSNYAN (SEQ ID NO: 4); (e) the CDR L2 amino acid sequence of GTNKRAP (SEQ ID NO:5); and (f) CDR L3 amino acid sequence of ALWYSNHWV (SEQ ID NO: 6) The light chain variable domain (VL) comprises:
[0136] In another particular embodiment, the antigen binding portion comprises: (a) the heavy chain complementarity determining region (CDR H) 1 amino acid sequence of RYWMN (SEQ ID NO: 1); (b) the CDR H2 amino acid sequence of EITPDSSTINYTPSLKG (SEQ ID NO: 40); (c) CDR H3 amino acid sequence of PYDYGAWFAS (SEQ ID NO:3); A heavy chain variable domain (VH) comprising: (d) the light chain (CDR L) 1 amino acid sequence of RSSTGAVTTSNYAN (SEQ ID NO: 4); (e) the CDR L2 amino acid sequence of GTNKRAP (SEQ ID NO:5); and (f) CDR L3 amino acid sequence of ALWYSNHWV (SEQ ID NO: 6) The light chain variable domain (VL) comprises:
[0137] In one embodiment, the antigen binding portion comprises a heavy chain variable domain (VH) comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:8, SEQ ID NO:41 and SEQ ID NO:44.
[0138] In one embodiment, the antigen-binding portion comprises a heavy chain variable domain (VH) comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:8.
[0139] In one embodiment, the antigen-binding portion comprises a heavy chain variable domain (VH) comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:41.
[0140] In one embodiment, the antigen-binding portion comprises a heavy chain variable domain (VH) comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:44.
[0141] In one embodiment, the antigen-binding portion comprises a heavy chain variable domain (VH) comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:126.
[0142] In one embodiment, the antigen-binding portion comprises a light chain variable domain (VL) comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:9.
[0143] In one embodiment, the antigen-binding portion comprises a light chain variable domain (VL) comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:127.
[0144] In one embodiment, the antigen-binding portion comprises a heavy chain variable domain (VH) comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:8, and a light chain variable domain (VL) comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:9.
[0145] In one embodiment, the antigen-binding portion comprises a heavy chain variable domain (VH) comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:41, and a light chain variable domain (VL) comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:9.
[0146] In one embodiment, the antigen-binding portion comprises a heavy chain variable domain (VH) comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:44, and a light chain variable domain (VL) comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:9.
[0147] In other embodiments, the antigen-binding portion comprises a heavy chain variable domain (VH) comprising an amino acid sequence at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 126, and a light chain variable domain (VL) comprising an amino acid sequence at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 127.
[0148] In a preferred embodiment, the antigen-binding portion comprises a heavy chain variable domain (VH) comprising the amino acid sequence of SEQ ID NO:8 and a light chain variable domain (VL) comprising the amino acid sequence of SEQ ID NO:9.
[0149] In another preferred embodiment, the antigen-binding portion comprises a heavy chain variable domain (VH) comprising the amino acid sequence of SEQ ID NO:126 and a light chain variable domain (VL) comprising the amino acid sequence of SEQ ID NO:127.
[0150] In one embodiment, the antigen-binding portion is an scFv or scFab. In a preferred embodiment, the antigen-binding portion is an scFv.
[0151] In one embodiment, the antigen-binding moiety comprises a heavy chain variable domain (VH) and a light chain variable domain (VL), the VH domain being linked to the VL domain, in particular via a peptide linker. In one embodiment, the C-terminus of the VL domain is linked to the N-terminus of the VH domain, in particular via a peptide linker. In a preferred embodiment, the C-terminus of the VH domain is linked to the N-terminus of the VL domain, in particular via a peptide linker. In one embodiment, the peptide linker comprises the amino acid sequence GGGGSGGGGSGGGGSGGGGS (SEQ ID NO: 16).
[0152] In one embodiment, the antigen-binding portion is an scFv, which is a polypeptide consisting of a heavy chain variable domain (VH), a light chain variable domain (VL) and a linker, wherein said variable domains and said linker have, from N-terminal to C-terminal direction, one of the following configurations: a) VH-linker-VL or b) VL-linker-VH. In a preferred embodiment, the scFv has the configuration VH-linker-VL.
[0153] In one embodiment, the antigen-binding portion comprises an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:10, SEQ ID NO:122 and SEQ ID NO:124.
[0154] In one embodiment, the antigen binding portion comprises an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 10. In one embodiment, the antigen binding portion comprises the amino acid sequence of SEQ ID NO:10.
[0155] In one embodiment, the antigen binding portion comprises an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 122. In one embodiment, the antigen binding portion comprises the amino acid sequence of SEQ ID NO:122.
[0156] In one embodiment, the antigen binding portion comprises an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 124. In one embodiment, the antigen binding portion comprises the amino acid sequence of SEQ ID NO:124.
[0157] Antigen-binding moieties comprising a heavy chain variable domain (VH) and a light chain variable domain (VL), such as the scFv and scFab fragments described herein, may be further stabilized by introducing an interchain disulfide bridge between the VH and VL domains. Thus, in one embodiment, the scFv fragment(s) and / or scFab fragment(s) comprised in the antigen-binding receptor according to the invention are further stabilized by the creation of an interchain disulfide bond via the insertion of a cysteine residue (e.g. at position 44 of the variable heavy chain and at position 100 of the variable light chain according to the Kabat numbering). In one embodiment, any one of the VH and / or VL sequences described above is provided, comprising at least one substitution of an amino acid by a cysteine (in particular at position 44 of the variable heavy chain and / or at position 100 of the variable light chain according to the Kabat numbering).
[0158] In one embodiment, the antigen binding portion comprises an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 128. In one embodiment, the antigen binding portion comprises the amino acid sequence of SEQ ID NO:128.
[0159] Anchor Transmembrane Domain (ATD) In the context of the present invention, the anchor transmembrane domain of the antigen-binding receptor of the present invention may be characterized by not having a mammalian protease cleavage site.In the context of the present invention, a protease refers to a proteolytic enzyme that can hydrolyze the amino acid sequence of the transmembrane domain that contains the protease cleavage site.The term protease includes both endopeptidases and exopeptidases.In the context of the present invention, any anchor transmembrane domain of a transmembrane protein, as specifically defined in the CD nomenclature, can be used to generate the antigen-binding receptor of the present invention.
[0160] Thus, in the context of the present invention, the anchor transmembrane domain may comprise a part of a murine / mouse transmembrane domain or preferably a part of a human transmembrane domain. An example of such an anchor transmembrane domain is e.g. the transmembrane domain of CD8 having the amino acid sequence shown in SEQ ID NO: 11 (encoded by the DNA sequence shown in SEQ ID NO: 24) herein. In the context of the present invention, the anchor transmembrane domain of the antigen-binding receptor of the present invention may comprise / consist of the amino acid sequence shown in SEQ ID NO: 11 (encoded by the DNA sequence shown in SEQ ID NO: 24).
[0161] In another embodiment, the antigen binding receptor provided herein comprises amino acids 153-179, 154-179, 155-179, 156-179, 157-179, 158-179, 159-179, 160-179, 161-179, 162-179, 163-179, 164-179, 165-179, 166-179, 167-179, 168-179, 169-200, 170-170, 171-170, 172-170, 173-170, 174-170, 175-170, 176-170, 177-170, 178-170, 179-200, 180-170, 181-170, 182-170, 183-170, 184-170, 185-170, 186-170, 187-170, 188-170, 189-200, 190-170, 191-170, 192-170, 193-170, 194-170, 195-170, 196-170, 197-170, 198-170, 199-200, 200-200, 2010-2010, 2011-2011, 2012-2012, 2013-2013, 2014-2014, 2015-2015, 79, 166-179, 167-179, 168-179, 169-179, 170-179, 171-179, 172-179, 173-179, 174-179, 175-179, 176-179, 177-179, or 178-179 (encoded by the cDNA shown in SEQ ID NO:70).
[0162] Alternatively, any protein having a transmembrane domain, particularly as provided by the CD nomenclature, can be used as an anchor transmembrane domain for the antigen-binding receptor protein of the present invention.
[0163] In some embodiments, the anchor transmembrane domain comprises a transmembrane domain or a transmembrane fragment thereof of any one of the group consisting of CD27 (SEQ ID NO:59 encoded by SEQ ID NO:58), CD137 (SEQ ID NO:67 encoded by SEQ ID NO:66), OX40 (SEQ ID NO:71 encoded by SEQ ID NO:70), ICOS (SEQ ID NO:75 encoded by SEQ ID NO:74), DAP10 (SEQ ID NO:80 encoded by SEQ ID NO:79), DAP12 (SEQ ID NO:83 encoded by SEQ ID NO:82), CD3z (SEQ ID NO:88 encoded by SEQ ID NO:87), FCGR3A (SEQ ID NO:90 encoded by SEQ ID NO:91), NKG2D (SEQ ID NO:94 encoded by SEQ ID NO:95), CD8 (SEQ ID NO:119 encoded by SEQ ID NO:120) that retains the ability to anchor an antigen binding receptor to the membrane.
[0164] Human sequences may be beneficial in the general inventive context, for example because (part of) the anchor transmembrane domain may be accessible from the extracellular space and thus accessible to the patient's immune system. In a preferred embodiment, the anchor transmembrane domain comprises a human sequence. In such embodiments, the anchor transmembrane domain comprises a transmembrane domain or a transmembrane fragment thereof of any one of the group consisting of human CD27 (SEQ ID NO:57 encoded by SEQ ID NO:56), human CD137 (SEQ ID NO:65 encoded by SEQ ID NO:64), human OX40 (SEQ ID NO:69 encoded by SEQ ID NO:68), human ICOS (SEQ ID NO:73 encoded by SEQ ID NO:72), human DAP10 (SEQ ID NO:78 encoded by SEQ ID NO:77), human DAP12 (SEQ ID NO:81 encoded by SEQ ID NO:80), human CD3z (SEQ ID NO:86 encoded by SEQ ID NO:85), human FCGR3A (SEQ ID NO:88 encoded by SEQ ID NO:89), human NKG2D (SEQ ID NO:92 encoded by SEQ ID NO:93), human CD8 (SEQ ID NO:117 encoded by SEQ ID NO:118), which retains the ability to anchor the antigen binding receptor to the membrane.
[0165] Stimulatory signaling domains (SSD) and costimulatory signaling domains (CSD) Preferably, the antigen binding receptors of the invention comprise at least one stimulatory signaling domain and / or at least one costimulatory signaling domain. Thus, the antigen binding receptors provided herein preferably comprise a stimulatory signaling domain that results in T cell activation. Antigen binding receptors provided herein can comprise a stimulatory signaling domain that is a fragment / polypeptide portion of murine / mouse or human CD3z (UniProt entry for human CD3z is P20963 (version number 177, SEQ ID NO:2); UniProt entry for mouse CD3z is P24161 (primary citable accession number) or Q9D3G3 (secondary citable accession number), version number 143, SEQ ID NO:1)), FCGR3A (UniProt entry for human FCGR3A is P08637 (version number 178, SEQ ID NO:2)), or NKG2D (UniProt entry for human NKG2D is P26718 (version number 151, SEQ ID NO:1); UniProt entry for mouse NKG2D is O54709 (version number 132, SEQ ID NO:2)).
[0166] Thus, the stimulatory signaling domain contained in the antigen-binding receptors provided herein may be a full-length fragment / polypeptide portion of CD3z, FCGR3A, or NKG2D. The amino acid sequence of murine / mouse full-length CD3z or NKG2D is set forth herein as SEQ ID NO: 86 (CD3z), 90 (Fcgr3A), or 94 (NKG2D) (murine / mouse is encoded by the DNA sequence set forth in SEQ ID NO: 87 (CD3z), 91 (FCGR3A), or 95 (NKG2D)). The amino acid sequence of human full-length CD3z, FCGR3A, or NKG2D is set forth herein as SEQ ID NO: 84 (CD3z), 88 (FCGR3A), or 92 (NKG2D) (human is encoded by the DNA sequence set forth in SEQ ID NO: 85 (CD3z), 89 (FCGR3A), or 93 (NKG2D)). The antigen-binding receptor of the present invention may comprise a fragment of CD3z, Fcgr3A or NKG2D as a stimulatory domain, provided that it comprises at least one signaling domain. In particular, any part / fragment of CD3z, FCGR3A or NKG2D is suitable as a stimulatory domain, as long as it comprises at least one signaling motif. More preferably, however, the antigen-binding receptor of the present invention comprises a polypeptide obtained from human origin. Thus, the antigen-binding receptor provided herein comprises an amino acid sequence set forth herein as SEQ ID NO: 84 (CD3z), 88 (FCGR3A) or 92 (NKG2D) (human is encoded by the DNA sequence set forth in SEQ ID NO: 85 (CD3z), 89 (FCGR3A) or 93 (NKG2D)). In one embodiment, the antigen-binding receptor of the present invention may comprise or consist of the amino acid sequence set forth in SEQ ID NO: 13 (encoded by the DNA sequence set forth in SEQ ID NO: 26).In a further embodiment, the antigen binding receptor comprises a sequence as set forth in SEQ ID NO: 13 or a sequence having up to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30 substitutions, deletions or insertions compared to SEQ ID NO: 13 and characterized in having stimulatory signaling activity. Specific configurations of antigen binding receptors comprising a stimulatory signaling domain (SSD) are shown herein below and in the Examples and Figures. Stimulatory signaling activity can be determined, for example, by enhanced cytokine release (measured by ELISA) (IL-2, IFNγ, TNFα), enhanced proliferative activity (measured by increased cell number) or enhanced lytic activity (measured by LDH release assay).
[0167] Additionally, the antigen binding receptors provided herein preferably contain at least one costimulatory signaling domain that provides additional activity to T cells. The antigen binding receptors provided herein include murine / mouse or human CD28 (the UniProt entry for human CD28 is P10747 (version number 173, SEQ ID NO: 1); the UniProt entry for mouse CD28 is P31041 (version number 134, SEQ ID NO: 2)), CD137 (the UniProt entry for human CD137 is Q07011 (version number 145, SEQ ID NO: 1); the UniProt entry for mouse CD137 is P20334 (version number 145, SEQ ID NO: 1)), and / or human CD28 (the UniProt entry for human CD28 is P10747 (version number 173, SEQ ID NO: 1); the UniProt entry for mouse CD28 is P31041 (version number 134, SEQ ID NO: 2)), CD137 (the UniProt entry for human CD137 is Q07011 (version number 145, SEQ ID NO: 1); the UniProt entry for mouse CD137 is P20334 (version number 145, SEQ ID NO: 1)). The UniProt entry for human OX40 is P23510 (version number 138, SEQ ID NO:1); the UniProt entry for mouse OX40 is P43488 (version number 119, SEQ ID NO:1); ICOS (the UniProt entry for human ICOS is Q9Y6W8 (SEQ ID NO:1, version number 126); the UniProt entry for mouse ICOS is Q9WV40 (primary citable accession number) or Q9JL1 7 (secondary citable accession number), version number 102, SEQ ID NO:2), CD27 (the UniProt entry for human CD27 is P26842 (version number 160, SEQ ID NO:2); the UniProt entry for mouse CD27 is P41272 (version number 137, SEQ ID NO:1)), 4-1-BB (the UniProt entry for mouse 4-1-BB is P20334 (version number 140, SEQ ID NO:1); the UniProt entry for human 4-1-BB is Q07 011 (version number 146, SEQ ID NO: 1), DAP10 (the UniProt entry for human DAP10 is Q9UBJ5 (version number 25, SEQ ID NO: 2); the UniProt entry for mouse DAP10 is Q9QUJ0 (primary citable accession number) or Q9R1E7 (secondary citable accession number), version number 101, SEQ ID NO: 1)) or DAP12 (the UniProt entry for human DAP12 is O43914 (version number 146, SEQ ID NO: 1);The UniProt entry for mouse DAP12 is O054885 (primary citable accession number) or Q9R1E7 (secondary citable accession number), version number 123, SEQ ID NO: 1). In a particular embodiment of the invention, the antigen binding receptor of the invention may comprise one or more, i.e. 1, 2, 3, 4, 5, 6 or 7, costimulatory signaling domains as described herein. Thus, in the context of the present invention, the antigen binding receptor of the invention may comprise as a first costimulatory signaling domain a fragment / polypeptide portion of murine / mouse CD137 or preferably a fragment / polypeptide portion of human CD137, and the second costimulatory signaling domain is selected from the group consisting of mouse or preferably human CD27, CD28, CD137, OX40, ICOS, DAP10 and DAP12 or fragments thereof. Preferably, the antigen binding receptor of the present invention comprises a costimulatory signaling domain obtained from human origin. Thus, more preferably, the one or more stimulatory signaling domains comprised in the antigen-binding receptor of the present invention may comprise or consist of the amino acid sequence set forth in SEQ ID NO: 12 (encoded by the DNA sequence set forth in SEQ ID NO: 25);
[0168] Thus, the costimulatory signaling domains optionally included in the antigen binding receptors provided herein are fragments / polypeptide portions of full length CD27, CD28, CD137, OX40, ICOS, DAP10, or DAP12. The amino acid sequences of murine / mouse full length CD27, CD28, CD137, OX40, ICOS, DAP12, DAP10, and DAP12 are set forth herein as SEQ ID NO:59 (CD3z), 63 (CD28), 67 (CD137), 71 (OX40), 75 (ICOS), 79 (DAP10), or 83 (DAP12) (mouse are encoded by the DNA sequences set forth in SEQ ID NO:58 (CD27), 62 (CD28), 66 (CD137), 70 (OX40), 74 (ICOS), 78 (DAP10), or 82 (DAP12)). However, since human sequences are most preferred in the context of the present invention, the costimulatory signaling domains that may optionally be included in the antigen binding receptor proteins provided herein are fragments / polypeptide portions of human full-length CD27, CD28, CD137, OX40, ICOS, DAP10, or DAP12. The amino acid sequences of human full-length CD27, CD28, CD137, OX40, ICOS, DAP10, or DAP12 are set forth herein as SEQ ID NO: 57 (CD27), 61 (CD28), 65 (CD137), 69 (OX40), 73 (ICOS), 77 (DAP10), or 81 (DAP12) (human is encoded by the DNA sequence set forth in SEQ ID NO: 56 (CD27), 60 (CD28), 64 (CD137), 68 (OX40), 72 (ICOS), 76 (DAP10), or 80 (DAP12)).
[0169] In a preferred embodiment, the antigen-binding receptor comprises CD28 or a fragment thereof as a costimulatory signaling domain. The antigen-binding receptors provided herein may comprise a fragment of CD28 as a costimulatory signaling domain, provided that at least one signaling domain of CD28 is included. In particular, any part / fragment of CD28 is suitable for the antigen-binding receptor of the present invention, as long as at least one signaling motif of CD28 is included. The costimulatory signaling domains PYAP (AA208 to 211 of CD28) and YMNM (AA191 to 194 of CD28) are beneficial for the function of the CD28 polypeptide and the functional effects listed above. The amino acid sequence of the YMNM domain is shown in SEQ ID NO: 96, and the amino acid sequence of the PYAP domain is shown in SEQ ID NO: 97. Thus, in the antigen-binding receptor of the present invention, the CD28 polypeptide preferably comprises a sequence from the intracellular domain of the CD28 polypeptide having the sequence YMNM (SEQ ID NO: 96) and / or PYAP (SEQ ID NO: 97). In other embodiments, in the antigen-binding receptor of the present invention, one or both of these domains are mutated to FMNM (SEQ ID NO: 98) and / or AYAA (SEQ ID NO: 99), respectively. Any of these mutations can be used to reduce the ability of transduced cells containing the antigen-binding receptor to release cytokines without affecting their own proliferation capacity, and advantageously to prolong the survival of the transduced cells, and thus enhance their therapeutic potential. In other words, such non-functional mutations preferably enhance the persistence of cells transduced with the antigen-binding receptors provided herein in vivo. However, these signaling motifs can be present at any site within the intracellular domain of the antigen-binding receptors provided herein.
[0170] In another preferred embodiment, the antigen-binding receptor comprises CD137 or a fragment thereof as a costimulatory signaling domain. The antigen-binding receptor provided herein may comprise a fragment of CD137 as a costimulatory signaling domain, provided that at least one signaling domain of CD137 is included. In particular, any part / fragment of CD137 is suitable for the antigen-binding receptor of the present invention, as long as at least one signaling motif of CD137 is included. In a preferred embodiment, the CD137 polypeptide comprised in the antigen-binding receptor protein of the present invention comprises or consists of the amino acid sequence shown in SEQ ID NO: 12 (encoded by the DNA sequence shown in SEQ ID NO: 25).
[0171] Specific configurations of antigen binding receptors that include a costimulatory signaling domain (CSD) are provided herein below and in the Examples and Figures. Costimulatory signaling activity can be determined, for example, by enhanced cytokine release (measured by ELISA) (IL-2, IFNγ, TNFα), enhanced proliferative activity (measured by increased cell number) or enhanced lytic activity (measured by LDH release assay). As mentioned above, in embodiments of the invention, the costimulatory signaling domain of the antigen binding receptor may be derived from human CD28 and / or CD137 gene T cell activity, defined as the cytokine production, proliferation and lytic activity of the transduced cells described herein, such as the transduced T cells. CD28 and / or CD137 activity can be measured by cytokine release by ELISA or flow cytometry for cytokines such as interferon gamma (IFN-γ) or interleukin 2 (IL-2), T cell proliferation measured by, for example, ki67 measurement, cell quantification by flow cytometry, or lytic activity assessed by real-time impedance measurement of target cells (see, e.g., Thakur et al., Biosens Bioelectron. 35(1)(2012), 503-506; Krutzik et al., Methods Mol Biol. 699(2011), 179-202; Ekkens et al., Infect Immun. 75(5)(2007), 2291-2296; Ge et al., Proc Natl Acad Sci USA. 99(5)(2002), 2983-2988; Duewell et al., Cell Death Differ. 21(12)(2014), 1825-1837 (Errata in Cell Death Differ. 21(12)(2014), 161) by using the ICELLligence instrument.
[0172] Linker and Signal Peptides Furthermore, the antigen-binding receptors provided herein may comprise at least one linker (or "spacer"). A linker is usually a peptide having a length of up to 20 amino acids. Thus, in the context of the present invention, the linker may have a length of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acids. For example, the antigen-binding receptors provided herein may comprise a linker between an extracellular domain, an anchor transmembrane domain, a costimulatory signaling domain, and / or a stimulatory signaling domain, comprising at least one antigen-binding moiety capable of specifically binding to a mutant Fc domain. Furthermore, the antigen-binding receptors provided herein may comprise a linker in the antigen-binding moiety, particularly between the immunoglobulin domains of the antigen-binding moiety (e.g., between the VH domain and the VL domain of an scFv). Such linkers have the advantage that they increase the probability that different polypeptides of an antigen-binding receptor (i.e., the extracellular domain comprising at least one antigen-binding moiety, the anchor transmembrane domain, the costimulatory signaling domain and / or the stimulatory signaling domain) will fold independently and function predictably. Thus, in the context of the present invention, the extracellular domain comprising at least one antigen-binding moiety, the anchor transmembrane domain, the costimulatory signaling domain and the stimulatory signaling domain may be comprised in a single-chain multifunctional polypeptide. A single-chain fusion construct may, for example, be composed of the extracellular domain(s) comprising at least one antigen-binding moiety, the anchor transmembrane domain(s), the costimulatory signaling domain(s) and / or the stimulatory signaling domain(s). Thus, the antigen-binding moiety, the anchor transmembrane domain, the costimulatory signaling domain and the stimulatory signaling domain may be linked by one or more identical or different peptide linkers as described herein. For example, in the antigen-binding receptors provided herein, the linker between the extracellular domain comprising at least one antigen-binding moiety and the anchor transmembrane domain can comprise or consist of the amino acid and amino acid sequence set forth in SEQ ID NO:17.In another embodiment, the linker between the antigen binding portion and the anchor transmembrane domain comprises or consists of the amino acid sequence set forth in SEQ ID NO: 19. Thus, the anchor transmembrane domain, the costimulatory signaling domain and / or the stimulatory domain may be linked to each other by a peptide linker or by direct fusion of the domains.
[0173] In a preferred embodiment of the present invention, the antigen-binding portion contained in the extracellular domain is a single chain variable fragment (scFv), which is a fusion protein in which the heavy chain variable domain (VH) and the light chain variable domain (VL) of an antibody are linked by a short linker peptide of 10 to about 25 amino acids. The linker is usually rich in glycine to increase flexibility and serine or threonine to increase solubility, and can link the N-terminus of VH to the C-terminus of VL, or vice versa. In a preferred embodiment, the linker links the N-terminus of the VL domain to the C-terminus of the VH domain. For example, in the antigen-binding receptor provided herein, the linker can have the amino acid and amino acid sequence shown in SEQ ID NO: 16. scFv antibodies are described, for example, in Houston, JS, Methods in Enzymol. 203 (1991) 46-96).
[0174] In some embodiments according to the present invention, the antigen-binding portion included in the extracellular domain is a single chain Fab fragment or scFab, which is a polypeptide consisting of a heavy chain variable domain (VH), an antibody constant domain 1 (CH1), an antibody light chain variable domain (VL), an antibody light chain constant domain (CL) and a linker, the antibody domains and the linker having one of the following orders from N-terminus to C-terminus: a) VH-CH1-linker-VL-CL, b) VL-CL-linker-VH-CH1, c) VH-CL-linker-VL-CH1, or d) VL-CH1-linker-VH-CL; wherein the linker is a polypeptide of at least 30 amino acids, preferably 32-50 amino acids. The single chain Fab fragment is stabilized by a native disulfide bond between the CL domain and the CH1 domain.
[0175] The antigen-binding receptors or portions thereof provided herein may include a signal peptide. Such a signal peptide will deliver the protein to the surface of the T cell membrane. For example, in the antigen-binding receptors provided herein, the signal peptide may have the amino acid sequence set forth in SEQ ID NO: 100 and the amino acid sequence (encoded by the DNA sequence set forth in SEQ ID NO: 101).
[0176] T-CELL ACTIVATING ANTIGEN-BINDING RECEPTOR CAPABLE OF SPECIFICALLY BINDING TO A MUTANT FC DOMAIN - Patent application The antigen binding receptor components described herein can be fused to each other in a variety of configurations to generate a T cell activating antigen binding receptor.
[0177] In some embodiments, the antigen-binding receptor comprises an extracellular domain composed of a heavy chain variable domain (VH) and a light chain variable domain (VL) linked to an anchor transmembrane domain. In a preferred embodiment, the VH domain is fused C-terminally to the N-terminus of the VL domain, optionally via a peptide linker. In other embodiments, the antigen-binding receptor further comprises a stimulatory signaling domain and / or a costimulatory signaling domain. In certain such embodiments, the antigen-binding receptor consists essentially of a VH domain and a VL domain linked by one or more peptide linkers, an anchor transmembrane domain, and optionally a stimulatory signaling domain, where the VH domain is fused C-terminally to the N-terminus of the VL domain, the VL domain is fused C-terminally to the N-terminus of the anchor transmembrane domain, and the anchor transmembrane domain is fused C-terminally to the N-terminus of the stimulatory signaling domain. Optionally, the antigen-binding receptor further comprises a costimulatory signaling domain. In one particular such embodiment, the antigen binding receptor consists essentially of a VH domain and a VL domain, an anchor transmembrane domain, a stimulatory signaling domain and a costimulatory signaling domain linked by one or more peptide linkers, where the VH domain is fused at its C-terminus to the N-terminus of the VL domain, the VL domain is fused at its C-terminus to the N-terminus of the anchor transmembrane domain, the anchor transmembrane domain is fused at its C-terminus to the N-terminus of the stimulatory signaling domain, and the stimulatory signaling domain is fused at its C-terminus to the N-terminus of the costimulatory signaling domain. In another embodiment, the costimulatory signaling domain is linked to the anchor transmembrane domain in place of the stimulatory signaling domain.In a preferred embodiment, the antigen binding receptor consists essentially of a VH domain and a VL domain, an anchor transmembrane domain, a costimulatory signaling domain, and a stimulatory signaling domain linked by one or more peptide linkers, where the VH domain is fused at its C-terminus to the N-terminus of the VL domain, the VL domain is fused at its C-terminus to the N-terminus of the anchor transmembrane domain, the anchor transmembrane domain is fused at its C-terminus to the N-terminus of the costimulatory signaling domain, and the costimulatory signaling domain is fused at its C-terminus to the N-terminus of the stimulatory signaling domain.
[0178] The antigen-binding portion, the anchor transmembrane domain, and the stimulatory signaling and / or costimulatory signaling domain may be fused directly to each other or via one or more peptide linkers comprising one or more amino acids, typically about 2-20 amino acids. Peptide linkers are known in the art and described herein. Suitable non-immunogenic peptide linkers include, for example, (G4S) n , (SG4) n , (G4S) n or G4 (SG4) n Peptide linkers are included, where "n" is usually a number between 1 and 10, typically between 2 and 4. A preferred peptide linker for linking the antigen-binding moiety and the anchor transmembrane moiety is GGGGS(G4S) according to SEQ ID NO: 17. Another preferred peptide linker for linking the antigen-binding moiety and the anchor transmembrane moiety is KPTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACD (CD8 stalk) according to SEQ ID NO: 19. An exemplary peptide linker suitable for linking the variable heavy domain (VH) and the variable light domain (VL) is GGGSGGGSGGGSGGGS(G4S)4 according to SEQ ID NO: 16.
[0179] Additionally, the linker may comprise (part of) an immunoglobulin hinge region. In particular, when the antigen-binding moiety is fused to the N-terminus of the anchor transmembrane domain, it may be fused via an immunoglobulin hinge region or part thereof, with or without an additional peptide linker.
[0180] As described herein, the antigen-binding receptor of the present invention comprises an extracellular domain that comprises at least one antigen-binding portion. Antigen-binding receptors with a single antigen-binding portion that can specifically bind to a target cell antigen are useful and preferred, particularly when high expression of the antigen-binding receptor is required. In such cases, the presence of two or more antigen-binding portions specific to a target cell antigen may limit the expression efficiency of the antigen-binding receptor. However, in other cases, it may be advantageous to have an antigen-binding receptor that comprises two or more antigen-binding portions specific to a target cell antigen, for example, to optimize targeting to a target site or to allow cross-linking of the target cell antigen.
[0181] In one particular embodiment, the antigen-binding receptor comprises one antigen-binding moiety capable of specifically binding to a mutated Fc domain comprising a P329G mutation (according to EU numbering), in particular an IgG1 Fc domain. In one embodiment, the antigen-binding moiety capable of specifically binding to the mutated Fc domain but not to the non-mutated parent Fc domain is an scFv.
[0182] In one embodiment, the antigen-binding portion is fused at the C-terminus of the scFv fragment to the N-terminus of the anchor transmembrane domain, optionally via a peptide linker. In one embodiment, the peptide linker comprises the amino acid sequence KPTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACD (SEQ ID NO: 19). In one embodiment, the anchor transmembrane domain is a transmembrane domain or a fragment thereof selected from the group consisting of CD8, CD4, CD3z, FCGR3A, NKG2D, CD27, CD28, CD137, OX40, ICOS, DAP10 or DAP12 transmembrane domains. In a preferred embodiment, the anchor transmembrane domain is a CD8 transmembrane domain or a fragment thereof. In a particular embodiment, the anchor transmembrane domain comprises or consists of the amino acid sequence IYIWAPLAGTCGVLLLSLVIT (SEQ ID NO: 11). In one embodiment, the antigen-binding receptor further comprises a costimulatory signaling domain (CSD). In one embodiment, the anchor transmembrane domain of the antigen binding receptor is fused C-terminally to the N-terminus of the costimulatory signaling domain. In one embodiment, the costimulatory signaling domain is individually selected from the group consisting of the intracellular domains of CD27, CD28, CD137, OX40, ICOS, DAP10, and DAP12, or fragments thereof, as described herein above. In a preferred embodiment, the costimulatory signaling domain is the intracellular domain of CD28, or a fragment thereof. In a preferred embodiment, the costimulatory signaling domain comprises the intracellular domain of CD28, or a fragment thereof that retains CD28 signaling. In another preferred embodiment, the costimulatory signaling domain comprises the intracellular domain of CD137, or a fragment thereof that retains CD137 signaling. In a particular embodiment, the costimulatory signaling domain comprises or consists of SEQ ID NO: 12. In one embodiment, the antigen binding receptor further comprises a stimulatory signaling domain. In one embodiment, the costimulatory signaling domain of the antigen binding receptor is fused C-terminally to the N-terminus of the stimulatory signaling domain.In one embodiment, at least one stimulatory signaling domain is individually selected from the group consisting of the intracellular domain of CD3z, FCGR3A and NKG2D, or fragments thereof. In a preferred embodiment, the costimulatory signaling domain is the intracellular domain of CD3z, or a fragment thereof that retains CD3z signaling. In a particular embodiment, the costimulatory signaling domain comprises or consists of SEQ ID NO:13.
[0183] In one embodiment, the antigen-binding receptor is fused to a reporter protein, in particular GFP or an enhanced analogue thereof. In one embodiment, the antigen-binding receptor is fused at the C-terminus to the N-terminus of eGFP (enhanced green fluorescent protein), optionally via a peptide linker as described herein. In a preferred embodiment, the peptide linker is GEGRGSLTCGDVEENPGP (T2A) according to SEQ ID NO: 18.
[0184] In a particular embodiment, the antigen-binding receptor comprises an anchor transmembrane domain and an extracellular domain comprising at least one antigen-binding moiety, where the at least one antigen-binding moiety is an scFv capable of specifically binding to a mutated Fc domain but not to a non-mutated parent Fc domain, and the mutated Fc domain comprises a P329G mutation (according to EU numbering). The P329G mutation reduces Fcγ receptor binding. In one embodiment, the antigen-binding receptor of the present invention comprises an anchor transmembrane domain (ATD), a costimulatory signaling domain (CSD), and a stimulatory signaling domain (SSD). In one such embodiment, the antigen-binding receptor has the following configuration: scFv-ATD-CSD-SSD. In a preferred embodiment, the antigen-binding receptor has the following configuration: VH-VL-ATD-CSD-SSD. In a more particular such embodiment, the antigen-binding receptor has the following configuration: VH-linker-VL-linker-ATD-CSD-SSD.
[0185] In a particular embodiment, the antigen binding portion is an scFv capable of specifically binding to a mutated Fc domain comprising a P329G mutation, wherein the antigen binding portion comprises at least one heavy chain complementarity determining region (CDR) selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, and SEQ ID NO:3, and at least one light chain CDR selected from the group consisting of SEQ ID NO:4, SEQ ID NO:5, and SEQ ID NO:6.
[0186] In another specific embodiment, the antigen binding portion is an scFv capable of specifically binding to a mutated Fc domain comprising a P329G mutation, wherein the antigen binding portion comprises at least one heavy chain complementarity determining region (CDR) selected from the group consisting of SEQ ID NO:1, SEQ ID NO:40, and SEQ ID NO:3, and at least one light chain CDR selected from the group consisting of SEQ ID NO:4, SEQ ID NO:5, and SEQ ID NO:6.
[0187] In a preferred embodiment, the antigen binding portion is an scFv capable of specifically binding to a mutant Fc domain comprising a P329G mutation, wherein the antigen binding portion comprises the amino acid sequence of complementarity determining region (CDR H) 1 RYWMN (SEQ ID NO: 1), the amino acid sequence of CDR H2 EITPDSSTINYAPSLKG (SEQ ID NO: 2), the amino acid sequence of CDR H3 PYDYGAWFAS (SEQ ID NO: 3), the amino acid sequence of light chain complementarity determining region (CDR L) 1 RSSTGAVTTSNYAN (SEQ ID NO: 4), the amino acid sequence of CDR L2 GTNKRAP (SEQ ID NO: 5), and the amino acid sequence of CDR L3 ALWYSNHWV (SEQ ID NO: 6).
[0188] In one embodiment, the present invention provides a polypeptide comprising, in order from N-terminus to C-terminus: (i) a heavy chain variable domain (VH) comprising a heavy chain complementarity determining region (CDR) 1 of SEQ ID NO: 1, a heavy chain CDR2 of SEQ ID NO: 2, and a heavy chain CDR3 of SEQ ID NO: 3; (ii) a peptide linker, in particular a peptide linker of SEQ ID NO: 16, (iii) a light chain variable domain (VL) comprising a light chain CDR1 of SEQ ID NO: 4, a light chain CDR2 of SEQ ID NO: 5, and a light chain CDR3 of SEQ ID NO: 6; (iv) a peptide linker, in particular a peptide linker of SEQ ID NO: 19, (v) an anchor transmembrane domain, in particular an anchor transmembrane domain of SEQ ID NO: 11; (vi) a costimulatory signaling domain, particularly a costimulatory signaling domain of SEQ ID NO: 12, and (vii) a stimulatory signaling domain, particularly a stimulatory signaling domain of SEQ ID NO: 13. The present invention provides an antigen-binding receptor comprising:
[0189] In one embodiment, the present invention provides a polypeptide comprising, in order from N-terminus to C-terminus: (i) a heavy chain variable domain (VH) comprising a heavy chain complementarity determining region (CDR) 1 of SEQ ID NO: 1, a heavy chain CDR2 of SEQ ID NO: 40, and a heavy chain CDR3 of SEQ ID NO: 3; (ii) a peptide linker, in particular a peptide linker of SEQ ID NO: 16, (iii) a light chain variable domain (VL) comprising a light chain CDR1 of SEQ ID NO: 4, a light chain CDR2 of SEQ ID NO: 5, and a light chain CDR3 of SEQ ID NO: 6; (iv) a peptide linker, in particular a peptide linker of SEQ ID NO: 19, (v) an anchor transmembrane domain, in particular an anchor transmembrane domain of SEQ ID NO: 11; (vi) a costimulatory signaling domain, particularly a costimulatory signaling domain of SEQ ID NO: 12, and (vii) a stimulatory signaling domain, particularly a stimulatory signaling domain of SEQ ID NO: 13. The present invention provides an antigen-binding receptor comprising:
[0190] In one embodiment, the present invention provides, in order from N-terminus to C-terminus, (i) a heavy chain variable domain (VH), (ii) a peptide linker, in particular a peptide linker of SEQ ID NO: 16, (iii) a light chain variable domain (VL) that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:9; wherein the VH and VL domains are capable of forming an antigen-binding portion that binds to an Fc domain that comprises the amino acid mutation P329G according to EU numbering, (iv) a peptide linker, in particular a peptide linker of SEQ ID NO: 19, (v) an anchor transmembrane domain, particularly an anchor transmembrane domain that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 11; (vi) a costimulatory signaling domain, particularly a costimulatory signaling domain that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 12, and (vii) a stimulatory signaling domain, particularly a stimulatory signaling domain that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 13. The present invention provides an antigen-binding receptor comprising:
[0191] In one embodiment, the present invention provides, in order from N-terminus to C-terminus, (i) a heavy chain variable domain (VH) that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:8; (ii) a peptide linker, in particular a peptide linker of SEQ ID NO: 16, (iii) a light chain variable domain (VL) that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:9; (iv) a peptide linker, in particular a peptide linker of SEQ ID NO: 19, (v) an anchor transmembrane domain, particularly an anchor transmembrane domain that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 11; (vi) a costimulatory signaling domain, particularly a costimulatory signaling domain that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 12, and (vii) a stimulatory signaling domain, particularly a stimulatory signaling domain that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 13. The present invention provides an antigen-binding receptor comprising:
[0192] In one embodiment, the present invention provides, in order from N-terminus to C-terminus, (i) a heavy chain variable domain (VH) that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 41; (ii) a peptide linker, in particular a peptide linker of SEQ ID NO: 16, (iii) a light chain variable domain (VL) that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:9; (iv) a peptide linker, in particular a peptide linker of SEQ ID NO: 19, (v) an anchor transmembrane domain, particularly an anchor transmembrane domain that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 11; (vi) a costimulatory signaling domain, particularly a costimulatory signaling domain that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 12, and (vii) a stimulatory signaling domain, particularly a stimulatory signaling domain that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 13. The present invention provides an antigen-binding receptor comprising:
[0193] In one embodiment, the present invention provides, in order from N-terminus to C-terminus, (i) a heavy chain variable domain (VH) that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 44; (ii) a peptide linker, in particular a peptide linker of SEQ ID NO: 16, (iii) a light chain variable domain (VL) that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:9; (iv) a peptide linker, in particular a peptide linker of SEQ ID NO: 19, (v) an anchor transmembrane domain, particularly an anchor transmembrane domain that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 11; (vi) a costimulatory signaling domain, particularly a costimulatory signaling domain that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 12, and (vii) a stimulatory signaling domain, particularly a stimulatory signaling domain that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 13. The present invention provides an antigen-binding receptor comprising:
[0194] In one embodiment, the present invention provides, in order from N-terminus to C-terminus, (i) a heavy chain variable domain (VH) that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 126; (ii) a peptide linker, in particular a peptide linker of SEQ ID NO: 16, (iii) a light chain variable domain (VL) that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 127; (iv) a peptide linker, in particular a peptide linker of SEQ ID NO: 19, (v) an anchor transmembrane domain, particularly an anchor transmembrane domain that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 11; (vi) a costimulatory signaling domain, particularly a costimulatory signaling domain that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 12, and (vii) a stimulatory signaling domain, particularly a stimulatory signaling domain that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 13. The present invention provides an antigen-binding receptor comprising:
[0195] In one embodiment, an antigen-binding receptor is provided that comprises an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 7. In one embodiment, an antigen-binding receptor is provided that comprises the amino acid sequence of SEQ ID NO: 7.
[0196] In one embodiment, an antigen-binding receptor is provided that comprises an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 121. In one embodiment, an antigen-binding receptor is provided that comprises the amino acid sequence of SEQ ID NO: 121.
[0197] In one embodiment, an antigen-binding receptor is provided that comprises an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 123. In one embodiment, an antigen-binding receptor is provided that comprises the amino acid sequence of SEQ ID NO: 123.
[0198] In one embodiment, an antigen-binding receptor is provided that comprises an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 125. In one embodiment, an antigen-binding receptor is provided that comprises the amino acid sequence of SEQ ID NO: 125.
[0199] In one embodiment, the antigen-binding receptor is fused to a reporter protein, in particular GFP or an enhanced analogue thereof. In one embodiment, the antigen-binding receptor is fused at the C-terminus to the N-terminus of eGFP (enhanced green fluorescent protein), optionally via a peptide linker as described herein. In a preferred embodiment, the peptide linker is GEGRGSLTCGDVEENPGP (T2A) of SEQ ID NO: 18.
[0200] In one embodiment, an antigen-binding receptor is provided that comprises an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:129.
[0201] In a preferred embodiment, there is provided an antigen-binding receptor comprising the amino acid sequence of SEQ ID NO: 129. In one such embodiment, the antigen-binding receptor consists of the amino acid sequence of SEQ ID NO:129.
[0202] In one embodiment, an antigen-binding receptor is provided that comprises an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:132.
[0203] In one embodiment, an antigen-binding receptor is provided that comprises the amino acid sequence of SEQ ID NO:132.
[0204] In one embodiment, an antigen-binding receptor is provided that consists of the amino acid sequence of SEQ ID NO:132.
[0205] In one embodiment, there is provided an antigen-binding receptor as described herein that does not comprise the amino acid sequence of SEQ ID NO:19.
[0206] Transduced cells capable of expressing the antigen-binding receptor of the present invention A further aspect of the present invention is a transduced T cell capable of expressing an antigen-binding receptor of the present invention. An antigen-binding receptor as described herein refers to a molecule that is not naturally contained within and / or on the surface of a T cell and is not (endogenously) expressed within or on a normal (non-transduced) T cell. Thus, an antigen-binding receptor of the present invention within and / or on the surface of a T cell is artificially introduced into the T cell. In the context of the present invention, said T cells, preferably CD8+ T cells, may be isolated / obtained from a subject to be treated as defined herein. Thus, an antigen-binding receptor as described herein that is artificially introduced and subsequently presented within and / or on the surface of said T cell comprises a domain that comprises one or more antigen-binding moieties that are accessible (in vitro or in vivo) to an (Ig-derived) immunoglobulin, preferably an antibody, in particular the Fc domain of an antibody. In the context of the present invention, these artificially introduced molecules are presented within and / or on the surface of said T cell after (retroviral, lentiviral or non-viral) transduction as described herein below. Thus, after transduction, the T cells according to the invention can be activated in the presence of target cells by immunoglobulins, preferably (therapeutic) antibodies comprising specific mutations in the Fc domain as described herein.
[0207] The present invention also relates to a transduced T cell expressing an antigen-binding receptor encoded by a nucleic acid molecule encoding an antigen-binding receptor of the present invention. Thus, in the context of the present invention, a transduced cell may comprise a nucleic acid molecule encoding an antigen-binding receptor of the present invention, or a vector of the present invention expressing an antigen-binding receptor of the present invention.
[0208] In the context of the present invention, the term "transduced T cells" relates to genetically modified T cells (i.e., T cells into which a nucleic acid molecule has been purposefully introduced). The transduced T cells provided herein may comprise a vector of the present invention. Preferably, the transduced T cells provided herein comprise a nucleic acid molecule encoding an antigen-binding receptor of the present invention and / or a vector of the present invention. The transduced T cells of the present invention may be T cells that transiently or stably express foreign DNA (i.e., a nucleic acid molecule introduced into the T cells). In particular, the nucleic acid molecule encoding the antigen-binding receptor of the present invention can be stably integrated into the genome of the T cells by using retroviral or lentiviral transduction. The nucleic acid molecule encoding the antigen-binding receptor of the present invention can be transiently expressed by using mRNA transfection. Preferably, the transduced T cells provided herein are genetically modified by introducing a nucleic acid molecule into the T cells via a viral vector (e.g., a retroviral or lentiviral vector). Thus, the expression of the antigen-binding receptor may be constitutive and the extracellular domain of the antigen-binding receptor may be detectable on the cell surface. This extracellular domain of the antigen-binding receptor may comprise the complete extracellular domain of the antigen-binding receptor as defined herein, but may also comprise a portion thereof. The size of the antigen-binding portion of the antigen-binding receptor is the minimum required size.
[0209] When the antigen-binding receptor is introduced into the T cells under the control of an inducible or repressible promoter, the expression may be conditional or inducible. An example of such an inducible or repressible promoter may be a transcription system comprising the alcohol dehydrogenase I (alcA) gene promoter and the transactivator protein AlcR. Different agricultural alcohol-based formulations are used to control the expression of the gene of interest linked to the alcA promoter. Furthermore, the tetracycline-responsive promoter system may function to either activate or repress the gene expression system in the presence of tetracycline. Elements of these systems include the tetracycline repressor protein (TetR), the tetracycline operator sequence (tetO), and the tetracycline transactivator fusion protein (tTA), which is a fusion of TetR with the herpes simplex virus protein 16 (VP16) activation sequence. Furthermore, steroid-responsive promoters, metal-regulated promoters, or virulence-related (PR) protein-related promoters may be used.
[0210] This expression can be constitutive or constitutive, depending on the system used. The antigen-binding receptor of the present invention can be expressed on the surface of the transduced T cells provided herein. The extracellular portion of the antigen-binding receptor (i.e., the extracellular domain of the antigen-binding receptor) can be detectable on the cell surface, while the intracellular portion (i.e., the costimulatory signaling domain(s) and the stimulatory signaling domain) is not detectable on the cell surface. Detection of the extracellular domain of the antigen-binding receptor can be performed by using an antibody that specifically binds to this extracellular domain, or by a mutated Fc domain to which the extracellular domain can bind. The extracellular domain can be detected by flow cytometry or microscopy using these antibodies or Fc domains.
[0211] Other cells may also be transduced with the antigen-binding receptor of the present invention and directed against target cells. These additional cells include, but are not limited to, B cells, natural killer (NK) cells, innate lymphoid cells, macrophages, monocytes, dendritic cells, or neutrophils. Preferably, the immune cells will be lymphocytes. The antigen-binding receptor of the present invention on the surface of a leukocyte triggers the cell to be cytotoxic against target cells, regardless of the lineage from which the cell originates, in combination with a therapeutic antibody comprising a mutated Fc domain. Cytotoxicity occurs regardless of the stimulatory or costimulatory signaling domain selected for the antigen-binding receptor, and is not dependent on exogenous supply of additional cytokines. Thus, the transduced cells of the present invention may be, for example, CD4+ T cells, CD8+ T cells, γδ T cells, natural killer (NK) T cells, tumor infiltrating lymphocytes (TILs), myeloid cells, or mesenchymal stem cells. Preferably, the transduced cells provided herein are T cells (e.g., autologous T cells), and more preferably, the transduced cells are CD8+ T cells. Thus, in the context of the present invention, the transduced cells are CD8+ T cells. Moreover, in the context of the present invention, the transduced cells are autologous T cells. Thus, in the context of the present invention, the transduced cells are preferably autologous CD8+ T cells. In addition to the use of autologous cells (e.g., T cells) isolated from the subject, the present invention also encompasses the use of allogeneic cells. Thus, in the context of the present invention, the transduced cells may be allogeneic cells, such as allogeneic CD8+ T cells. The term allogeneic refers to cells derived from an unrelated donor individual / subject that is human leukocyte antigen (HLA)-matched with the individual / subject to be treated with the transduced cells of the antigen-binding receptor expression type described herein. Autologous cells refer to cells isolated / obtained as described above from the subject to be treated with the transduced cells described herein.
[0212] The transduced cells of the invention can be co-transduced with additional nucleic acid molecules, for example nucleic acid molecules encoding cytokines.
[0213] The invention also relates to a method for producing transduced T cells expressing an antigen binding receptor of the invention, comprising the steps of transducing T cells with a vector of the invention, culturing the transduced T cells under conditions that allow expression of the antigen binding receptor in or on the transduced cells, and recovering the transduced T cells.
[0214] In the context of the present invention, the transduced cells of the present invention are preferably produced by isolating cells (e.g., T cells, preferably CD8+ T cells) from a subject (preferably a human patient). Methods for isolating / obtaining cells (e.g., T cells, preferably CD8+ T cells) from a patient or from a donor are well known in the art, and in the context of the present cells (e.g., T cells, preferably CD8+ T cells) from a patient or from a donor, for example, the cells may be isolated by blood collection or removal of bone marrow. After isolating / obtaining the cells as a patient sample, the cells (e.g., T cells) are separated from other components of the sample. Several methods of isolating cells (e.g., T cells) from a sample are known, including, but not limited to, leukapheresis to obtain cells from a peripheral blood sample of a patient or donor, isolating / obtaining cells by using a FACS cell sorter, etc. The isolated / obtained T cells are then cultured and expanded, for example, by using an anti-CD3 antibody, by using anti-CD3 and anti-CD28 monoclonal antibodies, and / or by using an anti-CD3 antibody, an anti-CD28 antibody and interleukin 2 (IL-2) (see, for example, Dudley, Immunother. 26 (2003), 332-342 or Dudley, Clin. Oncol. 26 (2008), 5233-5239).
[0215] In a subsequent step, cells (e.g., T cells) are artificially / genetically modified / transduced by methods known in the art (see, e.g., Lemoine, J Gene Med 6 (2004), 374-386). Methods for transducing cells (e.g., T cells) are known in the art and include, but are not limited to, electroporation, calcium phosphate, cationic lipid or liposome methods when nucleic acids or recombinant nucleic acids are transduced. The nucleic acid to be introduced can be transduced with high efficiency as conventionally by using commercially available transfection reagents, such as Lipofectamine (Invitrogen, Catalog No.: 11668027). When a vector is used, the vector can be transduced in the same manner as the above-mentioned nucleic acids, as long as the vector is a plasmid vector (i.e., a vector that is not a viral vector). In the context of the present invention, methods for transducing cells (e.g., T cells) include retroviral or lentiviral T cell transduction, non-viral vectors (e.g., Sleeping Beauty minicircle vector), as well as mRNA transfection. "mRNA transfection" refers to a method well known to those skilled in the art for transiently expressing a protein of interest, such as an antigen-binding receptor of the present invention, in the cells to be transduced. Briefly, cells can be electroporated with mRNA encoding the antigen-binding receptor of the present invention by using an electroporation system (e.g., Gene Pulser, Bio-Rad), and then cultured by standard cell (e.g., T cell) culture protocols as described above (see hao et al., Mol Ther. 13(1) (2006), 151-159). The transduced cells of the present invention can be generated by lentiviral transduction, or most preferably, retroviral transduction.
[0216] In this regard, suitable retroviral vectors for transducing cells are known in the art and include, for example, SAMEN CMV / SRa (Clay et al., J. Immunol. 163 (1999), 507-513), LZRS-id3-IHRES (Heemskerk et al., J. Exp. Med. 186 (1997), 1597-1602), FeLV (Neil et al., Nature 308 (1984), 814-820), SAX (Kantoff et al., Proc. Natl. Acad. Sci. USA 83 (1986), 6563-6567), pDOL (Desiderio, J. Exp. Med. 167 (1988), 372-388), N2 (Kasid et al., Proc. Natl. Acad. Sci. USA 87 (1990), 473-477), LNL6 (Tiberghien et al., Blood 84 (1994), 1333-1341), pZipNEO (Chen et al., J. Immunol. 153 (1994), 3630-3638), LASN (Mullen et al., Hum. Gene Ther.7(1996),1123-1129),pG1XsNa(Taylor et al.,J.Exp.Med.184(1996),2031-2036),LCNX(Sun et al.,Hum.Gene Ther.8(1997),1041-1048),SFG(Gallardo et al.,Blood 90 (1997), and LXSN (Sun et al., Hum. Gene Ther.8(1997),1041-1048), SFG(Gallardo et al.,Blood 90(1997),952-957),HMB-Hb-Hu(Vieillard et al.,Proc.Natl.Acad.Sci.USA 94(1997),11595-11600),pMV7(Cochlovius et al. al.,Cancer Immunol.Immunother.46(1998),61-66),pSTITCH(Weitjens et al.,Gene Ther 5(1998),1195-1203),pLZR(Yang et al.,Hum.Gene Ther.10(1999), 123-132), pBAG(Wu et al.,Hum.Gene Ther.10(1999),977-982),rKat.43.267bn(Gilham et al.,J.Immunother.25(2002),139-151),pLGSN(Engels et al.,Hum.Gene Ther.14(2003),1155-1168),pMP71(Engels et al.,Hum.Gene Ther.14(2003),1155-1168),pGCSAM(Morgan et al.,J.Immunol.171(2003),3287-3295),pMSGV(Zhao et al. al., J. Immunol. 174 (2005), 4415-4423), or pMX (de Witte et al., J. Immunol. 181 (2008), 5128-5136). In the context of the present invention, suitable lentiviral vectors for transducing cells (e.g. T cells) are, for example, the PL-SIN lentiviral vector (Hotta et al., Nat Methods. 6(5)(2009), 370-376), p156RRL-sinPPT-CMV-GFP-PRE / NheI (Campeau et al., PLoS One 4(8)(2009), e6529), pCMVR8.74 (Addgene Catalog Number: 22036), FUGW (Lois et al., Science 295(5556)(2002), 868-872, pLVX-EF1 (Addgene Catalog Number: 64368), pLVE (Brunger et al., Proc Natl Acad Sci USA 111(9)(2014), E798-806), pCDH1-MCS1-EF1 (Hu et al., al.,Mol Cancer Res.7(11)(2009),1756-1770),pSLIK(Wang et al.,Nat Cell Biol.16(4)(2014),345-356),pLJM1(Solomon et al.,Nat Genet.45(12)(2013),1428-30),pLX302(Kang et al.,Sci Signal.6(287)(2013),rs13),pHR-IG(Xie et al., J Cereb Blood Flow Metab.33(12)(2013),1875-85), pRRLSIN (Addgene Catalog Number: 62053), pLS (Miyoshi et al., J Virol.72(10)(1998),8150-8157), pLL3.7 (Lazebnik et al., J Biol Chem.283(7)(2008),11078-82), FRIG (Raissi et al., Mol Cell Neurosci.57(2013),23-32), pWPT (Ritz-Laser et al., Diabetologia.46(6)(2003),810-821), pBOB (Marr et al., J Mol Neurosci.22(1-2)(2004),5-11), or pLEX (Addgene Catalog Number: 27976). .
[0217] The transduced cells of the present invention are preferably grown under controlled conditions outside their natural environment. In particular, the term "culture" refers to the in vitro growth of cells (e.g., the transduced cells of the present invention) derived from a multicellular eukaryote (preferably from a human patient). Cell culture is an experimental technique for keeping cells alive that have been separated from their original tissue source. Here, the transduced cells of the present invention are cultured under conditions that allow the expression of the antigen-binding receptor of the present invention in or on said transduced cells. Conditions that allow the expression of the transgene (i.e., the antigen-binding receptor of the present invention) are generally known in the art and include, for example, the addition of agonistic anti-CD3 and anti-CD28 antibodies, and cytokines such as interleukin 2 (IL-2), interleukin 7 (IL-7), interleukin 12 (IL-12) and / or interleukin 15 (IL-15). After the antigen-binding receptor of the invention is expressed in the cultured transduced cells (e.g., CD8+ T), the transduced cells are harvested (i.e., re-extracted) from the culture (i.e., the culture medium).
[0218] Thus, the present invention also includes transduced cells, preferably T cells, in particular CD8+ T cells, expressing an antigen-binding receptor encoded by a nucleic acid molecule of the present invention obtainable by the method of the present invention.
[0219] nucleic acid molecule Further aspects of the present invention are nucleic acids and vectors encoding one or more antigen-binding receptors of the present invention. An exemplary nucleic acid molecule encoding an antigen-binding receptor of the present invention is shown in SEQ ID NO: 20. The nucleic acid molecule of the present invention may be under the control of a regulatory sequence. For example, a promoter, transcription enhancer and / or sequence that allows inducible expression of the antigen-binding receptor of the present invention may be employed. In the context of the present invention, the nucleic acid molecule is expressed under the control of a constitutive or inducible promoter. Suitable promoters include, for example, the CMV promoter (Qin et al., PLoS One 5(5)(2010), e10611), the UBC promoter (Qin et al., PLoS One 5(5)(2010), e10611), the PGK (Qin et al., PLoS One 5(5)(2010), e10611), the EF1A promoter (Qin et al., PLoS One 5(5)(2010), e10611), the CAGG promoter (Qin et al., PLoS One 5(5)(2010), e10611), the SV40 promoter (Qin et al., PLoS One 5(5)(2010), e10611), the COPIA promoter (Qin et al., PLoS One 5(5)(2010), e10611), the ACT5C ... al., PLoS One 5(5)(2010), e10611), TRE promoter (Qin et al., PLoS One.5(5)(2010), e10611), Oct3 / 4 promoter (Chang et al., Molecular Therapy 9(2004), S367-S367(doi:10.1016 / j.ymthe.2004.06.904)) or Nanog promoter (Wu et al., Cell Res.15(5)(2005), 317-24). The present invention therefore also relates to vector(s) comprising a nucleic acid molecule according to the present invention. The term vector herein refers to a circular or linear nucleic acid molecule capable of autonomously replicating in a cell into which it is introduced.Many suitable vectors are known to those skilled in the art of molecular biology, the choice of which depends on the desired function and includes plasmids, cosmids, viruses, bacteriophages, and other vectors conventionally used in genetic engineering. Various plasmids and vectors can be constructed using methods well known to those skilled in the art; see, for example, the techniques described in Sambrook et al. (loc cit.) and Ausubel, Current Protocols in Molecular Biology, Green Publishing Associates and Wiley Interscience, NY (1989), (1994). Alternatively, the polynucleotides and vectors of the invention can be reconstituted into liposomes for delivery to target cells. As will be described in more detail below, cloning vectors have been used to isolate individual sequences of DNA. When expression of a particular polypeptide is required, the relevant sequence can be introduced into an expression vector. Exemplary cloning vectors include pBluescript SK, pGEM, pUC9, pBR322, pGA18, and pGBT9. Exemplary expression vectors include pTRE, pCAL-n-EK, pESP-1, and pOP13CAT.
[0220] The present invention also relates to a vector comprising a nucleic acid molecule(s) that is a regulatory sequence operably linked to said nucleic acid molecule(s) encoding an antigen binding receptor as defined herein. In the context of the present invention, the vector may be polycistronic. Such regulatory sequences (control elements) are known to those skilled in the art and may include promoters, splice cassettes, translation initiation codons, translation and insertion sites for introducing inserts into the vector. In the context of the present invention, said nucleic acid molecule(s) is operably linked to said expression control sequence(s) allowing expression in eukaryotic or prokaryotic cells. It is envisaged that said vector is an expression vector(s) comprising a nucleic acid molecule(s) encoding an antigen binding receptor as defined herein. Operably linked refers to a juxtaposition in which the components so described are in a relationship permitting them to function in their intended manner. A control sequence operably linked to a coding sequence is ligated such that expression of the coding sequence is achieved under conditions compatible with the control sequences. It will be apparent to those skilled in the art that when the control sequence is a promoter, a double-stranded nucleic acid is preferably used.
[0221] In the context of the present invention, the described vector(s) are expression vector(s). An expression vector is a construct that can be used to transform a selected cell, providing expression of a coding sequence in the selected cell. An expression vector can be, for example, a cloning vector(s), a binary vector(s) or an integrating vector(s). Expression preferably comprises transcription of the nucleic acid molecule into a translatable mRNA. Regulatory elements ensuring expression in prokaryotes and / or eukaryotic cells are well known to those skilled in the art. In the case of eukaryotic cells, they usually comprise a promoter ensuring initiation of transcription and, optionally, a polyA signal ensuring termination of transcription and stabilization of the transcript. Possible regulatory elements allowing expression in prokaryotic host cells include, for example, the PL, lac, trp or tac promoters of E. coli, while examples of regulatory elements allowing expression in eukaryotic host cells include the AOX1 or GAL1 promoters of yeast, or the CMV, SV40, RSV promoters (Rous sarcoma virus), CMV enhancer, SV40 enhancer or globin introns in mammalian and other animal cells.
[0222] Besides elements responsible for the initiation of transcription, such regulatory elements may also include transcription termination signals, such as the SV40-polyA site or the tk-polyA site downstream of the polynucleotide. Furthermore, depending on the expression system used, leader sequences encoding signal peptides capable of directing the polypeptide to a cellular compartment or secreting it into the medium can be added to the coding sequence of the described nucleic acid sequences, which are well known in the art; see also the accompanying examples, for example.
[0223] The leader sequence(s) are assembled in appropriate step with the translation, initiation and termination sequences, and are preferably capable of directing secretion of the translated protein or a part thereof into the periplasmic space or into the extracellular medium. Optionally, the heterologous sequence can code for an antigen-binding receptor comprising an N-terminal identification peptide that confers desirable properties, such as stabilization or convenient purification of the expressed recombinant product; see supra. In this context, suitable expression vectors are known in the art, such as the Okayama-Berg cDNA expression vectors pcDV1 (Pharmacia), pCDM8, pRc / CMV, pcDNA1, pcDNA3 (In-vitrogene), pEF-DHFR, pEF-ADA or pEF-neo (Raum et al. Cancer Immunol Immunother 50 (2001), 141-150) or pSPORT1 (GIBCO BRL).
[0224] In the context of the present invention, the expression control sequences will be eukaryotic promoter systems in vectors capable of transforming or transfecting eukaryotic cells, although control sequences for prokaryotic cells may also be used. Once the vector is incorporated into a suitable cell, the cell is maintained as desired under conditions suitable for high level expression of the nucleotide sequence. Additional regulatory elements may include transcriptional enhancers as well as translational enhancers. Advantageously, the above vectors of the present invention include selectable and / or scorable markers. Selectable marker genes useful for the selection of transformed cells and, for example, plant tissues and plants, are well known to those of skill in the art and include, for example, antimetabolite resistance as the basis of selection, such as dhfr, which confers resistance to methotrexate (Reiss, Plant Physiol. (Life Sci. Adv.) 13 (1994), 143-149), npt, which confers resistance to the aminoglycosides neomycin, kanamycin, and paromycin (Herrera-Estrella, EMBO J. 2 (1983), 987-995), and hygro, which confers resistance to hygromycin (Marsh, Gene 32 (1984), 481-485). Additional selection genes have been described, namely trpB, which allows cells to utilize indole instead of tryptophan; hisD, which allows cells to utilize histinol instead of histidine (Hartman, Proc. Natl. Acad. Sci. USA 85 (1988), 8047); mannose-6-phosphate isomerase, which allows cells to utilize mannose (WO 94 / 20627) and ODC (ornithine decarboxylase), which confers resistance to the ornithine decarboxylase inhibitor 2-(difluoromethyl)-DL-ornithine, DFMO (McConlogue, 1987, In: Current Communications in Molecular Biology, Cold Spring Harbor Laboratory ed.) or deaminase from Aspergillus terreus, which confers resistance to blasticidin S (Tamura, Biosci. Biotechnol. Biochem. 59 (1995), 2336-2338).
[0225] Useful scorable markers are also known to those skilled in the art and are commercially available. Advantageously, said markers are genes encoding luciferase (Giacomin, Pl. Sci. 116 (1996), 59-72; Scikantha, J. Bact. 178 (1996), 121), green fluorescent protein (Gerdes, FEBS Lett. 389 (1996), 44-47) or β-glucuronidase (Jefferson, EMBO J. 6 (1987), 3901-3907). This embodiment is particularly useful for simple and rapid screening of cells, tissues and organisms containing the described vectors.
[0226] As mentioned above, the described nucleic acid molecules can be used alone or as part of a vector(s) to express the antigen-binding receptor of the present invention in cells, for example for adoptive T cell therapy, but also for gene therapy purposes. The nucleic acid molecule or vector(s) containing the DNA sequence(s) encoding any one of the antigen-binding receptors described herein is introduced into a cell, and then the polypeptide of interest is produced. Gene therapy is based on introducing therapeutic genes into cells by ex vivo or in vivo techniques and is one of the most important applications of gene transfer. Suitable vectors, methods or gene delivery systems for in vitro or in vivo gene therapy are described in the literature and are known to the skilled artisan; see, for example, Giordano, Nature Medicine 2 (1996), 534-539; Schaper, Circ. Res. 79 (1996), 911-919; Anderson, Science 256 (1992), 808-813; Verma, Nature 389 (1994), 239; Isner, Lancet 348 (1996), 370-374; Muhlhauser, Circ. Res. 77 (1995), 1077-1086; Onodera, Blood 91 (1998), 30-36; Verma, Gene Ther. 5 (1998), 692-699; Nabel, Ann. NY Acad. Sci. 811 (1997), 289-292; Verzeletti, Hum. Gene Ther. 9 (1998), 2243-51; Wang, Nature Medicine 2 (1996), 714-716; WO 94 / 29469; WO 97 / 00957; U.S. Patent No. 5,580,859; U.S. Patent No. 5,589,466; or Schaper, Current Opinion in Biotechnology 7 (1996), 635-640. The nucleic acid molecules and vectors described can be designed for direct introduction into cells or for introduction via liposomes or viral vectors (e.g., adenovirus, retrovirus).In the context of the present invention, said cell is a T cell, such as a CD8+ T cell, a CD4+ T cell, a CD3+ T cell, a γδ T cell or a natural killer (NK) T cell, preferably a CD8+ T cell.
[0227] In accordance with the above, the present invention relates to a method for deriving vectors, in particular plasmids, cosmids and bacteriophages, conventionally used in genetic engineering, comprising a nucleic acid molecule encoding a polypeptide sequence of an antigen-binding receptor as defined herein. In the context of the present invention, said vectors are expression vectors and / or gene transfer or targeting vectors. Expression vectors derived from viruses such as retroviruses, vaccinia viruses, adeno-associated viruses, herpes viruses or bovine papilloma viruses can be used for the delivery of said polynucleotides or vectors to a target cell population.
[0228] Methods well known to those skilled in the art can be used to construct the recombinant vector(s); see, for example, the techniques described in Sambrook et al. (loc cit.), Ausubel (1989, loc cit.) or other standard textbooks. Alternatively, the above nucleic acid molecules and vectors can be reconstituted into liposomes for delivery to target cells. The vectors containing the nucleic acid molecules of the invention can be introduced into host cells by well-known methods that vary depending on the type of cellular host. For example, calcium chloride transfection is commonly used for prokaryotic cells, while calcium phosphate treatment or electroporation is used for other cellular hosts (see Sambrook, supra). The vectors described can be, inter alia, pEF-DHFR, pEF-ADA or pEF-neo. The vectors pEF-DHFR, pEF-ADA and pEF-neo have been described in the art, for example in Mack et al. Proc. Natl. Acad. Sci. USA 92 (1995), 7021-7025 and Raum et al. Cancer Immunol Immunother 50 (2001), 141-150.
[0229] The present invention also provides a T cell transduced with a vector as described herein. The T cell may be produced by introducing at least one of the vectors or at least one of the nucleic acid molecules into a T cell or a precursor thereof. The presence of the at least one vector or at least one nucleic acid molecule in the T cell mediates the expression of a gene encoding the antigen-binding receptor comprising an extracellular domain that comprises an antigen-binding portion capable of specifically binding to a mutated Fc domain. The vector of the present invention may be polycistronic.
[0230] The described nucleic acid molecule(s) or vector(s) introduced into a T cell or its precursor cell can be integrated into the genome of the cell or maintained extrachromosomally.
[0231] target cell antigen As mentioned above, the (Ig-derived) domain of the antibodies described herein, consisting of a mutated Fc domain, in particular an Fc domain comprising the amino acid mutation P329G (according to EU numbering), comprises an antigen interaction site with specificity for a target cell surface molecule, e.g. a tumor-specific antigen naturally present on the surface of a tumor cell. In the context of the present invention, such an antibody brings a transduced T cell described herein, comprising an antigen-binding receptor of the present invention, into physical contact with a target cell (e.g. a tumor cell), and the transduced T cell is activated. Activation of the transduced T cell of the present invention preferentially leads to lysis of the target cell, as described herein.
[0232] Examples of target cell antigens (e.g., tumor markers) that naturally occur on the surface of target cells (e.g., tumors) are provided herein below and include, but are not limited to, FAP (fibroblast activation protein), CEA (carcinoembryonic antigen), p95 (p95HER2), BCMA (B cell maturation antigen), EpCAM (epithelial cell adhesion molecule), MSLN (mesothelin), MCSP (melanoma chondroitin sulfate proteoglycan), HER-1 (human epidermal growth factor 1), HER-2 (human epidermal growth factor 2), HER-3 (human epidermal growth factor 3), CD19, CD20, CD22, CD33, CD38, CD40, CD41, CD42, CD43, CD44, CD45, CD46, CD47, CD48, CD49, CD50, CD51, CD52, CD53, CD54, CD55, CD56, CD57, CD58, CD59, CD60, CD61, CD62, CD63, CD64, CD65, CD66, CD67, CD68, CD69, CD70, CD71, CD72, CD73, CD74, CD75, CD76, CD77, CD78, CD79, CD80, CD81, CD82, CD83, CD84, CD85, CD86, CD87, CD88, CD89, CD90, CD91, CD92, CD93, CD94, CD95, CD95, CD96, CD97, CD98, CD99, CD100, CD101, CD102, CD103, CD104, CD105, CD106, CD107, CD108, CD109, CD110, CD111, CD112, CD113, CD114, D52Flt3, folate receptor 1 (FOLR1), human trophoblast cell surface antigen 2 (Trop-2), cancer antigen 12-5 (CA-12-5), human leukocyte antigen-antigen D-related (HLA-DR), MUC-1 (mucin-1), A33 antigen, PSMA (prostate-specific membrane antigen), FMS-like tyrosine kinase 3 (FLT-3), PSMA (prostate-specific membrane antigen), PSCA (prostate stem cell antigen), transferrin receptor, TNC (tenascin), carbonic anhydrase IX (CA-IX), and / or peptides bound to molecules of the human major histocompatibility complex (MHC).
[0233] Thus, in the context of the present invention, the antigen binding receptors described herein comprise an Fc domain comprising the amino acid mutation P329G (according to EU numbering), i.e. FAP (fibroblast activation protein), CEA (carcinoembryonic antigen), p95 (p95HER2), BCMA (B cell maturation antigen), EpCAM (epithelial cell adhesion molecule), MSLN (mesothelin), MCSP (melanoma chondroitin sulfate proteoglycan), HER-1 (human epidermal growth factor 1), HER-2 (human epidermal growth factor 2), HER-3 (human epidermal growth factor 3), CD19, CD20, CD22, CD33, CD38, CD52Flt3, folate receptor 1 (FOLR1) , human trophoblast cell surface antigen 2 (Trop-2), cancer antigen 12-5 (CA-12-5), human leukocyte antigen-antigen D-related (HLA-DR), MUC-1 (mucin-1), A33 antigen, PSMA (prostate specific membrane antigen), FMS-like tyrosine kinase 3 (FLT-3), PSMA (prostate specific membrane antigen), PSCA (prostate stem cell antigen), transferrin receptor, TNC (tenascin), carbonic anhydrase IX (CA-IX), and / or peptides bound to molecules of the human major histocompatibility complex (MHC).
[0234] A33 antigen, BCMA (B cell maturation antigen), cancer antigen 12-5 (CA-12-5), carbonic anhydrase IX (CA-IX), CD19, CD20, CD22, CD33, CD38, CEA (carcinoembryonic antigen), EpCAM (epithelial cell adhesion molecule), FAP (fibroblast activation protein), FMS-like tyrosine kinase 3 (FLT-3), folate receptor 1 (FOLR1), HER-1 (human epidermal growth factor 1), HER-2 (human epidermal growth factor 2), HER-3 (human epidermal growth factor 3), human leukocyte antigen-antigen D-related (HLA-DR), MSLN (mesothelin), MCS Sequences of (human) members of P (melanoma chondroitin sulfate proteoglycan), MUC-1 (mucin-1), PSMA (prostate specific membrane antigen), PSMA (prostate specific membrane antigen), PSCA (prostate stem cell antigen), p95 (p95HER2), transferrin receptor, TNC (tenascin), human trophoblast cell surface antigen 2 (Trop-2) are available in the UniProtKB / Swiss-Prot database and can be obtained from http: / / www.uniprot.org / uniprot / ?query=reviewed%3Ayes. These (protein) sequences are also associated with annotated modified sequences. The present invention also provides techniques and methods in which homologous sequences of the concise sequences provided herein, and genetic allelic variants, etc. are used. Preferably, such variants of the concise sequences herein are used. Preferably, such variants are genetic variants. The skilled person can easily deduce the relevant coding regions of these (protein) sequences from the entries of these databanks, which contain entries for genomic DNA as well as mRNA / DNA: the sequence of (human) FAP (fibroblast activation protein) can be taken from Swiss-Prot database entry Q12884 (entry version 168, sequence version 5); the sequence of (human) CEA (carcinoembryonic antigen) can be taken from Swiss-Prot database entry P06731 (entry version 171, sequence version 3); the sequence of (human) EpCAM (epithelial cell adhesion molecule) can be taken from Swiss-Prot database entry P16422 (entry version 117, sequence version 2);The sequence of (human) MSLN (mesothelin) can be obtained from UniProt entry number Q13421 (version number 132, sequence version 2); the sequence of (human) FMS-like tyrosine kinase 3 (FLT-3) can be obtained from Swiss-Prot database entry P36888 (primary citable accession number) or Q13414 (secondary accession number), version number 165, sequence version 2; the sequence of (human) MCSP (melanoma chondroitin sulfate proteoglycan) can be obtained from UniProt entry number Q6 The sequence of (human) folate receptor 1 (FOLR1) can be obtained from UniProt entry no. P15328 (primary citable accession number) or Q53EW2 (secondary accession number), version no. 153 and sequence version 3; the sequence of (human) trophoblast surface antigen 2 (Trop-2) can be obtained from UniProt entry no. P09758 (primary citable accession number) or Q15658 (secondary accession number), version no. 172 and sequence version 3. The sequence of (human) PSCA (prostate stem cell antigen) can be obtained from UniProt entry number O43653 (primary citable accession number) or Q6UW92 (secondary accession number), version number 134 and sequence version 1; the sequence of (human) HER-1 (epidermal growth factor receptor) can be obtained from Swiss-Prot database entry P00533 (entry version 177, sequence version 2); the sequence of (human) HER-2 (receptor tyrosine protein kinase erbB-2) can be obtained from Swiss-Prot database entry P00533 (entry version 177, sequence version 2). can be obtained from Swiss-Prot database entry P04626 (entry version 161, sequence version 1); the sequence of (human) HER-3 (receptor tyrosine protein kinase erbB-3) can be obtained from Swiss-Prot database entry P21860 (entry version 140, sequence version 1); the sequence of (human) CD20 (B lymphocyte antigen CD20) can be obtained from Swiss-Prot database entry P11836 (entry version 117, sequence version 1);The sequence of (human) CD22 (B-lymphocyte antigen CD22) can be obtained from Swiss-Prot database entry P20273 (entry version 135, sequence version 2); the sequence of (human) CD33 (B-lymphocyte antigen CD33) can be obtained from Swiss-Prot database entry P20138 (entry version 129, sequence version 2); the sequence of (human) CA-12-5 (mucin 16) can be obtained from Swiss-Prot database entry The sequence of (human) HLA-DR can be obtained from Swiss-Prot database entry Q29900 (entry version 59, sequence version 1); the sequence of (human) MUC-1 (mucin-1) can be obtained from Swiss-Prot database entry P15941 (entry version 135, sequence version 3); the sequence of (human) A33 (cell surface A33 antigen) can be obtained from Swiss-Prot database entry P15941 (entry version 135, sequence version 3); , can be obtained from Swiss-Prot database entry Q99795 (entry version 104, sequence version 1); the sequence of (human) PSMA (glutamic acid carboxypeptidase 2) can be obtained from Swiss-Prot database entry Q04609 (entry version 133, sequence version 1); the sequence of (human) transferrin receptor can be obtained from Swiss-Prot database entries Q9UP52 (entry version 99, sequence version 1) and P02786 (entry version 152, sequence version 2); the sequence of (human) TNC (tenascin) can be obtained from Swiss-Prot database entry P24821 (entry version 141, sequence version 3); or the sequence of (human) CA-IX (carbonic anhydrase IX) can be obtained from Swiss-Prot database entry Q16790 (entry version 115, sequence version 2).
[0235] In a preferred embodiment, the target cell antigen is selected from the group consisting of fibroblast activation protein (FAP), carcinoembryonic antigen (CEA), mesothelin (MSLN), CD20, folate receptor 1 (FOLR1) and tenascin (TNC).
[0236] Antibodies capable of specifically binding to any of the above target cell antigens can be generated using methods well known in the art, such as immunization of a mammalian immune system and / or phage display using recombinant libraries.
[0237] The antibody used according to the invention comprises an Fc domain comprising a P329G mutation (according to EU numbering). The P329G mutation reduces Fc receptor binding and / or effector function and can be used in combination with further Fc mutations affecting binding and / or effector function. Thus, in a further embodiment, the mutated Fc domain of the antibody exhibits reduced binding affinity to Fc receptors and / or reduced effector function compared to a native IgG1 Fc domain. In one such embodiment, the mutated Fc domain (or an antibody comprising said Fc mutated domain) exhibits less than 50%, preferably less than 20%, more preferably less than 10%, most preferably less than 5% of the binding affinity to Fc receptors compared to a native IgG1 Fc domain (or an antibody comprising a native IgG1 Fc domain) and / or exhibits less than 50%, preferably less than 20%, more preferably less than 10%, most preferably less than 5% of the effector function compared to a native IgG1 Fc domain (or an antibody comprising a native IgG1 Fc domain). In one embodiment, the mutated Fc domain (or an antibody comprising said mutated Fc domain) does not substantially bind to an Fc receptor and / or does not induce effector function. In a particular embodiment, the Fc receptor is an Fcγ receptor. In one embodiment, the Fc receptor is a human Fc receptor. In one embodiment, the Fc receptor is an activating Fc receptor. In a particular embodiment, the Fc receptor is an activating human Fcγ receptor, more particularly human FcγRIIIa, FcγRI or FcγRIIa, most particularly human FcγRIIIa. In one embodiment, the effector function is one or more selected from the group of CDC, ADCC, ADCP and cytokine secretion. In a particular embodiment, the effector function is ADCC. In one embodiment, the mutated Fc domain exhibits substantially altered binding affinity for the neonatal Fc receptor (FcRn) compared to a native IgG1 Fc domain. In one embodiment, the antibody comprising the mutated Fc domain exhibits less than 20%, particularly less than 10%, more particularly less than 5% of the binding affinity to the Fc receptor compared to an antibody comprising a non-engineered Fc domain. In a particular embodiment, the Fc receptor is an Fcγ receptor. In some embodiments, the Fc receptor is a human Fc receptor.In some embodiments, the Fc receptor is an activating Fc receptor. In a particular embodiment, the Fc receptor is an activating human Fcγ receptor, more particularly human FcγRIIIa, FcγRI or FcγRIIa, most particularly human FcγRIIIa. Preferably, the binding to each of these receptors is reduced. In some embodiments, the binding affinity to complement components is also reduced, particularly the binding affinity to C1q.
[0238] In certain embodiments, the Fc domain of the antibody is mutated to reduce effector function compared to the non-mutated Fc domain. Reduced effector function may include, but is not limited to, one or more of the following: reduced complement-dependent cytotoxicity (CDC), reduced antibody-dependent cell-mediated cytotoxicity (ADCC), reduced antibody-dependent cellular phagocytosis (ADCP), reduced cytokine secretion, reduced immune complex-mediated antigen uptake by antigen-presenting cells, reduced binding to NK cells, reduced binding to macrophages, reduced binding to monocytes, reduced binding to polymorphonuclear cells, reduced direct signaling to induce apoptosis, reduced cross-linking of target-bound antibodies, reduced maturation of dendritic cells, or reduced priming of T cells. In one embodiment, the reduced effector function is one or more selected from the group of reduced CDC, reduced ADCC, reduced ADCP, and reduced cytokine secretion. In certain embodiments, the reduced effector function is reduced ADCC. In one embodiment, the reduced ADCC is less than 20% of the ADCC induced by a non-engineered Fc domain (or an antibody comprising a non-engineered Fc domain).
[0239] In one embodiment, the amino acid mutation that reduces the binding affinity and / or effector function of the Fc domain to the Fc receptor is an amino acid substitution. In one embodiment, the Fc domain comprises an amino acid substitution at a position selected from the group of E233, L234, L235, N297, and P331. In a more specific embodiment, the Fc domain comprises an amino acid substitution at the position L234 and / or L235. In some embodiments, the Fc domain comprises the amino acid substitutions L234A and L235A. In one such embodiment, the Fc domain is an IgG1 Fc domain, in particular a human IgG1 Fc domain. In a more specific embodiment, the further amino acid substitution is E233P, L234A, L235A, L235E, N297A, N297D, or P331S. In a preferred embodiment, the Fc domain comprises the amino acid mutations L234A, L235A, and P329G ("P329G LALA") according to EU numbering. In one such embodiment, the Fc domain is an IgG1 Fc domain, in particular a human IgG1 Fc domain. The "P329G LALA" combination of amino acid substitutions almost completely abolishes Fcγ receptor (and complement) binding of the human IgG1 Fc domain, as described in PCT Application Publication No. WO2012 / 130831, which is incorporated herein by reference in its entirety. WO2012 / 130831 also describes methods for preparing such mutant Fc domains and for determining properties such as Fc receptor binding or effector function.
[0240] In certain embodiments, the N-glycosylation of the Fc domain is ablated. In one such embodiment, the Fc domain comprises an amino acid mutation at position N297, in particular replacing the asparagine with alanine (N297A) or aspartic acid (N297D).
[0241] In addition to the Fc domains described herein and in PCT Publication No. WO2012 / 130831, Fc domains with reduced Fc receptor binding and / or effector function also include substitutions of one or more of Fc domain residues 238, 265, 269, 270, 297, 327 and 329 (U.S. Patent No. 6,737,056). Such Fc variants include Fc variants with substitutions at two or more of amino acid positions 265, 269, 270, 297 and 297, including the so-called "DANA" Fc variant in which residues 265 and 297 are mutated to alanine (U.S. Patent No. 7,332,581).
[0242] Variant Fc domains can be prepared by amino acid deletion, substitution, insertion or modification using genetic or chemical methods well known in the art. Genetic methods may include site-directed mutagenesis of the encoding DNA sequence, PCR, gene synthesis, etc. The exact nucleotide changes can be confirmed, for example, by screening.
[0243] Binding to Fc receptors can be easily determined, for example, by ELISA or by surface plasmon resonance (SPR) using standard equipment such as a BIAcore instrument (GE Healthcare) and Fc receptors that can be obtained by recombinant expression. Alternatively, the binding affinity of an Fc domain or a cell-activating bispecific antigen-binding molecule comprising an Fc domain to an Fc receptor can be assessed using a cell line known to express a particular Fc receptor (e.g., human NK cells expressing the FcγIIIa receptor).
[0244] The effector function of an Fc domain or an antibody containing an Fc domain can be measured by methods known in the art. Other examples of in vitro assays for evaluating the ADCC activity of a molecule of interest are described in U.S. Patent No. 5,500,362, Hellstrom et al. Proc Natl Acad Sci USA 83, 7059-7063 (1986) and Hellstrom et al., Proc Natl Acad Sci USA 82, 1499-1502 (1985), U.S. Patent No. 5,821,337, Bruggemann et al., J Exp Med 166, 1351-1361 (1987). Alternatively, non-radioactive assay methods may be used (e.g., the ACTI™ non-radioactive cytotoxicity assay for flow cytometry (CellTechnology, Inc. Mountain View, CA) and the CytoTox 96® non-radioactive cytotoxicity assay (Promega, Madison, WI)). Useful effector cells for such assays include peripheral blood mononuclear cells (PBMC) and natural killer (NK) cells. Alternatively, or additionally, ADCC activity of the molecule of interest may be assessed in vivo, e.g., in an animal model such as that disclosed in Clynes et al., Proc Natl Acad Sci USA 95, 652-656 (1998).
[0245] In some embodiments, binding of the Fc domain to complement components, particularly C1q, is reduced. Thus, in some embodiments in which the Fc domain is engineered to reduce effector function, said reduced effector function includes reduced CDC. C1q binding assays can be performed to determine whether an antibody can bind C1q and therefore has CDC activity. See, for example, the C1q and C3c binding ELISAs in WO 2006 / 029879 and WO 2005 / 100402. To assess complement activation, CDC assays may be performed (see, for example, Gazzano-Santoro et al., J Immunol Methods 202, 163 (1996); Cragg et al., Blood 101, 1045-1052 (2003); and Cragg and Glennie, Blood 103, 2738-2743 (2004)).
[0246] kit A further aspect of the invention is a kit comprising a nucleic acid encoding an antigen binding receptor of the invention and / or a cell, preferably a T cell for transduction with / to be transduced with an antigen binding receptor of the invention, and optionally an antibody / antibodies comprising a mutated Fc domain, wherein the antigen binding receptor is capable of specifically binding to the mutated Fc domain.
[0247] therefore, (A) a transduced T cell capable of expressing an antigen-binding receptor of the invention; and (B) An antibody that binds to a target cell antigen and comprises an Fc domain that includes the amino acid mutation P329G according to EU numbering. A kit is provided comprising:
[0248] moreover, (A) an isolated polynucleotide and / or vector encoding an antigen-binding receptor of the invention; and (B) An antibody that binds to a target cell antigen and contains an Fc domain that contains the amino acid mutation P329G according to EU numbering. A kit is provided comprising:
[0249] The kit of the invention may comprise transduced T cells, isolated polynucleotides and / or vectors, and one or more antibodies comprising an Fc domain comprising the amino acid mutation P329G according to EU numbering. In a particular embodiment, the antibody is a therapeutic antibody, for example a tumor-specific antibody as described herein above. Tumor-specific antigens are known in the art and described herein above. In the context of the present invention, the antibody is administered before, simultaneously with, or after administration of the transduced T cells expressing the antigen-binding receptor of the invention. The kit according to the invention comprises the transduced T cells or a polynucleotide / vector for generating the transduced T cells. In this context, the transduced T cells are universal T cells, since they are not specific for a particular tumor, but can be targeted to any tumor by using a therapeutic antibody comprising a mutated Fc domain. Provided herein are examples of antibodies that comprise an Fc domain that includes the amino acid mutation P329G according to EU numbering (e.g., SEQ ID NOs: 102-115), however, any antibody that comprises an Fc domain that includes the amino acid mutation P329G according to EU numbering can be used in accordance with the present invention and can be included in the kits provided herein.
[0250] In certain embodiments, the antibody comprising the mutated Fc region is capable of specifically binding to CD20 and comprises a heavy chain sequence of SEQ ID NO: 102 and a light chain sequence of SEQ ID NO: 103. In one embodiment, the antibody comprising the mutated Fc region is capable of specifically binding to FAP and comprises a heavy chain sequence of SEQ ID NO: 104 and a light chain sequence of SEQ ID NO: 105. In one embodiment, the antibody comprising the mutated Fc region is capable of specifically binding to CEA and comprises a heavy chain sequence of SEQ ID NO: 106 and a light chain sequence of SEQ ID NO: 107, a heavy chain sequence of SEQ ID NO: 108 and a light chain sequence of SEQ ID NO: 109, a heavy chain sequence of SEQ ID NO: 110 and a light chain sequence of SEQ ID NO: 111, or a heavy chain sequence of SEQ ID NO: 112 and a light chain sequence of SEQ ID NO: 113. In a further embodiment, the antibody comprising the mutated Fc region is capable of specifically binding to tenascin (TNC) and comprises a heavy chain sequence of SEQ ID NO: 114 and a light chain sequence of SEQ ID NO: 115.
[0251] In one embodiment of the invention, a kit is provided comprising transduced T cells capable of expressing the amino acid sequence of SEQ ID NO:7 ("VH3VL1-CD8ATD-CD137CSD-CD3zSSD"), or the kit comprises a polynucleotide encoding the amino acid sequence of SEQ ID NO:7 (e.g., the kit comprises a polynucleotide comprising the sequence of SEQ ID NO:20) in combination with an antibody comprising a heavy chain of SEQ ID NO:102 and a light chain of SEQ ID NO:103. The kit can be used to treat CD20 positive cancer.
[0252] In another embodiment, a kit is provided that comprises transduced T cells capable of expressing the amino acid sequence of SEQ ID NO:7 ("VH3VL1-CD8ATD-CD137CSD-CD3zSSD"), or the kit comprises a polynucleotide encoding the amino acid sequence of SEQ ID NO:7 (e.g., the kit comprises a polynucleotide comprising the sequence of SEQ ID NO:20) in combination with an antibody comprising a heavy chain of SEQ ID NO:104 and a light chain of SEQ ID NO:105. This kit can be used to treat FAP positive cancer.
[0253] In another embodiment, a kit is provided comprising transduced T cells capable of expressing the amino acid sequence of SEQ ID NO:7 ("VH3VL1-CD8ATD-CD137CSD-CD3zSSD"), or the kit comprises a polynucleotide encoding the amino acid sequence of SEQ ID NO:7 (e.g., the kit comprises a polynucleotide comprising the sequence of SEQ ID NO:20) in combination with an antibody comprising a heavy chain of SEQ ID NO:106 and a light chain of SEQ ID NO:107. Alternatively, a kit is provided comprising transduced T cells capable of expressing the amino acid sequence of SEQ ID NO:7 ("VH3VL1-CD28ATD-CD137CSD-CD3zSSD"), or the kit comprises a polynucleotide encoding the amino acid sequence of SEQ ID NO:7 (e.g., the kit comprises a polynucleotide comprising the sequence of SEQ ID NO:20) in combination with an antibody comprising a heavy chain of SEQ ID NO:108 and a light chain of SEQ ID NO:109. The kit can be used to treat FAP-positive cancer. Alternatively, kits are provided that include transduced T cells capable of expressing the amino acid sequence of SEQ ID NO:7 ("VH3VL1-CD28ATD-CD137CSD-CD3zSSD"), or kits that include a polynucleotide encoding the amino acid sequence of SEQ ID NO:7 (e.g., the kit includes a polynucleotide comprising the sequence of SEQ ID NO:20) in combination with an antibody comprising a heavy chain of SEQ ID NO:110 and a light chain of SEQ ID NO:111. In another embodiment, kits are provided that include transduced T cells capable of expressing the amino acid sequence of SEQ ID NO:7 ("VH3VL1-CD8ATD-CD137CSD-CD3zSSD"), or kits that include a polynucleotide encoding the amino acid sequence of SEQ ID NO:7 (e.g., the kit includes a polynucleotide comprising the sequence of SEQ ID NO:20) in combination with an antibody comprising a heavy chain of SEQ ID NO:112 and a light chain of SEQ ID NO:113. These kits can be used to treat CEA-positive cancers.
[0254] In another embodiment, a kit is provided that comprises transduced T cells capable of expressing the amino acid sequence of SEQ ID NO:7 ("VH3VL1-CD8ATD-CD137CSD-CD3zSSD"), or the kit comprises a polynucleotide encoding the amino acid sequence of SEQ ID NO:7 (e.g., the kit comprises a polynucleotide comprising the sequence of SEQ ID NO:20) in combination with an antibody comprising a heavy chain of SEQ ID NO:114 and a light chain of SEQ ID NO:115. This kit can be used to treat TNC positive cancer.
[0255] Furthermore, the parts of the kit of the invention can be packaged individually in vials or bottles or packaged in combination in a container or multi-container unit. Furthermore, the kit of the invention can comprise a (closed) bag cell incubation system in which the patient cells, preferably the T cells as described herein, can be transduced with the antigen binding receptor(s) of the invention and incubated under GMP (Good Manufacturing Practice as described in the Guidelines for Good Manufacturing Practice published by the European Commission under http: / / ec.europa.eu / health / documents / eudralex / index_en.htm) conditions. Furthermore, the kit of the invention comprises a (closed) bag cell incubation system in which the isolated / obtained patient T cells can be transduced with the antigen binding receptor of the invention and incubated under GMP. Furthermore, in the context of the present invention, the kit can also comprise a vector encoding the antigen binding receptor(s) as described herein. The kit of the invention can in particular be advantageously used for carrying out the method of the invention and can be employed for various applications as mentioned herein, e.g. as a research tool or medical tool. The manufacture of the kit preferably follows standard procedures known to the skilled person.
[0256] In this context, cells from a patient, preferably T cells, can be transformed with an antigen-binding receptor of the invention capable of specifically binding to a mutated Fc domain as described herein using a kit as described above. An extracellular domain comprising an antigen-binding portion capable of specifically binding to a mutated Fc domain is not naturally present in or on a T cell. Thus, a patient-derived cell transduced with a kit of the invention acquires the ability to specifically bind to a mutated Fc domain of an antibody, e.g., a therapeutic antibody, and is able to induce target cell elimination / lysis via interaction with a therapeutic antibody comprising a mutated Fc domain (which therapeutic antibody is capable of binding to a tumor-specific antigen naturally present (i.e. endogenously expressed) on the surface of a tumor cell). Binding of the extracellular domain of an antigen-binding receptor as described herein activates the T cell, bringing it into physical contact with the tumor cell via the therapeutic antibody comprising a mutated Fc domain. Non-transduced T cells or endogenous T cells (e.g., CD8+ T cells) are unable to bind to the mutated Fc domain of a therapeutic antibody comprising a mutated Fc domain. Transduced T cells expressing an antigen-binding receptor comprising an extracellular domain capable of specifically binding to a mutated Fc domain remain unaffected by a therapeutic antibody that does not comprise a mutation in the Fc domain as described herein. Thus, T cells expressing the antigen-binding receptor molecule of the present invention have the ability to lyse target cells in vivo and / or in vitro in the presence of an antibody comprising a mutation in the Fc domain as described herein. The corresponding target cells include cells expressing a surface molecule recognized by at least one, preferably two binding domains of a therapeutic antibody as described herein, i.e., a tumor-specific antigen naturally occurring on the surface of tumor cells. Such surface molecules are characterized herein as follows:
[0257] Lysis of target cells can be detected by methods known in the art. Such methods therefore include, in particular, physiological in vitro assays. Such physiological assays can monitor cell death, for example, due to loss of cell membrane integrity (e.g., FACS-based propidium iodide assay, trypan blue influx assay, photometric enzyme release assay (LDH), radiometric 51Cr release assay, fluorometric Europium release assay and calcein AM release assay). Further assays include, for example, photometric MTT, XTT, WST-1 and Alamar Blue assays, radioactive 3H-Thd incorporation assays, clonogenic assays measuring cell division activity, and fluorescent rhodamine 123 assays measuring mitochondrial transmembrane gradients to monitor cell viability. Furthermore, apoptosis can be monitored, for example, by FACS-based phosphatidylserine exposure assays, ELISA-based TUNEL tests, caspase activity assays (photometric, fluorimetric or ELISA-based) or by analyzing altered cell morphology (shrinkage, membrane blebbing).
[0258] Therapeutic Uses and Methods of Treatment The molecules or constructs (e.g., antigen-binding receptors, transduced T cells and kits) provided herein are particularly useful in medical settings, especially for the treatment of cancer. For example, tumors can be treated with transduced T cells expressing the antigen-binding receptor of the present invention in conjunction with a therapeutic antibody that binds to a target antigen on tumor cells and comprises a mutated Fc domain (i.e., an Fc domain comprising a P329G mutation according to EU numbering). Thus, in certain embodiments, the antigen-binding receptor, transduced T cells or kits are used in the treatment of cancer, especially cancers of epithelial, endothelial or mesothelial origin and hematological cancers.
[0259] The tumor specificity of the treatment is provided by a therapeutic antibody that binds to a target cell antigen, which is administered before, simultaneously with or after the administration of the transduced T cells expressing an antigen-binding receptor of the invention. In this context, the transduced T cells are universal T cells, since they are not specific for a given tumor, but can target any tumor depending on the specificity of the therapeutic antibody used according to the invention.
[0260] The cancer may be of epithelial, endothelial or mesothelial origin or of blood. In one embodiment, the cancer is selected from the group consisting of gastrointestinal cancer, pancreatic cancer, cholangiocarcinoma, lung cancer, breast cancer, ovarian cancer, skin cancer, oral cancer, gastric cancer, cervical cancer, B and T cell lymphoma, myeloid leukemia, ovarian cancer, leukemia, lymphocytic leukemia, nasopharyngeal cancer, colon cancer, prostate cancer, renal cell cancer, head and neck cancer, skin cancer (melanoma), cancer of the genitourinary tract, such as testicular cancer, ovarian cancer, endothelial cancer, cervical cancer, and kidney cancer, cancer of the bile duct, cancer of the esophagus, cancer of the salivary gland, and cancer of the thyroid gland, or other neoplastic diseases such as blood tumors, gliomas, sarcomas, or osteosarcomas.
[0261] For example, neoplastic diseases and / or lymphomas can be treated with specific constructs directed to these medical indications. For example, gastrointestinal cancer, pancreatic cancer, cholangiocarcinoma, lung cancer, breast cancer, ovarian cancer, skin cancer, and / or oral cancer can be treated with antibodies directed against (human) EpCAM (as a tumor-specific antigen naturally occurring on the surface of tumor cells).
[0262] Gastrointestinal cancer, pancreatic cancer, cholangiocarcinoma, lung cancer, breast cancer, ovarian cancer, skin cancer, and / or oral cancer can be treated with the transduced T cells of the invention administered before, simultaneously or after administration of a therapeutic antibody directed against HER1, preferably human HER1. Furthermore, gastrointestinal cancer, pancreatic cancer, cholangiocarcinoma, lung cancer, breast cancer, ovarian cancer, skin cancer, glioblastoma, and / or oral cancer can be treated with the transduced T cells of the invention administered before, simultaneously or after administration of a therapeutic antibody directed against MCSP, preferably human MCSP. Gastrointestinal cancer, pancreatic cancer, cholangiocarcinoma, lung cancer, breast cancer, ovarian cancer, skin cancer, glioblastoma, and / or oral cancer can be treated with the transduced T cells of the invention administered before, simultaneously or after administration of a therapeutic antibody directed against FOLR1, preferably human FOLR1. Gastrointestinal cancer, pancreatic cancer, cholangiocarcinoma, lung cancer, breast cancer, ovarian cancer, skin cancer, glioblastoma, and / or oral cancer can be treated with the transduced T cells of the invention administered before, simultaneously or after administration of a therapeutic antibody directed against Trop-2, preferably human Trop-2. Gastrointestinal cancer, pancreatic cancer, cholangiocarcinoma, lung cancer, breast cancer, ovarian cancer, skin cancer, glioblastoma, and / or oral cancer can be treated with the transduced T cells of the invention administered before, simultaneously or after administration of a therapeutic antibody directed against PSCA, preferably human PSCA. Gastrointestinal cancer, pancreatic cancer, cholangiocarcinoma, lung cancer, breast cancer, ovarian cancer, skin cancer, glioblastoma, and / or oral cancer can be treated with the transduced T cells of the invention administered before, simultaneously or after administration of a therapeutic antibody directed against EGFRvIII, preferably human EGFRvIII. Gastrointestinal cancer, pancreatic cancer, cholangiocarcinoma, lung cancer, breast cancer, ovarian cancer, skin cancer, glioblastoma, and / or oral cancer can be treated with the transduced T cells of the invention administered before, simultaneously or after administration of a therapeutic antibody directed against MSLN, preferably human MSLN. Gastric cancer, breast cancer, and / or cervical cancer can be treated with the transduced T cells of the invention administered before, simultaneously or after administration of a therapeutic antibody directed against HER2, preferably human HER2.Gastric and / or lung cancers can be treated with the transduced T cells of the invention administered before, simultaneously or after administration of a therapeutic antibody directed against HER3, preferably human HER3. B-cell and / or T-cell lymphomas can be treated with the transduced T cells of the invention administered before, simultaneously or after administration of a therapeutic antibody directed against CD20, preferably human CD20. B-cell and / or T-cell lymphomas can be treated with the transduced T cells of the invention administered before, simultaneously or after administration of a therapeutic antibody directed against CD22, preferably human CD22. Myeloid leukemias can be treated with the transduced T cells of the invention administered before, simultaneously or after administration of a therapeutic antibody directed against CD33, preferably human CD33. Ovarian, lung, breast and / or gastrointestinal cancer can be treated with the transduced T cells of the invention administered before, simultaneously or after administration of a therapeutic antibody directed against CA12-5, preferably human CA12-5. Gastrointestinal cancer, leukemia and / or nasopharyngeal carcinoma can be treated with the transduced T cells of the invention administered before, simultaneously or after administration of a therapeutic antibody directed against HLA-DR, preferably human HLA-DR. Colon cancer, breast cancer, ovarian cancer, lung and / or pancreatic cancer can be treated with the transduced T cells of the invention administered before, simultaneously or after administration of a therapeutic antibody directed against MUC-1, preferably human MUC-1. Colon cancer can be treated with the transduced T cells of the invention administered before, simultaneously or after administration of a therapeutic antibody directed against A33, preferably human A33. Prostate cancer can be treated with the transduced T cells of the invention administered before, simultaneously or after administration of a therapeutic antibody directed against PSMA, preferably human PSMA. Gastrointestinal cancer, pancreatic cancer, cholangiocarcinoma, lung cancer, breast cancer, ovarian cancer, skin cancer, and / or oral cancer can be treated with the transduced T cells of the invention administered before, simultaneously or after administration of a therapeutic antibody directed against the transferrin receptor, preferably the human transferrin receptor.Pancreatic cancer, lung cancer, and / or breast cancer can be treated with the transduced T cells of the invention administered before, simultaneously or after administration of a therapeutic antibody directed against the transferrin receptor, preferably the human receptor. Renal cancer can be treated with the transduced T cells of the invention administered before, simultaneously or after administration of a therapeutic antibody directed against CA-IX, preferably human CA-IX.
[0263] The invention also relates to a method for the treatment of diseases, such as malignant diseases, such as cancers of epithelial, endothelial or mesothelial origin and / or hematological cancers.In the context of the present invention, the subject is a human being.
[0264] In the context of the present invention, a particular method for the treatment of a disease comprises: (a) isolating T cells, preferably CD8+ T cells, from a subject; (b) transducing the isolated T cells, preferably CD8+ T cells, with an antigen-binding receptor as described herein; and (c) administering to said subject the transduced T cells, preferably CD8+ T cells. Includes.
[0265] In the context of the present invention, said transduced T cells, preferably CD8+ T cells, and / or one or more therapeutic antibodies are co-administered to said subject by intravenous infusion.
[0266] Furthermore, in the context of the present invention, (a) isolating T cells, preferably CD8+ T cells, from a subject; (b) transducing the isolated T cells, preferably CD8+ T cells, with an antigen-binding receptor as described herein; (c) optionally co-transducing the isolated T cells, preferably CD8+ T cells, with a T cell receptor; (d) expanding the T cells, preferably CD8+ T cells, with anti-CD3 and anti-CD28 antibodies; and (e) administering to said subject the transduced T cells, preferably CD8+ T cells. The present invention provides a method for treating diseases including
[0267] The above mentioned step (d) (referring to the step of expanding T cells such as TILs by anti-CD3 and / or anti-CD28 antibodies) can also be carried out in the presence of (stimulatory) cytokines such as interleukin 2 and / or interleukin 15 (IL-15). In the context of the present invention, the above mentioned step (d) (referring to the step of expanding T cells such as TILs by anti-CD3 and / or anti-CD28 antibodies) can also be carried out in the presence of interleukin 12 (IL-12), interleukin 7 (IL-7) and / or interleukin 21 (IL-21).
[0268] The method of treatment further comprises the administration of an antibody used according to the invention. Said antibody may be administered before, simultaneously or after the administration of the transduced T cells. In the context of the present invention, the administration of the transduced T cells will be performed by intravenous infusion. In the context of the present invention, the transduced T cells are isolated / obtained from the subject to be treated.
[0269] The present invention further contemplates co-administration protocols with other compounds, such as molecules capable of providing activation signals for immune effector cells, cell proliferation or cell stimulation, which may be, for example, additional primary activation signals for T cells (e.g., additional costimulatory molecules: molecules of the B7 family, Ox40L, 4.1BBL, CD40L, anti-CTLA-4, anti-PD-1), or additional cytokine interleukins (e.g., IL-2).
[0270] The compositions of the invention as described above may also be diagnostic compositions, optionally further comprising means and methods for detection.
[0271] composition Furthermore, the present invention provides a composition (medicament) comprising an antibody molecule(s) with mutated Fc domain(s) and / or a transduced T cell(s) comprising an antigen-binding receptor of the present invention and / or a nucleic acid molecule(s) and vector(s) encoding an antigen-binding receptor according to the present invention. Furthermore, the present invention provides a kit comprising one or more of said compositions. In the context of the present invention, said composition is a pharmaceutical composition optionally further comprising suitable formulations being carriers, stabilizers and / or additives. Thus, in the context of the present invention, a pharmaceutical composition (medicament) is provided comprising an antibody molecule comprising a mutated Fc domain as defined herein, administered in combination with a transduced T cell comprising an antigen-binding receptor as described herein and / or a composition comprising said transduced T cell, wherein said antibody molecule is administered before, simultaneously or after administration of a transduced T cell comprising an antigen-binding receptor of the present invention.
[0272] The use of the term "in combination" does not limit the order in which components of a therapeutic regimen are administered to a subject. Thus, the pharmaceutical compositions / medicaments described herein encompass administration of an antibody as defined herein before, simultaneously with, or after administration of a transduced T cell comprising an antigen-binding receptor of the present invention. "In combination" as used herein also does not limit the timing of administration of an antibody as defined above and a transduced T cell comprising an antigen-binding receptor as defined herein. Thus, when the two components are not administered simultaneously / together, their administration may be spaced apart by 1 minute, 5 minutes, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 12 hours, 24 hours, 48 hours, or 72 hours, or any suitable time period that is readily determined by the skilled artisan and / or as described herein.
[0273] In the context of the present invention, the term "in combination" also encompasses the situation where an antibody as defined herein and a transduced T cell comprising an antigen-binding receptor according to the present invention are pre-incubated together before administration to a subject. Thus, these two components may be pre-incubated for, for example, 1 minute, 5 minutes, 10 minutes, 15 minutes, 30 minutes, 45 minutes or 1 hour before administration, or any suitable time that can be easily determined by a person skilled in the art. In another preferred embodiment, the present invention relates to a therapeutic regimen in which an antibody as defined herein and a transduced T cell comprising an antigen-binding receptor as defined herein are administered simultaneously / together. In the context of the present invention, an antibody as defined herein may be administered prior to administration of a transduced T cell comprising an antigen-binding receptor.
[0274] Moreover, "in combination" as used herein does not limit the disclosed therapeutic regimen to the administration of the antibody as defined herein and the transduced T cells (preferably CD8+ T cells) comprising the antigen-binding receptor of the invention in sequential order (i.e., administration of one of these two components followed (at a certain time interval) by the other without administration and / or implementation of any other therapeutic protocol in between). Thus, the therapeutic regimen also encompasses the separate administration of the antibody molecule as defined herein and the transduced T cells (preferably CD8+ T cells) comprising the antigen-binding receptor according to the invention, separated by one or more therapeutic protocols necessary and / or suitable for the treatment or prevention of the disease or its symptoms. Examples of such intervening therapeutic protocols include, but are not limited to, administration of analgesics, administration of chemotherapeutic agents, surgical treatment of the disease or its symptoms, etc. Thus, the therapeutic regimens disclosed herein comprise the administration of an antibody as defined herein and a transduced T cell (preferably a CD8+ T cell) comprising an antigen-binding receptor as defined herein, together with one or more therapeutic protocols suitable for the treatment or prevention of a disease or a symptom thereof, as described herein or as known in the art.
[0275] In particular, it is envisaged that said one or more pharmaceutical compositions / medications are administered to the patient via infusion or injection. In the context of the present invention, transduced T cells comprising the antigen-binding receptors described herein will be administered to the patient via infusion or injection. The administration of suitable compositions / medications can be performed by different methods: intravenous, intraperitoneal, subcutaneous, intramuscular, topical or intradermal administration.
[0276] The pharmaceutical composition / medicine of the present invention may further comprise a pharma- ceutically acceptable carrier. Examples of suitable pharmaceutical carriers are well known in the art and include phosphate buffered saline, water, emulsions such as oil-in-water emulsions, various types of wetting agents, sterile solutions, and the like. Compositions containing such carriers can be formulated by well-known conventional methods. These pharmaceutical compositions can be administered to subjects in appropriate doses. The administration regimen is determined by the attending physician and clinical factors. As is well known in the medical field, the dosage for one patient depends on many factors, including the patient's size, body surface area, age, the specific compound administered, sex, time and route of administration, general condition, and other drugs administered at the same time. Usually, the regimen for regular administration of the pharmaceutical composition is preferably in the range of 1 μg to 5 g units per day. However, more preferred dosages for continuous infusion would be in the range of 0.01 μg to 2 mg per kg of body weight per hour, preferably 0.01 μg to 1 mg, more preferably 0.01 μg to 100 μg, even more preferably 0.01 μg to 50 μg, and most preferably 0.01 μg to 10 μg increments. Particularly preferred dosages are described hereinafter. Progress can be monitored by periodic evaluation. Dosages vary, but a preferred dosage for intravenous administration of DNA is approximately 10 of the DNA molecule. 6 From 10 12 It's a copy.
[0277] The compositions of the invention may be administered locally or systemically. Typically, administration is parenteral (e.g., intravenously), and transduced T cells may be administered, for example, by catheter, directly to a target site, or to a site in an artery. Preparations for parenteral administration include sterile aqueous or non-aqueous solutions, suspensions, and emulsions. Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate. Aqueous carriers include water, alcoholic / aqueous solutions, emulsions or suspensions, including saline and buffered media. Parenteral vehicles include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, Ringer's lactate, or fixed oils. Intravenous vehicles include fluid and nutrient replenishers, electrolyte replenishers (e.g., those based on Ringer's dextrose), and the like. Preservatives and other additives may also be present, such as antimicrobials, antioxidants, chelating agents, and inert gases and the like. Furthermore, the pharmaceutical composition of the present invention may comprise a proteinaceous carrier, such as, for example, serum albumin or immunoglobulin (preferably of human origin). It is envisaged that the pharmaceutical composition of the present invention, in addition to the proteinaceous antibody construct (as described in the present invention) or the nucleic acid molecule or vector encoding it, and / or the cells, may comprise further biologically active agents depending on the intended use of the pharmaceutical composition. Such agents may be drugs acting on the gastrointestinal system, drugs acting as cytostatica, drugs preventing hyperurikemia, drugs inhibiting immune responses (e.g. corticosteroids), drugs acting on the cardiovascular system, and / or drugs such as T cell costimulatory molecules or cytokines known in the art.
[0278] These and other embodiments are disclosed and encompassed by the description and examples of the present invention. Further literature on any one of the antibodies, methods, uses and compounds employed according to the present invention can be retrieved from public libraries and databases, for example using electronic devices. For example, the public database "Medline" available on the Internet can be accessed at http: / / www.ncbi.nlm.nih.gov / PubMed / medline.html. Further databases and addresses, such as http: / / www.ncbi.nlm.nih.gov / , http: / / www.infobiogen.fr / , http: / / www.fmi.ch / biology / research_tools.html, http: / / www.tigr.org / , etc., are known to those skilled in the art and can be accessed at, for example, http: / / www.lycos.com.
[0279] Exemplary Sequences Table 2: Exemplary VH3VL1 P329G-CAR amino acid sequence: Kabat CDR definition TIFF2024543152000001.tif207170 Table 3: Exemplary VH3 x VL1 P329G-CAR DNA sequences: TIFF2024543152000002.tif253170TIFF2024543152000003.tif254170TIFF2024543152000004.tif121170Table 4: Exemplary VL1VH3 P329G-CAR amino acid sequence: Kabat CDR definition TIFF2024543152000005.tif132170 Table 5: Exemplary VL1VH3 P329G-CAR DNA sequences: TIFF2024543152000006.tif254170TIFF2024543152000007.tif121170Table 6: Exemplary anti-P329G antibodies Kabat CDR definition TIFF2024543152000008.tif253170TIFF2024543152000009.tif244170TIFF2024543152000010.tif248170TIFF2024543152000011.tif76170Table 7: P329G IgG1 Fc variants TIFF2024543152000012.tif22170Table 8 TIFF2024543152000013.tif253170TIFF2024543152000014.tif254170TIFF202454 3152000015.tif253170TIFF2024543152000016.tif254170TIFF2024543152000017. tif254170TIFF2024543152000018.tif254170TIFF2024543152000019.tif251170TIFF2024543152000020.tif250170TIFF2024543152000021.tif233170Table 9: Exemplary VH1VL1 P329G-CAR amino acid sequences: Kabat CDR definition TIFF2024543152000022.tif157170 Table 10: Exemplary VH2VL1 P329G-CAR amino acid sequence: Kabat CDR definition TIFF2024543152000023.tif157170 Table 11: Exemplary disulfide stabilized VH3VL1 P329G-CAR amino acid sequence: Kabat CDR definition TIFF2024543152000024.tif174170 Table 12: Further exemplary VH3VL1 P329G-CAR amino acid sequences (HuR968B): Kabat CDR definition TIFF2024543152000025.tif255170 TIFF2024543152000026.tif27170 Table 13: Further exemplary VH3VL1 P329G-CAR amino acid sequence (HuR9684M): Kabat CDR definition TIFF2024543152000027.tif255170TIFF2024543152000028.tif31170Table 14: Further exemplary antibody VH / VL domains: TIFF2024543152000029.tif51170 EXAMPLES
[0280] Working Example The following are examples of methods and compositions of the present invention. Given the general description provided above, it will be understood that other various embodiments may be practiced.
[0281] Recombinant DNA Technology Standard methods were used to manipulate DNA as described by Sambrook et al., Molecular Cloning: A laboratory manual; Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1989. Molecular biology reagents were used according to the manufacturer's instructions. General information relating to the nucleotide sequences of human immunoglobulin light and heavy chains can be found in Kabat, EA et al., (1991) Sequences of Proteins of Immunological Interest, 5 th ed., NIH Publication No. 91-3242.
[0282] DNA sequencing The DNA sequence was determined by double-stranded sequencing.
[0283] Gene synthesis Desired gene segments were generated by PCR using appropriate templates, as appropriate, or synthesized by Geneart AG (Regensburg, Germany) from synthetic oligonucleotides and PCR products by automated gene synthesis. If the exact gene sequence was not available, oligonucleotide primers were designed based on sequences from the closest homologues, and genes were isolated by RT-PCR from RNA derived from the appropriate tissue. Gene segments flanked by specific restriction endonuclease cleavage sites were cloned into standard cloning / sequencing vectors. Plasmid DNA was purified from transformed bacteria and concentrations were measured by UV spectroscopy. DNA sequences of subcloned gene fragments were confirmed by DNA sequencing. Gene segments were designed with appropriate restriction sites to allow subcloning into the respective expression vectors. All constructs were designed with a 5'-terminal DNA sequence encoding a leader peptide that targets the protein for secretion in eukaryotic cells.
[0284] Production of IgG-like proteins in HEK293 EBNA or CHO EBNA cells Antibodies and bispecific antibodies were produced by transient transfection into HEK293 EBNA or CHO EBNA cells. Cells were centrifuged and the medium was replaced with pre-warmed CD CHO medium (Thermo Fisher, Cat. No. 10743029). Expression vectors were mixed in CD CHO medium, PEI (polyethyleneimine, Polysciences, Inc, Cat. No. 23966-1) was added, the solution was vortexed and incubated at room temperature for 10 minutes. Cells (2 Mio / mL) were then mixed with the vector / PEI solution, transferred to a flask and incubated at 37°C for 3 hours in a shaking incubator with a 5% CO2 atmosphere. After incubation, Excel medium containing supplements (80% of the total volume) was added (W. Zhou and A. Kantardjieff, Mammalian Cell Cultures for Biologics Manufacturing, DOI:10.1007 / 978-3-642-54050-9;2014). One day after transfection, supplements (Feed, 12% of the total volume) were added. After 7 days, cell supernatants were harvested by centrifugation and subsequent filtration (0.2 μm filter), and proteins were purified from the harvested supernatants by standard methods as described below.
[0285] Production of IgG-like protein in CHO K1 cells Alternatively, the antibodies and bispecific antibodies described herein were prepared by Evitria using a proprietary vector system and conventional (non-PCR-based) cloning techniques in suspension-adapted CHO K1 cells (originally acquired from ATCC and adapted by Evitria to serum-free growth in suspension culture). For production, Evitria used proprietary animal component-free serum-free media (eviGrow and eviMake2) and a proprietary transfection reagent (eviFect). Supernatants were harvested by centrifugation followed by filtration (0.2 μm filter) and proteins were purified from the harvested supernatants by standard methods.
[0286] Purification of IgG-like proteins Proteins were purified from filtered cell culture supernatants with reference to standard protocols. Briefly, Fc-containing proteins were purified from cell culture supernatants by Protein A affinity chromatography (equilibration buffer: 20 mM sodium citrate, 20 mM sodium phosphate, pH 7.5, elution buffer: 20 mM sodium citrate, pH 3.0). Elution was achieved at pH 3.0, followed immediately by neutralization of the pH of the sample. Proteins were concentrated by centrifugation (Millipore Amicon® ULTRA-15 (Art.Nr.:UFC903096)) and aggregated proteins were separated from monomeric proteins by size-exclusion chromatography in 20 mM histidine, 140 mM sodium chloride, pH 6.0.
[0287] Analysis of IgG-like proteins The concentration of purified proteins was determined by measuring the absorbance at 280 nm using the mass extinction coefficient calculated based on the amino acid sequence according to Pace, et al., Protein Science, 1995, 4, 2411-1423. Protein purity and molecular weight were analyzed by CE-SDS in the presence and absence of reducing agents using LabChip GXII or LabChip GX Touch (Perkin Elmer). Determination of aggregate content was performed by HPLC chromatography at 25° C. using an analytical size exclusion column (TSKgel G3000 SW XL or UP-SW3000) equilibrated in running buffer (200 mM KH2PO4, 250 mM KCl pH 6.2, 0.02% NaN3).
[0288] Preparation of lentiviral supernatant and transduction into Jurkat-NFAT cells Lipofectamine LTX™-based transfection was performed using approximately 80% confluent Hek293T cells (ATCC CRL3216) and the transfer vector encoding CAR and the packaging vectors pCAG-VSVG and psPAX2 at a molar ratio of 2:2:1 (Giry-Laterriere M, et al Methods Mol Biol. 2011;737:183-209, Myburgh R, et al Mol Ther Nucleic Acids. 2014). After 66 hours, the supernatant was collected, centrifuged at 350×g for 5 minutes, and filtered through a 0.45 μm polyethersulfone filter to collect and purify the viral particles. Viral particles were either used directly or concentrated (Lenti-x-Concentrator, Takara) and used for spinfection of Jurkat NFAT T cells (GloResponse Jurkat NFAT-RE-luc2P, Promega #CS176501) at 900 × g for 2 h at 31 °C.
[0289] Jurkat NFAT activation assay The Jurkat NFAT activation assay measures T cell activation of a human acute lymphoblastic leukemia reporter cell line (GloResponse Jurkat NFAT-RE-luc2P, Promega #CS176501). This immortalized T cell line is engineered to stably express a luciferase reporter driven by the NFAT response element (NFAT-RE). In addition, the cell line expresses a chimeric antigen receptor (CAR) construct with a CD3z signaling domain. Binding of the CAR to an immobilized adapter molecule (such as a tumor antigen binding adapter molecule) results in cross-linking of the CAR, leading to T cell activation and expression of luciferase. After addition of substrate, cellular changes in NFAT activity can be measured as relative light units (Darowski et al. Protein Engineering, Design and Selection, Volume 32, Issue 5, May 2019, Pages 207-218, https: / / doi.org / 10.1093 / protein / gzz027). Typically, the assay was performed in 384-well plates (Falcon #353963 white, clear bottom). Target cells (CAR-Jurkat-NFAT cells) and effector cells were seeded in triplicate in a 1:5 ratio (2000 target cells, 10000 effector cells) in 10 μl each in RPMI-1640 + 10% FCS + 1% Glutamax (growth medium). Additionally, serial dilutions of the antibody of interest were prepared in growth medium to give final concentrations in the assay plate ranging from 67 nM to 0.000067 nM in a total final volume of 30 μl per well. The 384-well plates were centrifuged at 300 g for 1 min at room temperature and incubated at 37°C in a humidified atmosphere with 5% CO2. After 7 hours of incubation, 20% of the final volume of ONE-Glo™ Luciferase Assay (E6120, Promega) was added and the plate was centrifuged at 350×g for 1 minute. Relative luminescence units (RLU) were then measured immediately per second per well using a Tecan microplate reader. Concentration-response curves were fitted using GraphPad Prism version 7 to obtain EC 50p values were calculated using the New England Journal of Medicine style described in GraphPad Prism 7. * P ≤ 0,033; ** P ≤ 0,002; *** means P≦0.001.
[0290] Example 1 Generation and characterization of humanized anti-P329G antibodies Parental and humanized anti-P329G antibodies were produced in HEK cells and purified by Protein A affinity and size-exclusion chromatography. All antibodies were purified to high quality (Table 2).
[0291] Table 2 - Biochemical analysis of anti-P329G antibodies. Monomer content was determined by analytical size exclusion chromatography. Purity was determined by non-reducing SDS capillary electrophoresis. TIFF2024543152000030.tif26170
[0292] Binding of the parent and six humanized variants of anti-P329G binder M-1.7.24 to human Fc (P329G) Equipment:Biacore T200 Chip: CM5(#772) Fc1~4: Anti-human Fab specific (GE Healthcare 28-9583-25) Capture: 50nM IgG, 60 seconds Analyte: Human Fc (P329G) (P1AD9000-004) Running buffer: HBS-EP Temperature: 25℃ Dilution: 2-fold dilution from 0.59 to 37.5 nM in HBS-EP Flow rate: 30μl / min Meeting 240 seconds Dissociation: 800 seconds Regeneration: 10mM glycine pH 2.1 2x60 seconds
[0293] SPR experiments were performed on a Biacore T200 using HBS-EP+ (0.01 M HEPES pH 7.4, 0.15 M NaCl, 0.005% surfactant P20 (BR-1006-69, GE Healthcare)) as running buffer. Anti-human Fab specific antibodies (GE Healthcare 28-9583-25) were directly immobilized on a CM5 chip (GE Healthcare) by amine coupling. IgG was captured at 50 nM for 60 s. A two-fold dilution series of human Fc (P329G) was passed over the ligand at 30 μl / min for 240 s and the association phase was recorded. The dissociation phase was monitored for 800 s and triggered by switching from the sample solution to HBS-EP+. The chip surface was regenerated every cycle by two injections of 10 mM glycine, pH 2.1 for 60 s. Bulk refractive index differences were corrected by subtracting the response obtained with the reference flow cell 1. Affinity constants were derived from the rate constants by fitting to 1:1 Langmuir binding using Biaeval software (GE Healthcare). Measurements were performed in triplicate with independent dilution series.
[0294] The following samples were analyzed for binding to human Fc(P329G) (Table 3).
[0295] Table 3: Description of samples analyzed for binding to human Fc(P329G). TIFF2024543152000031.tif51170
[0296] Human Fc(P329G) was prepared by plasmin digestion of human IgG1, followed by affinity purification with Protein A and size exclusion chromatography.
[0297] Binding of the parent and six humanized variants of anti-P329G binder M-1.7.24 to human Fc (P329G) The dissociation phase was fitted to a curve to help characterize the off-rate. The ratio of bound to captured response levels was calculated (Table 4).
[0298] Table 4: Binding evaluation of the six humanized variants for binding to human Fc(P329G). TIFF2024543152000032.tif75170
[0299] Affinity of the parent and three humanized variants of the anti-P329G binder M-1.7.24 to human Fc (P329G) Three humanized variants with similar binding patterns to the parent were evaluated in more detail. The 1:1 Langmuir binding rate constants are summarized in Table 5.
[0300] Table 5: Kinetic constants (1:1 Langmuir binding). Means and standard deviations (in brackets) for independent triplicates (independent dilution series within the same experiment). TIFF2024543152000033.tif42170
[0301] conclusion Six humanized variants were generated, three of which (VH4VL1, VH1VL2, VH1VL3) showed reduced binding to human Fc (P329G) compared to the parent M-1.7.24, while the other three humanized variants (VH1VL1, VH2VL1, VH3VL1) showed binding kinetics very similar to the parent binder and no affinity was lost upon humanization.
[0302] Example 2 Preparation of humanized anti-P329G antigen-binding receptor To evaluate the functionality of the humanized P329G variant, different variable domain DNA sequences of the heavy (VH) and light (VL) chains encoding binders specific for the P329G Fc mutation were cloned as single-chain variable fragment (scFv) binding moieties and used as antigen-binding domains of second-generation chimeric antigen receptors (CARs).
[0303] The different humanized variants of the P329G binder contain an Ig heavy chain variable main domain (VL) and an Ig light chain variable domain (VL). The VH and VL are linked via a (G4S)4 linker. The scFv antigen binding domain is fused to the anchor transmembrane domain (ATD) CD8a (Uniprot P01732[183-203]), which is fused to the intracellular costimulatory signaling domain (CSD) CD137 (Uniprot Q07011AA 214-255), which is further fused to the stimulatory signaling domain (SSD) CD3ζ (Uniprot P20963 AA 52-164). The scFv of the anti-P329G CAR was constructed in two different orientations: VHxVL (Figure 1A) or VLxVH (Figure 1B). A schematic of an exemplary expression construct (including a GFP reporter) for the VHVL configuration is shown in FIG. 1C and for the VLVH configuration in FIG. 1D.
[0304] Example 3 Expression of anti-P329G antigen-binding receptor in Jurkat-NFAT cells Different humanized anti-P329G antigen-binding receptors were virally transduced into Jurkat (GloResponse Jurkat NFAT-RE-luc2P, Promega #CS176501) cells.
[0305] The expression of anti-P329G antigen-binding receptors was evaluated by flow cytometry. Jurkat cells using different humanized anti-P329G antigen-binding receptors were harvested, washed with PBS and seeded at 50,000 cells per well in 96-well flat-bottom plates. After staining with antibodies containing the P329G mutation in the Fc domain at different concentrations (1:5 serial dilutions from 500 nM to 0 nM) for 45 min in the dark and in the refrigerator (4-8 °C), the samples were washed three times with FACS buffer (PBS containing 2% FBS, 10% 0.5 M EDTA, pH 8 and 0.5 g / L NaN3). Afterwards, the samples were stained with 2.5 μg / mL polyclonal anti-human IgG Fcγ fragment-specific and PE-conjugated AffiniPure F(ab')2 goat fragment antibodies for 30 min in the dark in the refrigerator and analyzed by flow cytometry (Fortessa BD). In addition, the anti-P329G antigen-binding receptor contained an intracellular GFP reporter (see Fig. 1C ).
[0306] Compared to the humanized versions of the P329G binder (VH1VL1, VH2VL1, and VH3VL1), the original non-humanized binder shows weak CAR labeling at the cell surface (Figure 2A), but comparable GFP expression. Interestingly, the VL1VH1 construct (see Figure 1D) shows high GFP expression, but also weak CAR labeling at the cell surface, indicating an unfavorable conformation of the binder.
[0307] Overall, and unexpectedly, the VH3VL1 version shows the highest GFP expression and CAR surface expression. Moreover, all tested constructs in the VHVL conformation (VH1VL1, VH2VL1, and VH3VL1) show enhanced GFP signals when transduced into Jurkat T cells compared to the original non-humanized P329G antigen-binding receptor and, interestingly, the construct in the VLVH conformation (VL1VH3).
[0308] In conclusion, VHVL conformation appears to favor the expression level and precise targeting of antigen-binding receptors to the cell surface.
[0309] Furthermore, various studies were performed to characterize the selectivity, specificity and safety of the humanized anti-P329G antigen-binding receptor.
[0310] Example 4 Specific T cell activation in the presence of a targeting antibody containing the P329G mutation in the Fc domain To exclude non-specific binding of the different humanized anti-P329G-scFv variants, activation of Jurkat NFAT cells expressing antigen-binding receptors containing these variants was assessed in the presence of CD20-positive WSUDLCL2 target cells and anti-CD20 (GA101) antibodies with different Fc variants (Fc wild type, Fc P329G mutation, LALA mutation, D246A mutation or combinations thereof). CAR-Jurkat NFAT activation assays were performed as described above and potential non-specific binding was assessed using anti-CD20(GA101) wild type IgG1 (Figure 3A, anti-CD20(GA101) P329G LALA IgG1 (Figure 3B), anti-CD20(GA101) LALA IgG1 (Figure 3D), anti-CD20(GA101) D246A P329G IgG1 (Figure 3F) or non-specific DP-47 P329G LALA IgG1 (Figure 3E). No non-specific anti-P329G CAR activation could be detected for anti-CD20(GA101) wild type IgG1 (Figure 3A), anti-CD20(GA101) LALA IgG1 (Figure 3D) or non-specific DP-47 P329G LALA IgG1 (Figure 3E).
[0311] Specific anti-P329G CAR activation could be detected in the presence of anti-CD20(GA101)P329G LALA IgG1 (Figure 3B) and anti-CD20(GA101)D246A P329G IgG1 (Figure 3F). 50 was comparable between all humanized anti-P329G variants and was significantly higher than that of the original binder. 50There was nothing different.
[0312] Interestingly, the antigen-binding receptor containing the scFv binder in the VHVL conformation leads to stronger activation of Jurkat NFAT T cells compared to the original non-humanized binder and the humanized binder in the VLVH conformation. The higher plateau (see e.g. FIG. 3F) may be due to the higher expression levels and / or improved trafficking to the cell surface by the antigen-binding receptor, leading to stronger activation. Furthermore, this conformation may affect binding to the P329G mutation.
[0313] To examine the risk of antigen-binding domain clustering resulting in tonic signaling or non-specific activation of T cells, Jurkat NFAT activation assays were performed as above, but increasing initial antibody concentrations were used, serial dilutions started with 100 nM GA101 P329G LALA IgG1, and no target cells were seeded.
[0314] As depicted in Figure 3C, no activation was detected with all humanized P329G variants tested, indicating detectable receptor clustering or non-specific activation in the absence of target cells.
[0315] Example 5 Sensitivity of different humanized P329G antigen-binding receptor variants as assessed by T cell activation against target cells expressing different levels of antigen To further characterize the sensitivity and selectivity of the humanized anti-P329G antigen-binding receptor, a Jurkat NFAT activation assay was performed as described above.
[0316] Jurkat NFAT reporter cells expressing different humanized anti-P329G-scFv variants antigen-binding receptors were evaluated for their ability to discriminate between high (HeLa-FolR1), medium (Skov3) and low (HT29) FolR1 positive target cells. Different variants of anti-P329G conjugates were used as scFv antigen recognition scaffolds in combination with antibodies exhibiting high (16D5) (Figure 4A,D,G), medium (16D5 W96Y) (Figure 4B,E,H) or low (16D5 G49S / K53A) affinity for FolR1 (Figure 4C,F,I) in the Jurkat-Reporter cell line. Highly expressing target cells, HeLa-FolR1, showed dose-dependent activation in combination with high affinity anti-FolR1 16D5 (Figure 4A), medium affinity anti-FolR1 16D5 W96Y (Figure 4B), and low affinity adaptor-IgG anti-FolR1 G49S K53A (Figure 4C). Medium expressing target cells, Skov3, showed dose-dependent activation in combination with high affinity anti-FolR1 16D5 (Figure 4D), medium affinity anti-FolR1 16D5 W96Y (Figure 4E), and low affinity adaptor-IgG anti-FolR1 G49S K53A (Figure 4F). For the low expressing target cells HT29, no signal was detected in combination with the different affinity binders anti-FolR1 16D5 (Figure 4G), anti-FolR1 16D5 W96Y (Figure 4H) or low affinity adaptor-IgG anti-FolR1 G49S K53A (Figure 4I). Moreover, interestingly, the antigen binding receptor in VHVL format leads to stronger activation of Jurkat NFAT T cells compared to the original non-humanized binder and the humanized binder in VLVH format. The humanized variant VH3VL1 scFv binder leads to the highest signal intensity of all constructs (Figures 4A-F).
[0317] Furthermore, the HeLa(FolR1) used in combination with either anti-FolR1 16D5 P329G LALA IgG1 (Figure 5) or anti-HER2 P329G LALA IgG1 (Figure 6) + and HER2 +) cells, a Jurkat NFAT activation assay was performed, both confirming the finding that the VHVL orientation is superior to the VLVH orientation. The humanized variant VH3VL1 results in the strongest activation of Jurkat NFAT T cells.
[0318] Example 6 Expression of additional anti-P329G antigen-binding receptors in Jurkat-NFAT cells Disulfide-humanized anti-P329G antigen-binding receptor was virally transduced into Jurkat (GloResponse Jurkat NFAT-RE-luc2P, Promega#CS176501) cells. Anti-P329G antigen-binding receptor expression was evaluated by flow cytometry. Jurkat cells using disulfide-stabilized humanized anti-P329G antigen-binding receptor were harvested, washed with PBS and seeded at 50.000 cells / well in 96-well flat-bottom plates. After staining with antibodies containing the P329G mutation in the Fc domain at different concentrations (1:10 serial dilutions from 600 nM to 0 nM) for 45 min in the dark and in a refrigerator (4-8 °C), the samples were washed three times with FACS buffer (PBS containing 2% FBS, 10% of 0.5 M EDTA, pH 8 and 0.5 g / L NaN3). Samples were then stained with 2.5 μg / mL polyclonal anti-human IgG Fcγ fragment specific and PE-conjugated AffiniPure F(ab')2 goat fragment antibody in the refrigerator for 30 min in the dark and analyzed by flow cytometry (Fortessa BD). Additionally, the anti-P329G antigen-binding receptor contained an intracellular GFP reporter (see Figure 1C). CAR expression was normalized to the GFP signal.
[0319] Compared to the humanized versions VH3VL1 and VL1VH3, the disulfide-stabilized P329G binder shows comparable CAR labeling on the cell surface (Figure 7).
[0320] Example 7 Expression of additional anti-P329G antigen-binding receptors in HEK293-T cells To verify the expression of HuR968B and HuR9684M CAR constructs, 1.5x106 HEK293-T cells were seeded in 6-well plates and, after an 8-24 h adhesion period, transfected with a PEI (Polyscience, 24765) / sodium chloride (Baxter, A6E1307) mixture containing 2 μM CAR-encoding plasmid DNA (1 μg / μL). After a 48 h culture period, the HEK293T culture supernatant was discarded and CAR expression in HEK293T cells was analyzed using flow cytometry. For this, 3*105 HEK293T cells per well were transferred to a 96-well plate and washed twice with FACS buffer (5 min, 300 g). Alexa Fluor 647-WT IgG or Alexa Fluor 647-PG IgG as primary antibodies were diluted in FACS buffer to obtain a 1:50 diluted working solution. HEK293T cells were suspended in the antibody solution and stained for 30 min at 4°C. After washing with FACS buffer (5 min, 300g), cells were fixed for 20 min using 3% Fixation solution (Thermo Scientific Cat.:28908). Cells were then analyzed by flow cytometry for GFP and APC labeling. Both HuR968B and HuR9684M CARs were expressed and detected in HEK239 T cells (Figure 9).
[0321] Example 8 Expression of additional anti-P329G antigen-binding receptors on T cells CAR T cells were prepared by lentivirus transduction, and CAR expression was confirmed by flow cytometry. For CAR detection, an appropriate amount of transduced T cells was washed once with FACS buffer at 300 × g for 5 min. FACS buffer containing LIVE / DEAD fixable dead cells and Biotin-SP (long spacer) AffiniPure F(ab')2 fragment goat anti-human IgG (Jackson ImmunoResearch, 109-066-006) was added, and cells were stained for 30-45 min at 4 °C. Then, cells were washed twice and the respective antibodies were added: PerCP-Cy5.5-CD3 (BD, 560835), BUV805-CD8 (BD, 749366), APC streptavidin (Biolegend, 405207), and stained for 30-45 min at 4 °C. After incubation, cells were washed twice with FACS buffer, resuspended, and then evaluated by flow cytometry. Data were analyzed using GraphPad Prism 7. CD3 similar to T cell populations + After gating the cells, the percentage of CAR T positive cells was detected as 27% for HuR9684M and 18% for HuR968B (Figure 10B).
[0322] Example 9 Specific T cell killing induced by HuR968B and HuR9684M anti-P329G antigen-binding receptors and A6 IgG containing the P329G mutation T cells expressing HuR968B or HuR9684M CAR were prepared from a blood donor (PCH20201100004) and compared in a killing assay using DAN-G18.2 as target cells and A6 PG IgG or WT A6 (VH / VL SEQ ID NO: 136 / 137 and P329G mutation in Fc, e.g. SEQ ID NO: 55) that binds to Claudin 18.2 on the target cell surface. Target and effector cells were seeded at a ratio of E:T=1:2 with either 100ng / ml PG IgG or WT IgG. Target cell killing was measured for 60 hours using xCELLigence (Figures 11A and B).
[0323] In the presence of P329G and WT A6 antibodies, non-transduced UNT cells did not produce a killing effect. HuR968B and HuR9684M CAR T cells induced potent tumor cell lysis when incubated with PG IgG (Figure 11A). No cell killing was observed when incubated with control WT IgG lacking the PG mutation (Figure 11B).
[0324] Example 10 Specific T cell killing induced by HuR968B anti-P329G antigen-binding receptor and A6 and Zmab IgG containing the P329G mutation HuR968B CAR-T cells were co-cultured for 24 hours in the presence of different antibody concentrations of A6 PG IgG and Zmab PG IgG (VH / VL SEQ ID NO: 136 / 137 or 138 / 139, and P329G mutation in Fc, e.g. SEQ ID NO: 55), both of which target claudin 18.2. The E:T ratio was 1:1. The assay was performed in 96-well round-bottom plates, and after 24 hours, the supernatant of each well was observed for LDH release and cytotoxicity was calculated according to the manufacturer's suggestions (CytoTox 96 non-radioactive cytotoxicity assay Promega G1780). Both PG IgGs show potent target cell lysis of DAN-G18.2 target cells expressing high levels of claudin 18.2 (Figure 12).
Claims
1. An antigen-binding receptor comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:
129.
2. An antigen-binding receptor comprising the amino acid sequence of SEQ ID NO:
129.
3. An antigen-binding receptor consisting of the amino acid sequence of SEQ ID NO:
129.
4. An antigen-binding receptor comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:
132.
5. An antigen-binding receptor comprising the amino acid sequence of SEQ ID NO:
132.
6. An antigen-binding receptor consisting of the amino acid sequence of SEQ ID NO:
132.
7. The antigen-binding receptor of any one of claims 1 to 6, which does not comprise the amino acid sequence of SEQ ID NO:
19.
8. An isolated polynucleotide encoding the antigen-binding receptor of any one of claims 1 to 7.
9. An isolated polynucleotide comprising the sequence of SEQ ID NO:
130.
10. An isolated polynucleotide comprising the sequence of SEQ ID NO:
133.
11. A polypeptide encoded by the isolated polynucleotide of any one of claims 8 to 10.
12. A vector, particularly an expression vector, comprising a polynucleotide according to any one of claims 8 to 10.
13. A transduced T cell comprising a polynucleotide according to any one of claims 8 to 10 or a vector according to claim 12.
14. A transduced T cell capable of expressing an antigen-binding receptor according to any one of claims 1 to 7.
15. (A) a transduced T cell capable of expressing an antigen-binding receptor according to any one of claims 1 to 7; and (B) An antibody that binds to a target cell antigen and comprises an Fc domain that comprises the amino acid mutation P329G according to EU numbering. Kit including:
16. (A) an isolated polynucleotide encoding an antigen-binding receptor according to any one of claims 1 to 7; and (B) An antibody that binds to a target cell antigen and comprises an Fc domain that comprises the amino acid mutation P329G according to EU numbering. Kit including:
17. (A) an isolated polynucleotide according to any one of claims 8 to 10, or a vector according to claim 12; and (B) An antibody that binds to a target cell antigen and comprises an Fc domain that comprises the amino acid mutation P329G according to EU numbering. Kit including:
18. The kit according to any one of claims 15 to 17, wherein the Fc domain is an IgG1 or IgG4 Fc domain, in particular a human IgG1 Fc domain.
19. The kit according to any one of claims 15 to 18, wherein the target cell antigen is selected from the group consisting of fibroblast activation protein (FAP), carcinoembryonic antigen (CEA), mesothelin (MSLN), CD20, folate receptor 1 (FOLR1) and tenascin (TNC).
20. A kit according to any one of claims 15 to 19 for use as a medicine.
21. 15. The antigen binding receptor of any one of claims 1 to 7 or the transduced T cell of claim 13 or 14 for use as a medicament, wherein the transduced T cell expressing said antigen binding receptor is administered before, simultaneously with or after administration of an antibody that binds to a target cell antigen, in particular a cancer cell antigen, and comprises an Fc domain that comprises the amino acid mutation P329G according to EU numbering.
22. A kit according to any one of claims 15 to 19 for use in the treatment of a disease, in particular for use in the treatment of cancer.
23. 15. The antigen binding receptor of any one of claims 1 to 7 or the transduced T cell of claim 13 or 14 for use in the treatment of cancer, wherein said treatment comprises administering a transduced T cell expressing said antigen binding receptor prior to, simultaneously with or following administration of an antibody which binds to a cancer cell antigen and comprises an Fc domain which comprises the amino acid mutation P329G according to EU numbering.
24. 24. The antigen binding receptor, transduced T cell or kit for use of claim 22 or 23, wherein the cancer is selected from cancers of epithelial, endothelial or mesothelial origin and hematological cancers.
25. 25. The antigen binding receptor, transduced T cell or kit for use of claim 24, wherein the cancer antigen is selected from the group consisting of fibroblast activation protein (FAP), carcinoembryonic antigen (CEA), mesothelin (MSLN), CD20, folate receptor 1 (FOLR1) and tenascin (TNC).
26. 26. The antigen binding receptor, transduced T cell or kit for use according to any one of claims 23 to 25, wherein said transduced T cell is derived from cells isolated from the subject to be treated.
27. 27. The antigen binding receptor, transduced T cell or kit for use of any one of claims 23 to 26, wherein the transduced T cell is not derived from cells isolated from the subject to be treated.
28. 13. A method of treating a disease in a subject, comprising administering to the subject transduced T cells capable of expressing an antigen binding receptor according to any one of claims 1 to 7, and administering, prior to, simultaneously with or after administration of the transduced T cells, a therapeutically effective amount of an antibody that binds to a target cell antigen and comprises an Fc domain that comprises the amino acid mutation P329G according to EU numbering.
29. 29. The method of claim 28, additionally comprising isolating T cells from the subject and generating said transduced T cells by transducing said isolated T cells with a polynucleotide according to any one of claims 8 to 10 or a vector according to claim 12.
30. 30. The method of claim 29, wherein the T cells are transduced with a retroviral or lentiviral vector construct, or a non-viral vector construct.
31. The method of any one of claims 28 to 30, wherein the transduced T cells are administered to the subject by intravenous infusion.
32. The method of any one of claims 28 to 31, wherein the transduced T cells are contacted with an anti-CD3 antibody and / or an anti-CD28 antibody prior to administration to the subject.
33. 33. The method of any one of claims 28 to 32, wherein the transduced T cells are contacted with at least one cytokine prior to administration to the subject, preferably interleukin-2 (IL-2), interleukin-7 (IL-7), interleukin-15 (IL-15) and / or interleukin-21 or variants thereof.
34. The method of any one of claims 28 to 33, wherein the disease is cancer.
35. 35. The method of claim 34, wherein the cancer is selected from cancers of epithelial, endothelial or mesothelial origin and hematological cancers.
36. 10. A method of inducing lysis of a target cell, comprising contacting said target cell with a transduced T cell capable of expressing an antigen-binding receptor according to any one of claims 1 to 7 in the presence of an antibody that binds to a target cell antigen and comprises an Fc domain that comprises the amino acid mutation P329G according to EU numbering.
37. 37. The method of claim 36, wherein the target cell is a cancer cell.
38. 38. The method of claim 36 or 37, wherein the target cells express an antigen selected from the group consisting of fibroblast activation protein (FAP), carcinoembryonic antigen (CEA), mesothelin (MSLN), CD20, folate receptor 1 (FOLR1) and tenascin (TNC).
39. Use of an antigen-binding receptor according to any one of claims 1 to 7, a polynucleotide according to any one of claims 8 to 10, or a transduced T cell according to claim 13 or 14 for the manufacture of a medicament.
40. 40. The use according to claim 39, wherein the medicament is for the treatment of cancer.
41. 41. The use according to claim 40, characterized in that the cancer is selected from cancers of epithelial, endothelial or mesothelial origin and hematological cancers.
Citation Information
Patent Citations
Improved antigen-binding receptors
JP2020515256A
Universal reporter cell assay for specificity testing of novel antigen-binding moieties
JP2021508043A
